Section 72

EurekaMag Full Text Articles Chapter 71,291


Morse, M.A.; Liu, E.; Joish, V.N.; Huynh, L.; Cheng, M.; Duh, M.S.; Seth, K.; Lapuerta, P.; Metz, D.C. 2020: Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: the TELEACE Real-World Chart Review Study. Cancer Management and Research 12: 6607-6614
Xie, C.-L.; Zhang, D.; Lin, T.; He, Z.-H.; Yan, Q.-X.; Cai, Q.; Zhang, X.-K.; Yang, X.-W.; Chen, H.-F. 2020: Antiproliferative Sorbicillinoids from the Deep-Sea-Derived Penicillium allii-sativi. Frontiers in Microbiology 11: 636948
Dawod, M.; Gordoa, T.A.; Cives, M.; De Mestier, L.; Crona, J.; Spada, F.; Oberg, K.; Pavel, M.; Lamarca, A. 2021: Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Current Treatment Options in Oncology 22(8): 73
Zheng, X.; Kadir, A.; Zheng, G.; Jin, P.; Qin, D.; Maiwulanjiang, M.; Aisa, H.A.; Yao, G. 2020: Antiproliferative abietane quinone diterpenoids from the roots of Salvia deserta. Bioorganic Chemistry 104: 104261
Petricoin, E.F.; Ito, S.; Williams, B.L.; Audet, S.; Stancato, L.F.; Gamero, A.; Clouse, K.; Grimley, P.; Weiss, A.; Beeler, J.; Finbloom, D.S.; Shores, E.W.; Abraham, R.; Larner, A.C. 1997: Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling. Nature 390(6660): 629-632
Chen, G-Lin.; Tian, Y-Qiang.; Wu, J-Lin.; Li, N.; Guo, M-Quan. 2016: Antiproliferative activities of Amaryllidaceae alkaloids from Lycoris radiata targeting DNA topoisomerase I. Scientific Reports 6: 38284
Zhang, W.; Zhang, C.; Liu, F.; Mao, Y.; Xu, W.; Fan, T.; Sun, Q.; He, S.; Chen, Y.; Guo, W.; Tan, Y.; Jiang, Y. 2018: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Scientific Reports 8(1): 15753
Xu, X.; Roseblade, A.; Rawling, T.; Ung, A.T. 2020: Antiproliferative activities of tricyclic amides derived from β-caryophyllene via the Ritter reaction against MDA-MB-231 breast cancer cells. Rsc Medicinal Chemistry 11(1): 118-124
Ang, K.P.; Chan, P.F.; Hamid, R.A. 2021: Antiproliferative activity exerted by tricyclohexylphosphanegold(I) n-mercaptobenzoate against MCF-7 and A2780 cell lines: the role of p53 signaling pathways. Biometals: An International Journal on the Role of Metal Ions in Biology Biochemistry and Medicine 34(1): 141-160
Arshad, N.; Yaseen, M.; Hashim, J.; Ullah, I.; Khan, R.; Safi, I.; Rafique, A.; Hanif, Q.-U.-A.; Kulsoom, U.A. 2021: Antiproliferative activity of 3,5-disubstituted tetrahydro-2H-1,3,5-thiadiazine thione (THTT) derivatives and evaluation as potential prodrug. Pakistan Journal of Pharmaceutical Sciences 34(2 Supplary): 773-779
McMicken, H.W.; Bates, P.J.; Chen, Y. 2003: Antiproliferative activity of G-quartet-containing oligonucleotides generated by a novel single-stranded DNA expression system. Cancer Gene Therapy 10(12): 867-869
Benhadji, K.A.; Serova, M.; Ghoul, A.; Cvitkovic, E.; Le Tourneau, C.; Ogbourne, S.M.; Lokiec, F.; Calvo, F.; Hammel, P.; Faivre, S.; Raymond, E. 2008: Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. British Journal of Cancer 99(11): 1808-1815
Haritunians, T.; Mori, A.; O'Kelly, J.; Luong, Q.T.; Giles, F.J.; Koeffler, H.P. 2007: Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21(2): 333-339
Rummun, N.; Serag, A.; Rondeau, P.; Ramsaha, S.; Bourdon, E.; Bahorun, T.; Farag, M.A.; Neergheen, V.S. 2021: Antiproliferative activity of Syzygium coriaceum, an endemic plant of Mauritius, with its UPLC-MS metabolite fingerprint: a mechanistic study. Plos one 16(6): E0252276
Fouotsa, H.; Dzoyem, J.Paul.; Lannang, A.Meli.; Stammler, H-Georg.; Mbazoa, C.Djama.; Luhmer, M.; Nkengfack, A.Ephrem.; Allémann, Éric.; Delie, F.; Meyer, F.; Sewald, N. 2020: Antiproliferative activity of a new xanthone derivative from leaves of Garcinia nobilis Engl. Natural Product Research 2020: 1-8
Cogoi, S.; Ballico, M.; Bonora, G-Maria.; Xodo, L.E. 2004: Antiproliferative activity of a triplex-forming oligonucleotide recognizing a Ki-ras polypurine/polypyrimidine motif correlates with protein binding. Cancer Gene Therapy 11(7): 465-476
Martino, R.; Barreiro Arcos, Mía.Laura.; Peralta, I.; Marrassini, C.; Saint Martin, E.Malén.; Cogoi, L.; Cremaschi, G.; Alonso, Mía.Rosario.; Anesini, C. 2021: Antiproliferative activity of aqueous and polyphenol-rich extracts of Larrea divaricata Cav. on a melanoma cell line. Natural Product Research 2021: 1-4
Takebayashi, Y.; Pourquier, P.; Zimonjic, D.B.; Nakayama, K.; Emmert, S.; Ueda, T.; Urasaki, Y.; Kanzaki, A.; Akiyama, S.I.; Popescu, N.; Kraemer, K.H.; Pommier, Y. 2001: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nature Medicine 7(8): 961-966
Jilani, H.èn.; Cilla, A.; Barberá, R.; Hamdi, M. 2020: Antiproliferative activity of green, black tea and olive leaves polyphenols subjected to biosorption and in vitro gastrointestinal digestion in Caco-2 cells. Food Research International 136: 109317
Soh, Désiré.; Ernestine, N.; Tchana Satchet, E.Marthe.; Defokou, U.Dzo.; Schneider, B.; Giovanni, V.; Nyassé, Bélemy. 2021: Antiproliferative activity of semisynthetic xylopic acid derivatives. Natural Product Research 2021: 1-8
De Paula, J.és.C.; Bakoshi, A.B.K.; Lazarin-Bidóia, D.; Ud Din, Z.; Rodrigues-Filho, E.; Ueda-Nakamura, T.; Nakamura, C.V. 2020: Antiproliferative activity of the dibenzylideneacetone derivate (E)-3-ethyl-4-(4-nitrophenyl)but‑3-en-2-one in Trypanosoma cruzi. Acta Tropica 211: 105653
Guerrero-Pepinosa, N.Y.; Cardona-Trujillo, M.ía.C.; Garzón-Castaño, S.C.; Veloza, L.A.; Sepúlveda-Arias, J.C. 2021: Antiproliferative activity of thiazole and oxazole derivatives: a systematic review of in vitro and in vivo studies. Biomedicine and PharmacoTherapy 138: 111495
de Araújo, Jé.Ismael.F.; Aires, Nália.L.; Almeida-Neto, F.W.Q.; Marinho, Márcia.M.; Marinho, E.M.; Paula Magalhães, E.; de Menezes, R.R.P.P.B.; Sampaio, T.L.; Maria Costa Martins, A.; Teixeira, E.H.; Rafaela Freitas Dotto, A.; Amaral, W.do.; Teixeira, A.Magno.R.; de Lima-Neto, P.; Marinho, E.S.; Dos Santos, Hélcio.S. 2021: Antiproliferative activity on Trypanosoma cruzi (Y strain) of the triterpene 3β,6β,16β-trihidroxilup-20 (29)-ene isolated from Combretum leprosum. Journal of Biomolecular Structure and Dynamics 2021: 1-14
Omar, A.-M.M.E.; AboulWafa, O.M.; Amr, M.E.; El-Shoukrofy, M.S. 2021: Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells. Bioorganic Chemistry 109: 104752
Lv, Y.; Zheng, J.; Zhou, Q.; Jia, L.; Wang, C.; Liu, N.; Zhao, H.; Ji, H.; Li, B.; Cao, W. 2017: Antiproliferative and Apoptosis-inducing Effect of exo-Protoporphyrin IX based Sonodynamic Therapy on Human Oral Squamous Cell Carcinoma. Scientific Reports 7: 40967
Sarigul Sezenoz, A.; Akkoyun, I.; Helvacioglu, F.; Haberal, N.; Dagdeviren, A.; Bacanli, D.; Yilmaz, G.; Oto, S. 2021: Antiproliferative and Mitochondrial Protective Effects of Apigenin in an Oxygen-Induced Retinopathy in Vivo Mouse Model. Journal of Ocular Pharmacology and Therapeutics: the Official Journal of the Association for Ocular Pharmacology and Therapeutics 37(10): 580-590
Xiang, L.; Yi, X.; Wang, Y.; He, X. 2016: Antiproliferative and anti-inflammatory polyhydroxylated spirostanol saponins from Tupistra chinensis. Scientific Reports 6: 31633
Serrano-Márquez, L.; Trigos, Án.; Couttolenc, A.; Padrón, J.é M.; Shnyreva, A.V.; Mendoza, G. 2021: Antiproliferative and antibacterial activity of extracts of Ganoderma strains grown in vitro. Food Science and Biotechnology 30(5): 711-721
Popescu, R.; Filimon, M.N.; Vlad, D.C.; Verdes, D.; Moatar, A.; Moise, G.; Guran, K.; Caraba, I.V.; Ciochina, L.P.; Pinzaru, I.; Dehelean, C.A.; Dumitrescu, G. 2021: Antiproliferative and antibacterial potential of tetrahexylammonium bromide-based ionic liquids. Experimental and Therapeutic Medicine 22(1): 672
Olar, R.; Badea, M.; Bacalum, M.; Răileanu, M.; Ruţă, L.L.; Farcaşanu, I.C.; Rostas, A.M.; Vlaicu, I.D.; Popa, M.; Chifiriuc, M.C. 2021: Antiproliferative and antibacterial properties of biocompatible copper(II) complexes bearing chelating N,N-heterocycle ligands and potential mechanisms of action. Biometals: An International Journal on the Role of Metal Ions in Biology Biochemistry and Medicine 34(5): 1155-1172
Kulmány, Ág.E.; Frank, Év.; Kovács, D.ór.; Kirisits, K.; Krupitza, G.; Neuperger, P.íc.; Alföldi, R.ób.; Puskás, L.ás.ó G.; Szebeni, G.áb.J.; Zupkó, I.án. 2021: Antiproliferative and antimetastatic characterization of an exo-heterocyclic androstane derivative against human breast cancer cell lines. Biomedicine and PharmacoTherapy 140: 111728
Reza, A.S.M.A.; Haque, M.A.; Sarker, J.; Nasrin, M.S.; Rahman, M.M.; Tareq, A.M.; Khan, Z.; Rashid, M.; Sadik, M.G.; Tsukahara, T.; Alam, A.K. 2021: Antiproliferative and antioxidant potentials of bioactive edible vegetable fraction of Achyranthes ferruginea Roxb. in cancer cell line. Food Science and Nutrition 9(7): 3777-3805
Maduraiveeran, H.; Raja, K.; Chinnasamy, A. 2021: Antiproliferative and antioxidant properties of nematocysts crude venom from jellyfish Acromitus flagellatus against human cancer cell lines. Saudi Journal of Biological Sciences 28(3): 1954-1961
Laghchioua, F.E.; Kouakou, A.; Eddahmi, M.; Viale, M.; Monticone, M.; Gangemi, R.; Maric, I.; El Ammari, L.; Saadi, M.; Baltas, M.; Kandri Rodi, Y.; Rakib, E.M. 2020: Antiproliferative and apoptotic activity of new indazole derivatives as potential anticancer agents. Archiv der Pharmazie 353(12): E2000173
Ghosh, S.K.; Sanyal, T. 2020: Antiproliferative and apoptotic effect of ethanolic extract of Calocybe indica on PANC-1 and MIAPaCa2 cell lines of pancreatic cancer. Experimental Oncology 42(3): 178-182
Palanivel, S.; Murugesan, A.; Subramanian, K.; Yli-Harja, O.; Kandhavelu, M. 2020: Antiproliferative and apoptotic effects of indole derivative, N-(2-hydroxy-5-nitrophenyl (4'-methylphenyl) methyl) indoline in breast cancer cells. European Journal of Pharmacology 881: 173195
Molčanová, L.; Kauerová, T.; Dall'Acqua, S.; Maršík, P.; Kollár, P.; Šmejkal, K. 2021: Antiproliferative and cytotoxic activities of C-Geranylated flavonoids from Paulownia tomentosa Steud. Fruit. Bioorganic Chemistry 111: 104797
Fernández, J.; Silván, B.; Entrialgo-Cadierno, R.; Villar, C.J.; Capasso, R.; Uranga, J.é A.; Lombó, F.; Abalo, R. 2021: Antiproliferative and palliative activity of flavonoids in colorectal cancer. Biomedicine and PharmacoTherapy 143: 112241
Jin, L.; Tabe, Y.; Kimura, S.; Zhou, Y.; Kuroda, J.; Asou, H.; Inaba, T.; Konopleva, M.; Andreeff, M.; Miida, T. 2011: Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. British Journal of Cancer 104(1): 91-100
Nguyen, V.T. 2021: Antiproliferative capacity of combined extracts from Paramignya trimera and Phyllanthus amarus against cancer cell lines. Journal of Cancer Research and Therapeutics 17(2): 471-476
Zhou, G.-Z.; Guo, S.-S.; Liu, D.-X.; Zhang, L.; Sun, G.-C. 2020: Antiproliferative effect and autophagy induction of curcumin derivative ZYX02-Na on the human lung cancer cells A549. Journal of Biochemical and Molecular Toxicology 34(12): E22592
Thiagarajan, K.; Mohan, S.; Roy, T.Kumar.; Chandrasekaran, R. 2020: Antiproliferative effect of Acacia nilotica (L.) leaf extract rich in ethyl gallate against human carcinoma cell line KB. Indian Journal of Pharmacology 52(6): 488-494
Kolodziej, M.A.; Gött, H.; Kopischke, B.; Bender, M.K.F.; Weigand, M.A.; Di Fazio, P.; Schwarm, F.P.; Uhle, F. 2021: Antiproliferative effect of GTS-21 in glioblastoma cells. Oncology Letters 22(5): 759
Kouhpayeh, S.; Einizadeh, A.R.; Hejazi, Z.; Boshtam, M.; Shariati, L.; Mirian, M.; Darzi, L.; Sojoudi, M.; Khanahmad, H.; Rezaei, A. 2016: Antiproliferative effect of a synthetic aptamer mimicking androgen response elements in the LNCaP cell line. Cancer Gene Therapy 23(8): 254-257
Hernández-Padilla, L.; Reyes de la Cruz, H.; Campos-García, J.ús. 2020: Antiproliferative effect of bacterial cyclodipeptides in the Hela line of human cervical cancer reveals multiple protein kinase targeting, including mTORC1/C2 complex inhibition in a TSC1/2-dependent manner. Apoptosis: An International Journal on Programmed Cell Death 25(9-10): 632-647
Zuckerman, L.M.; Frames, W.L.; Mirshahidi, H.R.; Williams, N.L.; Shields, T.G.; Otoukesh, S.; Mirshahidi, S. 2020: Antiproliferative effect of bupivacaine on patient-derived sarcoma cells. Molecular and Clinical Oncology 13(3): 7
Correa, M.G.; Couto, J.S.; Trindade, B.B.; Abreu, J.P.; Nakajima, V.M.; Oliveira, F.L.; Farah, A.; Teodoro, A.J. 2020: Antiproliferative effect of guava fruit extracts in MDA-MB-435 and MCF-7 human breast cancer cell lines. Anais da Academia Brasileira de Ciencias 92(2): E20191500
Koning, G.A.; Gorter, A.; Scherphof, G.L.; Kamps, J.A. 1999: Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells. British Journal of Cancer 80(11): 1718-1725
Casulari, L.A.; Dondi, D.; Pratesi, G.; Piva, F.; Milani, M.; Piccolella, M.; Maggi, R. 2020: Antiproliferative effect of mifepristone (RU486) on human neuroblastoma cells (SK-N-SH): in vitro and in vivo studies. Brazilian Journal of Medical and Biological Research 53(11): E10067
Wang, R.; Li, Y.; Dehaen, W. 2020: Antiproliferative effect of mitochondria-targeting allobetulin 1,2,3-triazolium salt derivatives and their mechanism of inducing apoptosis of cancer cells. European Journal of Medicinal Chemistry 207: 112737
Vermeulen, K.; Strnad, M.; Krystof, V.; Havlícek, L.; Van der Aa, A.; Lenjou, M.; Nijs, G.; Rodrigus, I.; Stockman, B.; van Onckelen, H.; Van Bockstaele, D.R.; Berneman, Z.N. 2002: Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases. Leukemia 16(3): 299-305
Wang, C.; Xu, H.; Wang, Y. 2021: Antiproliferative effect of secofriedelanophyllemblicine, a triterpenoid present in the roots of Phyllanthus emblica L. Natural Product Research 2021: 1-5
Chabbert-de Ponnat, I.; Buffard, Vérie.; Leroy, K.; Bagot, M.; Bensussan, A.; Wolkenstein, P.; Marie-Cardine, A. 2006: Antiproliferative effect of semaphorin 3F on human melanoma cell lines. Journal of Investigative Dermatology 126(10): 2343-2345
Moosavi, F.; Ebadi, A.; Mohabbati, M.; Damghani, T.; Mortazavi, M.; Miri, R.; Firuzi, O. 2021: Antiproliferative effect, alteration of cancer cell cycle progression and potential MET kinase inhibition induced by 3,4-dihydropyrimidin-2(1H)-one C5 amide derivatives. European Journal of Pharmacology 894: 173850
Chen, T.; Zhang, J.; Zeng, H.; Zhang, Y.; Zhang, Y.; Zhou, X.; Zhou, H. 2020: Antiproliferative effects of L-asparaginase in acute myeloid leukemia. Experimental and Therapeutic Medicine 20(3): 2070-2078
del Rio, M.; Sunkel, C.; Larcher, F.; Ortega, M.P. 1997: Antiproliferative effects of PCA-4230, a new antithrombotic drug, in vascular smooth muscle cells. British Journal of Pharmacology 120(7): 1360-1366
Eroglu Ozkan, E.; Seyhan, M.F.; Kurt Sirin, O.; Yilmaz-Ozden, T.; Ersoy, E.; Hatipoglu Cakmar, S.D.; Goren, A.C.; Yilmaz Aydogan, H.; Ozturk, O. 2021: Antiproliferative effects of Turkish pomegranate (Punica granatum L.) extracts on MCF-7 human breast cancer cell lines with focus on antioxidant potential and bioactive compounds analyzed by LC-MS/MS. Journal of Food Biochemistry 45(9): E13904
Matalińska, J.; Świć, A.; Lipiński, P.; Misicka, A. 2020: Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells. Folia Neuropathologica 58(3): 237-244
Tronstad, K.J.; Bruserud, Ø.; Berge, K.; Berge, R.K. 2002: Antiproliferative effects of a non-beta-oxidizable fatty acid, tetradecylthioacetic acid, in native human acute myelogenous leukemia blast cultures. Leukemia 16(11): 2292-2301
Ding, Q.; Wu, R.A.; Shi, T.; Yu, Y.; Yan, Y.; Sun, N.; Sheikh, A.R.; Luo, L.; He, R.; Ma, H. 2021: Antiproliferative effects of mealworm larvae (Tenebrio molitor) aqueous extract on human colorectal adenocarcinoma (Caco-2) and hepatocellular carcinoma (HepG2) cancer cell lines. Journal of Food Biochemistry 45(7): E13778
Meireles, C.G.; Lourenço de Lima, C.; Martins de Paula Oliveira, M.; Abe da Rocha Miranda, R.; Romano, L.; Yo-Stella Brashaw, T.; Neves da Silva Guerra, E.; de Assis Rocha Neves, F.; Chapple, J.P.; Simeoni, L.A.; Lofrano-Porto, A. 2022: Antiproliferative effects of metformin in cellular models of pheochromocytoma. Molecular and Cellular Endocrinology 539: 111484
Irace, C.; Misso, G.; Capuozzo, A.; Piccolo, M.; Riccardi, C.; Luchini, A.; Caraglia, M.; Paduano, L.; Montesarchio, D.; Santamaria, R. 2017: Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action. Scientific Reports 7: 45236
Serova, M.; Galmarini, C.M.; Ghoul, A.; Benhadji, K.; Green, S.R.; Chiao, J.; Faivre, S.; Cvitkovic, E.; Le Tourneau, C.; Calvo, F.; Raymond, E. 2007: Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. British Journal of Cancer 97(5): 628-636
Barnouin, K.; Fredersdorf, S.; Eddaoudi, A.; Mittnacht, S.; Pan, L.X.; Du, M.Q.; Lu, X. 1999: Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells. Oncogene 18(46): 6388-6397
Arango-Varela, S.S.; Luzardo-Ocampo, I.; Reyes-Dieck, C.; Yahia, E.M.; Maldonado-Celis, M.E. 2021: Antiproliferative potential of Andean Berry (Vaccinium meridionale Swartz) juice in combination with Aspirin in human SW480 colon adenocarcinoma cells. Journal of Food Biochemistry 45(6): E13760
Hamed, A.N.E.; Abdelaty, N.A.; Attia, E.Z.; Amin, M.N.; Ali, T.F.S.; Afifi, A.H.; Abdelmohsen, U.R.; Desoukey, S.Y. 2021: Antiproliferative potential of moluccella laevis L. aerial parts family lamiaceae (labiatae), supported by phytochemical investigation and molecular docking study. Natural Product Research 2021: 1-5
Li, N.; Wen, S.; Chen, G.; Wang, S. 2021: Antiproliferative potential of piperine and curcumin in drug-resistant human leukemia cancer cells are mediated via autophagy and apoptosis induction, S-phase cell cycle arrest and inhibition of cell invasion and migration. Journal of Buon: Official Journal of the Balkan Union of Oncology 26(3): 1181
Ogami, K.; Hosoda, N.; Funakoshi, Y.; Hoshino, S. 2014: Antiproliferative protein Tob directly regulates c-myc proto-oncogene expression through cytoplasmic polyadenylation element-binding protein CPEB. Oncogene 33(1): 55-64
Zhaorigetu; Farrag, I.M.; Belal, A.; Badawi, M.H.A.; Abdelhady, A.A.; Galala, F.M.A.A.; El-Sharkawy, A.; El-Dahshan, A.A.; Mehany, A.B.M. 2021: Antiproliferative, Apoptotic Effects and Suppression of Oxidative Stress of Quercetin against Induced Toxicity in Lung Cancer Cells of Rats: in vitro and in vivo Study. Journal of Cancer 12(17): 5249-5259
Frâncica, L.S.; Gonçalves, E.V.; Santos, A.A.; Vicente, Y.S.; Silva, T.S.; Gonzalez, R.S.; Almeida, P.M.; Feitoza, L.L.; Bueno, P.A.A.; Souza, D.C.; Peron, A.P. 2021: Antiproliferative, genotoxic and mutagenic potential of synthetic chocolate food flavoring. Brazilian Journal of Biology 82: E243628
Khan, I.I.; Karshieva, S.S.; Sokolova, D.V.; Spirina, T.S.; Zolottsev, V.A.; Latysheva, A.S.; Anisimova, N.Y.; Komarova, M.V.; Yakunina, M.N.; Nitetskaya, T.A.; Misharin, A.Y.; Pokrovsky, V.S. 2022: Antiproliferative, proapoptotic, and tumor-suppressing effects of the novel anticancer agent alsevirone in prostate cancer cells and xenografts. Archiv der Pharmazie 355(1): E2100316
Huang, Y.-S.; Mao, J.-X.; Zhang, L.; Guo, H.-W.; Yan, C.; Chen, M. 2021: Antiprostate Cancer Activity of Ineupatolide Isolated from Carpesium cernuum L. Biomed Research International 2021: 5515961
Liern, M.; Colazo, A.; Vallejo, G.; Zotta, E. 2021: Antiproteinuric action of amiloride in paediatric patient with corticoresistant nephrotic syndrome. Nefrologia 41(3): 304-310
Liern, M.; Colazo, A.; Vallejo, G.; Zotta, E. 2021: Antiproteinuric action of amiloride in paediatric patient with corticoresistant nephrotic syndrome. Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 2021
Nicotera, R.; Casarella, A.; Longhitano, E.; Bolignano, D.; Andreucci, M.; De Sarro, G.; Cernaro, V.; Russo, E.; Coppolino, G. 2020: Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases. Pharmacological Research 159: 105019
Kino, J.; Tsuji, S.; Kitao, T.; Akagawa, Y.; Yamanouchi, S.; Kimata, T.; Kaneko, K. 2018: Antiproteinuric effect of an endothelin-1 receptor antagonist in puromycin aminonucleoside-induced nephrosis in rat. Pediatric Research 83(5): 1041-1048
Fujita, T.; Ando, K.; Nishimura, H.; Ideura, T.; Yasuda, G.; Isshiki, M.; Takahashi, K. 2007: Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney International 72(12): 1543-1549
Staessen, J.A. 2008: Antiproteinuric effects of cilnidipine. Kidney International 73(9): 1095; Author Reply 1095-6
Wolf, G. 2008: Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis. Nature Clinical Practice. Nephrology 4(9): 474-475
Chayoua, W.; Nicolson, P.L.R.; Meijers, J.C.M.; Kardeby, C.; Garcia-Quintanilla, L.; Devreese, K.M.J.; de Laat, B.; Watson, S.P.; de Groot, P.G. 2021: Antiprothrombin antibodies induce platelet activation: a possible explanation for anti-FXa therapy failure in patients with antiphospholipid syndrome?. Journal of Thrombosis and Haemostasis: Jth 19(7): 1776-1782
Kavanagh, J.N.; Currell, F.J.; Timson, D.J.; Savage, K.I.; Richard, D.J.; McMahon, S.J.; Hartley, O.; Cirrone, G.A.P.; Romano, F.; Prise, K.M.; Bassler, N.; Holzscheiter, M.H.; Schettino, G. 2013: Antiproton induced DNA damage: proton like in flight, carbon-ion like near rest. Scientific Reports 3: 1770
Elso, O.G.; Clavin, M.; Hernandez, N.; Sgarlata, Tás.; Bach, Hán.; Catalan, César.A.N.; Aguilera, E.; Alvarez, G.; Sülsen, V.P. 2021: Antiprotozoal Compounds from Urolepis hecatantha (Asteraceae). Evidence-BasedComplementaryandAlternativeMedicine:Ecam 2021: 6622894
Ababu, A.; Endashaw, D.; Fesseha, H.; Mathewos, M. 2021: Antiprotozoal Drug Handling and Management Practices in Asella District, Central Oromia, Ethiopia. Veterinary Medicine International 2021: 6648328
Nossa González, D.L.; Gómez Castaño, J.A.; Rozo Núñez, W.E.; Duchowicz, P.R. 2021: Antiprotozoal QSAR modelling for trypanosomiasis (Chagas disease) based on thiosemicarbazone and thiazole derivatives. Journal of Molecular Graphics and Modelling 103: 107821
Phillipson, J.D.; Wright, C.W. 1991: Antiprotozoal agents from plant sources. Planta Medica 57(7 Suppl): S53-S59
Fernandes, V.ór.d.S.; da Rosa, R.; Zimmermann, L.A.; Rogério, K.R.; Kümmerle, A.E.; Bernardes, L.S.C.; Graebin, C.S. 2022: Antiprotozoal agents: how have they changed over a decade?. Archiv der Pharmazie 355(2): E2100338
El-Bali, M.A.; Abdulhakim, A.; Mohamed, R.T.; El-Malky, M.A.; Bakri, R.A.; Al-Harthi, S.A. 2020: Antiprotozoal potential of Salvadora persica against three virulent subtypes of Blastocystis sp. Journal of Parasitic Diseases: Official Organ of the Indian Society for Parasitology 44(4): 694-701
Chen, X.; Zhu, C.; Zhang, Y.; Yang, N.; Shi, H.; Yang, W.; Yang, Y.; Liang, J.; Chen, L.; Zeng, X.; Cai, R.; Wu, G.; Tang, Z. 2020: Antipruritic Effect of Ethyl Acetate Extract from Fructus cnidii in Mice with 2,4-Dinitrofluorobenzene-Induced Atopic Dermatitis. Evidence-BasedComplementaryandAlternativeMedicine:Ecam 2020: 6981386
Parisi, P.; Barbieri, L.L. 1949: Antipruritic action of riboflavin, vitamin B2, in eczema and other itchy dermatoses. Archivio Italiano di Dermatologia Sifilografia e Venereologia 22(3): 185-192
Yun, J-Won.; Seo, J.A.; Jang, W-Hee.; Koh, H.Ju.; Bae, I-Hong.; Park, Y-Ho.; Lim, K-Min. 2011: Antipruritic effects of TRPV1 antagonist in murine atopic dermatitis and itching models. Journal of Investigative Dermatology 131(7): 1576-1579
Rabiei, M.M.; Asadi, K.; Shokouhi, S.; Nasiri, M.J.; Alavi Darazam, I. 2020: Antipseudomonal β-Lactams Resistance in Iran. International Journal of Microbiology 2020: 8818315
Amigó, M.; Payá, M.; De Rosa, S.; Terencio, M.C. 2007: Antipsoriatic effects of avarol-3'-thiosalicylate are mediated by inhibition of TNF-alpha generation and NF-kappaB activation in mouse skin. British Journal of Pharmacology 152(3): 353-365
Murányi, J. 1971: Antipsychiatry. Lakartidningen 68(14): 1569-1571
Glatzel, J. 1981: Antipsychiatry. Therapie der Gegenwart 120(2): 109-126
Giusti-Rodríguez, P.; Xenakis, J.G.; Crowley, J.J.; Nonneman, R.J.; DeCristo, D.M.; Ryan, A.; Quackenbush, C.R.; Miller, D.R.; Shaw, G.D.; Zhabotynsky, V.; Sullivan, P.F.; Manuel de Villena, F.P.; Zou, F. 2020: Antipsychotic Behavioral Phenotypes in the Mouse Collaborative Cross Recombinant Inbred Inter-Crosses (RIX). G3 10(9): 3165-3177
Takeuchi, H.; MacKenzie, N.E.; Samaroo, D.; Agid, O.; Remington, G.; Leucht, S. 2020: Antipsychotic Dose in Acute Schizophrenia: a Meta-analysis. Schizophrenia Bulletin 46(6): 1439-1458
Feng, R.; Womer, F.Y.; Edmiston, E.K.; Chen, Y.; Wang, Y.; Chang, M.; Yin, Z.; Wei, Y.; Duan, J.; Ren, S.; Li, C.; Liu, Z.; Jiang, X.; Wei, S.; Li, S.; Zhang, X.; Zuo, X.-N.; Tang, Y.; Wang, F. 2020: Antipsychotic Effects on Cortical Morphology in Schizophrenia and Bipolar Disorders. Frontiers in Neuroscience 14: 579139
Singappuli, P.; Sonuga-Barke, E.; Kyriakopoulos, M. 2022: Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions. Cns Spectrums 27(5): 570-587
Kuo, C.-M.; Liao, W.-J.; Huang, C.-C.; Lan, T.-H.; Lin, C.-H.; Wang, S.-P.; Lee, C.-H.; Lui, P.-W. 2020: Antipsychotic Medication in Schizophrenic Patients is Associated with Higher Risks of Developing Bone Fractures and Refractures. Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology 18(4): 562-570
Lohr, W.D.; Jawad, K.; Feygin, Y.; Le, J.; Creel, L.; Pasquenza, N.; Williams, P.G.; Jones, V.F.; Myers, J.; Davis, D.W. 2022: Antipsychotic Medications for Low-Income Preschoolers: Long Duration and Psychotropic Medication Polypharmacy. Psychiatric Services 73(5): 510-517
Ijaz, S.; Blanca Bolea; Davies, S.; Savović, J.; Richards, A.; Sullivan, S.; Moran, P. 2020: Antipsychotic Polypharmacy and Metabolic Syndrome in Schizophrenia: a Review of Systematic Reviews. Focus 18(4): 482-492
Pae, C.-U. 2020: Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?. Chonnam Medical Journal 56(3): 157-165
Doane, M.J.; Sajatovic, M.; Weiden, P.J.; O'Sullivan, A.K.; Maher, S.; Bjorner, J.B.; Sikora Kessler, A.; Carpenter-Conlin, J.; Bessonova, L.; Velligan, D.I. 2020: Antipsychotic Treatment Experiences of people with Schizophrenia: Patient Perspectives from an Online Survey. Patient Preference and Adherence 14: 2043-2054
El Abdellati, K.; De Picker, L.; Morrens, M. 2020: Antipsychotic Treatment Failure: a Systematic Review on Risk Factors and Interventions for Treatment Adherence in Psychosis. Frontiers in Neuroscience 14: 531763
Hernandez, N.M.; Vakharia, R.M.; Mont, M.A.; Roche, M.W.; Seyler, T.M. 2021: Antipsychotic use Is Associated with Longer In-hospital Lengths of Stay and Higher Rates of Venous Thromboembolism and Costs of Care After Primary Total Knee Arthroplasty. Journal of the American Academy of Orthopaedic Surgeons 29(13): E675-E680
Hernandez, N.M.; Vakharia, R.M.; Mont, M.A.; Roche, M.W.; Seyler, T.M. 2021: Antipsychotic use Is Associated with Longer In-hospital Lengths of Stay and Higher Rates of Venous Thromboembolism and Costs of Care After Primary Total Knee Arthroplasty. Journal of the American Academy of Orthopaedic Surgeons 29(13): E675-E680
Brandt, L.; Bschor, T.; Henssler, J.; Müller, M.; Hasan, A.; Heinz, A.; Gutwinski, S. 2020: Antipsychotic Withdrawal Symptoms: a Systematic Review and Meta-Analysis. Frontiers in Psychiatry 11: 569912
Min, K-j.; Seo, B.R.; Bae, Y.C.; Yoo, Y.H.; Kwon, T.K. 2014: Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L). Cell Death and Disease 5: E1063
Henderson, A.; Kinnear, D.; Fleming, M.; Stanley, B.; Greenlaw, N.; Young-Southward, G.; Pell, J.P.; Cooper, S.-A. 2021: Antipsychotic and antidepressant prescribing for 704 297 children and young people with and without intellectual disabilities: record linkage study. British Journal of Psychiatry: the Journal of Mental Science 218(1): 58-62
Ma'u, E.; Burton, J.; Fussell, E. 2021: Antipsychotic and sedative medication use in long-term care facilities providing dementia care. New Zealand Medical Journal 134(1537): 56-65
Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K. 1976: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261(5562): 717-719
Girgis, R.R.; Javitch, J.A.; Lieberman, J.A. 2008: Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Molecular Psychiatry 13(10): 918-929
Thomas, E.A.; George, R.C.; Danielson, P.E.; Nelson, P.A.; Warren, A.J.; Lo, D.; Sutcliffe, J.G. 2003: Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Molecular Psychiatry 8(12): 983
Narayanan, S.; Beusterien, K.M.; Thomas, S.K.; Musher, J.; Strunk, B. 2006: Antipsychotic drug use among nursing home residents taking rivastigmine. Journal of the American Medical Directors Association 7(1): 12-16
Lacruz, A.; Baptista, T.; de Mendoza, S.; Mendoza-Guillén, J.M.; Hernández, L. 2000: Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin and body weight during sulpiride treatment. Molecular Psychiatry 5(1): 70-76
Cope, M.B.; Nagy, T.R.; Fernández, J.R.; Geary, N.; Casey, D.E.; Allison, D.B. 2005: Antipsychotic drug-induced weight gain: development of an animal model. International Journal of Obesity 29(6): 607-614
Byun, N.E.; Grannan, M.; Bubser, M.; Barry, R.L.; Thompson, A.; Rosanelli, J.; Gowrishankar, R.; Kelm, N.D.; Damon, S.; Bridges, T.M.; Melancon, B.J.; Tarr, J.C.; Brogan, J.T.; Avison, M.J.; Deutch, A.Y.; Wess, Jürgen.; Wood, M.R.; Lindsley, C.W.; Gore, J.C.; Conn, P.Jeffrey.; Jones, C.K. 2014: Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 39(7): 1578-1593
Fernø, J.; Raeder, M.B.; Vik-Mo, A.O.; Skrede, S.; Glambek, M.; Tronstad, K-J.; Breilid, H.; Løvlie, R.; Berge, R.K.; Stansberg, C.; Steen, V.M. 2005: Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. Pharmacogenomics Journal 5(5): 298-304
Rammes, G.; Eisensamer, B.; Ferrari, U.; Shapa, M.; Gimpl, G.; Gilling, K.; Parsons, C.; Riering, K.; Hapfelmeier, G.; Bondy, B.; Zieglgänsberger, W.; Holsboer, F.; Rupprecht, R. 2004: Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Molecular Psychiatry 9(9): 846
Weissenrieder, J.S.; Reed, J.L.; Moldovan, G.-L.; Johnson, M.T.; Trebak, M.; Neighbors, J.D.; Mailman, R.B.; Hohl, R.J. 2021: Antipsychotic drugs elicit cytotoxicity in glioblastoma multiforme in a calcium-dependent, non-D2 receptor-dependent, manner. Pharmacology Research and Perspectives 9(3): E00689
Basta-Kaim, A.; Budziszewska, Bława.; Jaworska-Feil, L.; Tetich, M.; Kubera, M.; Leśkiewicz, M.; Otczyk, M.; Lasoń, Władysław. 2006: Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 31(4): 853-865
Huber, M.; Kölzsch, M.; Rapp, M.A.; Wulff, I.; Kalinowski, S.; Bolbrinker, J.; Hofmann, W.; Scholze, J.; Dräger, D.; Kreutz, R. 2012: Antipsychotic drugs predominate in pharmacotherapy of nursing home residents with dementia. Pharmacopsychiatry 45(5): 182-188
Kristiana, I.; Sharpe, L.J.; Catts, V.S.; Lutze-Mann, L.H.; Brown, A.J. 2010: Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol. Pharmacogenomics Journal 10(5): 396-407
Seeman, P.; Tallerico, T. 1998: Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Molecular Psychiatry 3(2): 123-134
Swerdlow, N.R.; Talledo, J.; Sutherland, A.N.; Nagy, D.; Shoemaker, J.M. 2006: Antipsychotic effects on prepulse inhibition in normal 'low gating' humans and rats. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 31(9): 2011-2021
Brylewski, J.; Duggan, L. 2001: Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database of Systematic Reviews 3: Cd000377
Duggan, L.; Brylewski, J. 2001: Antipsychotic medication for those with both schizophrenia and learning disability. Cochrane Database of Systematic Reviews 1: Cd000030
Duggan, L.; Brylewski, J. 2001: Antipsychotic medication for those with both schizophrenia and learning disability. Cochrane Database of Systematic Reviews 2: Cd000030
Duggan, L.; Brylewski, J. 2001: Antipsychotic medication for those with both schizophrenia and learning disability. Cochrane Database of Systematic Reviews 3: Cd000030
Bosqui, T.; Väänänen, A.; Koskinen, A.; Buscariolli, Aé.; O'reilly, D.; Airila, A.; Toivanen, M.; Kouvonen, A. 2020: Antipsychotic medication use among working-age first-generation migrants resident in Finland: An administrative data linkage study. Scandinavian Journal of Public Health 48(1): 64-71
Morrison, A.P.; Pyle, M.; Maughan, D.; Johns, L.; Freeman, D.; Broome, M.R.; Husain, N.; Fowler, D.; Hudson, J.; MacLennan, G.; Norrie, J.; Shiers, D.; Hollis, C.; James, A.; Morrison, A.P.; Pyle, M.; Maughan, D.; Johns, L.; Freeman, D.; Broome, M.R.; Husain, N.; Fowler, D.; Hudson, J.; MacLennan, G.; Norrie, J.; Shiers, D.; Hollis, C.; Birchwood, M.; Bhogal, R.; Bowe, S.; Byrne, R.; Clacey, J.; Davies, L.; Dudley, R.; Emsley, R.; Fialho, R.; Fraser, R.; French, P.; Goodall, T.; Goodby, E.; Haddad, P.; Joyce, E.; Khozoee, N.; Kirkham, M.; Langman, A.; Larkin, A.; Laughton, H.; Liew, A.; Longden, E.; Teale, A.L.; McCartney, L.; Murphy, E.; Padgett, F.; Palmier-Claus, J.; Peters, S.; Sacadura, C.; Smith, J.; Smith, V.; Steele, A.; Upthegrove, 2020: Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. LANCET. Psychiatry 7(9): 788-800
Chang, C.-K.; Chen, P.-H.; Pan, C.-H.; Su, S.-S.; Tsai, S.-Y.; Chen, C.-C.; Kuo, C.-J. 2020: Antipsychotic medications and the progression of upper respiratory infection to pneumonia in patients with schizophrenia. Schizophrenia Research 222: 327-334
Takeuchi, H.; Sanches, M.; Borlido, C.; Agid, O.; Remington, G. 2021: Antipsychotic nonadherence measured by electronic adherence monitoring in stabilized chronic schizophrenia: Clinical implications. Schizophrenia Research 237: 202-207
Stevenson, J.M.; Reilly, J.L.; Harris, M.S.H.; Patel, S.R.; Weiden, P.J.; Prasad, K.M.; Badner, J.A.; Nimgaonkar, V.L.; Keshavan, M.S.; Sweeney, J.A.; Bishop, J.R. 2016: Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes. Translational Psychiatry 6: E739
Azorin, J-Michel.; Simon, N. 2020: Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale. Expert Opinion on Drug Metabolism and Toxicology 16(12): 1175-1186
Howard, R.; Burns, A.; Schneider, L. 2020: Antipsychotic prescribing to people with dementia during COVID-19. LANCET. Neurology 19(11): 892
Imran, S.; Datta, S.S.; Vincent, E.; Whitfield, J.; Clark, A.F. 2011: Antipsychotic prescribing: old wine in new bottles?. Child and Adolescent Mental Health 16(4): 218-221
Vivacqua, M.ía.N.; Abudarham, T.ás.; Pagotto, V.; Faccioli, J.é L. 2021: Antipsychotic prescription prevalence and metabolic monitoring of patients under chronic treatment. Revista de la Facultad de Ciencias Medicas 78(3): 276-282
Joo, S.W.; Kim, H.; Jo, Y.T.; Choi, Y.J.; Ahn, S.; Lee, J. 2023: Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study. Psychological Medicine 53(1): 181-188
Bessonova, L.; Velligan, D.I.; Weiden, P.J.; O'Sullivan, A.K.; Yarlas, A.; Bayliss, M.; Baranwal, N.; Rychlec, K.; Carpenter-Conlin, J.; Doane, M.J.; Sajatovic, M. 2020: Antipsychotic treatment experiences of people with bipolar i disorder: patient perspectives from an online survey. Bmc Psychiatry 20(1): 354
Simmel, C.; Bowden, C.F.; Neese-Todd, S.; Hyde, J.; Crystal, S. 2021: Antipsychotic treatment for youth in foster care: Perspectives on improving youths' experiences in providing informed consent. American Journal of Orthopsychiatry 91(2): 258-270
Bastiampillai, T.; Chan, S.K.W.; Allison, S.; Copolov, D.; Looi, J.C. 2022: Antipsychotic treatment in clinical high risk for psychosis: Iatrogenesis related to dopamine supersensitivity psychosis?. Australian and New Zealand Journal of Psychiatry 56(1): 97
Raballo, A.; Poletti, M.; Preti, A. 2021: Antipsychotic treatment in clinical high risk for psychosis: Protective, iatrogenic or further risk flag?. Australian and New Zealand Journal of Psychiatry 55(5): 442-444
Taipale, H.; Puranen, A.; Mittendorfer-Rutz, E.; Tiihonen, J.; Tanskanen, A.; Cervenka, S.; Lähteenvuo, M. 2020: Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences. Nordic Journal of Psychiatry 2020: 1-8
Di, X.; Chen, M.; Shen, S.; Cui, X. 2021: Antipsychotic use and Risk of Venous Thromboembolism: a Meta-Analysis. Psychiatry Research 296: 113691
Ferraris, A.; Angriman, F.; Szmulewicz, A.G. 2021: Antipsychotic use and psychiatric disorders in COVID-19. LANCET. Healthy Longevity 2(2): E64
Taylor, M.; Dangelo-Kemp, D.; Liu, D.; Kisely, S.; Graham, S.; Hartmann, J.; Colman, S. 2022: Antipsychotic utilisation and persistence in Australia: a nationwide 5-year study. Australian and New Zealand Journal of Psychiatry 56(9): 1155-1163
Garcia-Rizo, C. 2020: Antipsychotic-Induced Weight Gain and Clinical Improvement: a Psychiatric Paradox. Frontiers in Psychiatry 11: 560006
Ibi, D.; de la Fuente Revenga, M.; Kezunovic, N.; Muguruza, C.; Saunders, J.M.; Gaitonde, S.A.; Moreno, Jé.L.; Ijaz, M.K.; Santosh, V.; Kozlenkov, A.; Holloway, T.; Seto, J.; García-Bea, A.; Kurita, M.; Mosley, G.E.; Jiang, Y.; Christoffel, D.J.; Callado, L.F.; Russo, S.J.; Dracheva, S.; López-Giménez, J.F.; Ge, Y.; Escalante, C.R.; Meana, J.Javier.; Akbarian, S.; Huntley, G.W.; González-Maeso, J. 2017: Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects. Nature Neuroscience 20(9): 1247-1259
Ali, T.; Sisay, M.; Tariku, M.; Mekuria, A.N.; Desalew, A. 2021: Antipsychotic-induced extrapyramidal side effects: a systematic review and meta-analysis of observational studies. Plos one 16(9): E0257129
May, M.; Slitzky, M.; Rostama, B.; Barlow, D.; Houseknecht, K.L. 2020: Antipsychotic-induced immune dysfunction: A consideration for COVID-19 risk. BrainBehaviorandImmunity-Health 6: 100097
Lugg, W. 2022: Antipsychotic-induced supersensitivity - a reappraisal. Australian and New Zealand Journal of Psychiatry 56(5): 437-444
Bakker, P.R.; van Harten, P.N.; van Os, J. 2008: Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Molecular Psychiatry 13(5): 544-556
Crowley, J.J.; Adkins, D.E.; Pratt, A.L.; Quackenbush, C.R.; van den Oord, E.J.; Moy, S.S.; Wilhelmsen, K.C.; Cooper, T.B.; Bogue, M.A.; McLeod, H.L.; Sullivan, P.F. 2012: Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. Pharmacogenomics Journal 12(2): 147-155
Ior, L.D.; Otimenyin, S.O.; Okwuasaba, F.K. 2021: Antipsychotic-like effect of ethyl acetate fraction of Terminalia macroptera leaf in mice. Ibro Neuroscience Reports 10: 83-89
Takakuwa, M.; Watanabe, Y.; Saijo, T.; Murata, M.; Anabuki, J.; Tezuka, T.; Sato, S.; Kojima, K.; Hashimoto, K. 2020: Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats. Pharmacology Biochemistry and Behavior 196: 172972
Bortolato, M.; Frau, R.; Orrù, M.; Bourov, Y.; Marrosu, F.; Mereu, G.; Devoto, P.; Gessa, G.L. 2008: Antipsychotic-like properties of 5-alpha-reductase inhibitors. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 33(13): 3146-3156
Bardin, L.; Kleven, M.S.; Barret-Grévoz, C.; Depoortère, R.; Newman-Tancredi, A. 2006: Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 31(9): 1869-1879
Hieronymus, F.; Kølbæk, P.; Correll, C.U.; Østergaard, Søren.D. 2021: Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis. Npj Schizophrenia 7(1): 41
Johnson, S.T. 1997: Antipsychotics. Rn 60(8): 45-49; Quiz 50
Umeda, K. 2011: Antipsychotics. Chudoku Kenkyu: Chudoku Kenkyukai Jun Kikanshi 24(4): 311-317
Remington, G.; Kapur, S. 2020: Antipsychotics Circa 2020: what are we thinking?. Neuropharmacology 175: 108181
Cohen, T.; Sundaresh, S.; Levine, F. 2013: Antipsychotics activate the TGFβ pathway effector SMAD3. Molecular Psychiatry 18(3): 347-357
Lao, K.S.J.; Zhao, J.; Blais, J.E.; Lam, L.; Wong, I.C.K.; Besag, F.M.C.; Chang, W.C.; Castle, D.J.; Chan, E.W. 2020: Antipsychotics and Risk of Neuroleptic Malignant Syndrome: a Population-Based Cohort and Case-Crossover Study. Cns Drugs 34(11): 1165-1175
Sutar, R.; Atlani, M.K.; Chaudhary, P. 2021: Antipsychotics and hemodialysis: a systematic review. Asian Journal of Psychiatry 55: 102484
Taylor, D.; Horowitz, M.A. 2020: Antipsychotics and mortality - more clarity needed. Psychological Medicine 50(16): 2814-2815
Davey, K.J.; Cotter, P.D.; O'Sullivan, O.; Crispie, F.; Dinan, T.G.; Cryan, J.F.; O'Mahony, S.M. 2013: Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Translational Psychiatry 3: E309
Mainio, A.; Kuusisto, L.; Hakko, Hä.; Riipinen, P. 2020: Antipsychotics as a method of suicide: population based follow-up study of suicide in Northern Finland. Nordic Journal of Psychiatry 2020: 1-5
Nielsen, J.; Skadhede, Søren.; Correll, C.U. 2010: Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 35(9): 1997-2004
Richelson, E. 1977: Antipsychotics block muscarinic acetylcholine receptor-mediated cyclic GMP formation in cultured mouse neuroblastoma cells. Nature 266(5600): 371-373
Badran, A.; Tul-Wahab, A.; Zafar, H.; Mohammad, N.; Imad, R.; Ashfaq Khan, M.; Baydoun, E.; Choudhary, M.I. 2020: Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro. Plos one 15(8): E0235676
Tierney, E.; Arnold, L.Eugene. 2008: Antipsychotics for aggressive behavior in patients with intellectual disability--an acceptable standard of care?. Nature Clinical Practice. Neurology 4(8): 418-419
Sabe, M.; Zhao, N.; Crippa, A.; Kaiser, S. 2021: Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials. Npj Schizophrenia 7(1): 43
Dervaux, A. 2020: Antipsychotics for schizophrenia and substance misuse. Lancet 395(10241): 1902
Ballard, C.; Fossey, J.; Sharp, S. 2007: Antipsychotics in patients with Alzheimer's disease--what is their clinical value?. Nature Clinical Practice. Neurology 3(5): 248-249
Albert, U. 2020: Antipsychotics in pregnancy: balancing between risks of untreated illness and risks of drug-related adverse effects. Reproductive Toxicology 97: 1
Polho, G.B.; Cardillo, G.M.; Kerr, D.S.; Chile, T.; Gattaz, W.F.; Forlenza, O.V.; Brentani, H.P.; De-Paula, V.J. 2022: Antipsychotics preserve telomere length in peripheral blood mononuclear cells after acute oxidative stress injury. Neural Regeneration Research 17(5): 1156-1160
Bak, M.; Drukker, M.; Cortenraad, S.; Vandenberk, E.; Guloksuz, S. 2021: Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: a meta-analysis. Plos one 16(2): E0244944
Beumer, S.; Hamers, P.; Oppewal, A.; Maes-Festen, D. 2021: Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial. Bmc Psychiatry 21(1): 439
Young, A.H.; Jauhar, S. 2021: Antipsychotics, the heartland of clinical psychopharmacology?. Journal of Psychopharmacology 35(9): 1027-1029
Williamson, J.; Rudge, E.A. 1948: Antipyretic action and catalase activity. Biochemical Journal 43(1): 15
Ten CATE, J.; Knoppers, A.T. 1946: Antipyretic action of some cinchona alkaloids on rats. Archives Internationales de Pharmacodynamie et de Therapie 72: 224-231
Xu, X.-R.; Tang, J.-F.; Zhang, H.; Ran, F.; Liao, W.; Wang, F.; Yang, X.-B.; Lin, J.-Z.; Yang, M.; Zhang, D.-K.; Han, L. 2021: Antipyretic activity and potential mechanism of Indigo Naturalis on 2,4-dinitrophenol-induced fever rat model. Zhongguo Zhong Yao Za Zhi 46(13): 3205-3212
Emon, N.U.; Alam, S.; Rudra, S.; Haidar, I.K.A.; Farhad, M.; Rana, M.E.H.; Ganguly, A. 2021: Antipyretic activity of Caesalpinia digyna (Rottl.) leaves extract along with phytoconstituent's binding affinity to COX-1, COX-2, and mPGES-1 receptors: in vivo and in silico approaches. Saudi Journal of Biological Sciences 28(9): 5302-5309
Oudart, N. 1999: Antipyretics. Revue de l'Infirmiere 47: 49-51
De Juan Martín, F. 1988: Antipyretics in pediatric practice. Anales Espanoles de Pediatria 29(Suppl 32): 205-208
Piroli, R.J.; Passananti, G.T.; Shively, C.A.; Vesell, E.S. 1981: Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia. Clinical Pharmacology and Therapeutics 30(6): 810-816
Sonne, J.; Døssing, M.; Loft, S.; Andreasen, P.B. 1985: Antipyrine clearance in pneumonia. Clinical Pharmacology and Therapeutics 37(6): 701-704
Bodendorf, K.; Raaf, H. 1955: Antipyrine derivatives of ethylenedia. Arzneimittel-Forschung 5(12): 695-698
Berlin, C.M.; Vesell, E.S. 1982: Antipyrine disposition in milk and saliva of lactating women. Clinical Pharmacology and Therapeutics 31(1): 38-44
Wensing, G.; Ohnhaus, E.E.; Hoensch, H.P. 1990: Antipyrine elimination and hepatic microsomal enzyme activity in patients with liver disease. Clinical Pharmacology and Therapeutics 47(6): 698-705
Mehta, M.U.; Venkataramanan, R.; Burckart, G.J.; Ptachcinski, R.J.; Yang, S.L.; Gray, J.A.; Van Thiel, D.H.; Starzl, T.E. 1986: Antipyrine kinetics in liver disease and liver transplantation. Clinical Pharmacology and Therapeutics 39(4): 372-377
Riester, E.F.; Pantuck, E.J.; Pantuck, C.B.; Passananti, G.T.; Vesell, E.S.; Conney, A.H. 1980: Antipyrine metabolism during the menstrual cycle. Clinical Pharmacology and Therapeutics 28(3): 384-391
Watzman, H. 2005: Antiquities fraud: reality check. Nature 434(7029): 13-15
Rössner, G.E.; Costeur, L.ïc.; Scheyer, T.M. 2020: Antiquity and fundamental processes of the antler cycle in Cervidae (Mammalia). Die Naturwissenschaften 108(1): 3
Tiemei, C.; Quan, Y.; En, W. 1994: Antiquity of Homo sapiens in China. Nature 368(6466): 55-56
Spolsky, C.M.; Phillips, C.A.; Uzzell, T. 1992: Antiquity of clonal salamander lineages revealed by mitochondrial DNA. Nature 356(6371): 706-708
Tarduno, J.A.; Watkeys, M.K.; Huffman, T.N.; Cottrell, R.D.; Blackman, E.G.; Wendt, A.; Scribner, C.A.; Wagner, C.L. 2015: Antiquity of the South Atlantic Anomaly and evidence for top-down control on the geodynamo. Nature Communications 6: 7865
Ruben, J.A.; Bennett, A.F. 1980: Antiquity of the vertebrate pattern of activity metabolism and its possible relation to vertebrate origins. Nature 286(5776): 886-888
Robinson, K.; Drame, I.; Turner, M.R.; Brown, C. 2021: Developing the "Upstreamist" through Antiracism Teaching in Pharmacy Education. American Journal of Pharmaceutical Education 85(9): 8585
Gouvea, J.S. 2021: Antiracism and the Problems with "Achievement Gaps" in STEM Education. Cbe Life Sciences Education 20(1): Fe2
Avakame, E.F.; October, T.W.; Dixon, G.L. 2021: Antiracism in Academic Medicine: Fixing the Leak in the Pipeline of Black Physicians. Ats Scholar 2(2): 193-201
Vora, S. 2020: Antiracism: a new Simulation Frontier. Simulation in Healthcare: Journal of the Society for Simulation in Healthcare 15(4): 223-224
Fletcher, F.E.; Jiang, W.; Best, A.L. 2021: Antiracist Praxis in Public Health: a Call for Ethical Reflections. Hastings Center Report 51(2): 6-9
Sergazy, S.; Gulyayev, A.; Amangeldiyeva, A.; Nurgozhina, A.; Nurgaziyev, M.; Shulgau, Z.; Chulenbayeva, L.; Khassenbekova, Z.; Kushugulova, A.; Aljofan, M. 2021: Antiradical and Cytoprotective Properties of Allium nutans L. Honey Against CCL4-Induced Liver Damage in Rats. Frontiers in Pharmacology 12: 687763
Kwok, J.S.Y.; Leung, A.Y.H.; Lie, A.K.W.; Lee, T.L.; Lau, Y.L.; Chu, P.; Jones, B.; Hawkins, B.; Liang, R. 2004: Antirecipient helper and cytotoxic T-cell frequencies in bone marrow transplantation. Bone Marrow Transplantation 34(3): 207-213
Zhao, Z.C.; McKenzie, D.R. 2017: Antireflection coating of barriers to enhance electron tunnelling: exploring the matter wave analogy of superluminal optical phase velocity. Scientific Reports 7(1): 12772
Debourdeau, A.; Vitton, V.ér.; Monino, L.; Barthet, M.; Gonzalez, J.-M. 2020: Antireflux Mucosectomy Band (ARM-b) in Treatment of Refractory Gastroesophageal Reflux Disease After Bariatric Surgery. Obesity Surgery 30(11): 4654-4658
Fedorova, E.; Watson, T.J. 2021: Antireflux and Endoscopic Therapies for Barrett Esophagus and Superficial Esophageal Neoplasia. Surgical Clinics of North America 101(3): 391-403
Tyselskyi, V.; Poylin, V.; Tkachuk, O.; Kebkalo, A. 2021: Antireflux surgery is required after endoscopic treatment for Barrett's esophagus. Polski Przeglad Chirurgiczny 93(5): 1-5
Hoang, V.T.; Dobrakowski, D.; Stępniewski, G.; Kasztelanic, R.ł; Pysz, D.; Dinh, K.X.; Klimczak, M.; Śmietana, M.; Buczyński, R. 2020: Antiresonant fibers with single- and double-ring capillaries for optofluidic applications. Optics Express 28(22): 32483-32498
Li, M.; Xu, D. 2020: Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site. Proceedings of the National Academy of Sciences of the United States of America 117(29): 17187-17194
Shavlovskaya, O.A.; Zolotovskaya, I.A.; Prokofyeva, Y.S. 2020: Antiresorptive activity of pharmacological chondroitin sulfate in the older age group. Terapevticheskii Arkhiv 92(12): 75-79
Fujieda, Y.; Atsumi, T. 2020: Antiresorptive agents-related osteonecrosis of the jaw (ARONJ) in rheumatoid arthritis. Journal of Bone and Mineral Metabolism 38(5): 739-741
Chen, J.Sheng.; Sambrook, P.N. 2011: Antiresorptive therapies for osteoporosis: a clinical overview. Nature Reviews. Endocrinology 8(2): 81-91
Meunier, A.; Palm, L.; Aspenberg, P.; Schilcher, Jörg. 2021: Antiresorptive treatment and talar collapse after displaced fractures of the talar neck: a long-term follow-up of 19 patients. Acta Orthopaedica 2021: 1-6
Hadaya, D.; Soundia, A.; Gkouveris, I.; Bezouglaia, O.; Dry, S.M.; Pirih, F.Q.; Aghaloo, T.L.; Tetradis, S. 2021: Antiresorptive-Type and Discontinuation-Timing Affect ONJ Burden. Journal of Dental Research 100(7): 746-753
Zolotovskaya, I.A.; Davydkin, I.L. 2020: Antiresorptive-cytokine effects of the chondroprotective therapy in patients with lower back pain. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 120(4): 65-71
Kudryavtseva, A.A.; Okhrimenko, I.S.; Didina, V.S.; Zavilgelsky, G.B.; Manukhov, I.V. 2020: Antirestriction Protein ArdB (R64) Interacts with DNA. BIOCHEMISTRY. Biokhimiia 85(3): 318-325
Bogomolets, A.A. 1945: Antireticular Cytotoxic Serum as a Pathogenic Therapeutic Resource. Revista Cubana de Medicina Sovietica 1: 5-19
Benson, C.; Wang, X.; Dunn, K.J.; Li, N.; Mesana, L.; Lai, J.; Wong, E.Y.; Chow, W.; Hardy, H.; Song, J.; Brown, K. 2020: Antiretroviral Adherence, Drug Resistance, and the Impact of Social Determinants of Health in HIV-1 Patients in the US. Aids and Behavior 24(12): 3562-3573
Hoque, T.M.D.; Cattin, A.él.; Whyte-Allman, S.-K.; Winchester, L.; Fletcher, C.V.; Routy, J.-P.; Ancuta, P.; Bendayan, R. 2021: Antiretroviral Drug Transporters and Metabolic Enzymes in Circulating Monocytes and Monocyte-Derived Macrophages of ART-Treated people Living with HIV and HIV-Uninfected Individuals. Journal of Acquired Immune Deficiency Syndromes 87(4): 1093-1101
DeMarino, C.; Pleet, M.L.; Cowen, M.; Barclay, R.A.; Akpamagbo, Y.; Erickson, J.; Ndembi, N.; Charurat, M.; Jumare, J.; Bwala, S.; Alabi, P.; Hogan, M.; Gupta, A.; Noren Hooten, N.; Evans, M.K.; Lepene, B.; Zhou, W.; Caputi, M.; Romerio, F.; Royal, W.; El-Hage, N.; Liotta, L.A.; Kashanchi, F. 2018: Antiretroviral Drugs Alter the Content of Extracellular Vesicles from HIV-1-Infected Cells. Scientific Reports 8(1): 7653
Kashyap, S.; Mukker, A.; Gupta, D.; Datta, P.K.; Rappaport, J.; Jacobson, J.M.; Ebert, S.N.; Gupta, M.K. 2021: Antiretroviral Drugs Regulate Epigenetic Modification of Cardiac Cells Through Modulation of H3K9 and H3K27 Acetylation. Frontiers in Cardiovascular Medicine 8: 634774
Guo, P.-L.; He, H.-L.; Chen, X.-J.; Chen, J.-F.; Chen, X.-T.; Lan, Y.; Wang, J.; Du, P.-S.; Zhong, H.-L.; Li, H.; Liu, C.; Li, L.-Y.; Hu, F.-Y.; Tang, X.-P.; Cai, W.-P.; Li, L.-H. 2020: Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study from Guangdong, China. Frontiers in Pharmacology 11: 569766
Chang, R.C.; Soontornniyomkij, B.; Umlauf, A.; Soontornniyomkij, V. 2021: Antiretroviral Tenofovir Induces Senescence-Associated β-Galactosidase Activity in Primary Human Brain Vascular Cells in Multi-Layer Three-Dimensional Co-Culture. Cureus 13(5): E15327
Armstead, A.B.; Wilkerson, J.Michael.; Gemeinhardt, G.; Nyitray, A.; Collins, D.M. 2021: Antiretroviral Therapy Adherence, Functional Independence, and Falls among People with HIV. Occupational Therapy in Health Care 2021: 1-18
Walker, C.K.; Shaw, C.M.; Moss Perry, M.V.; Claborn, M.K. 2022: Antiretroviral Therapy Management in Adults with HIV During ICU Admission. Journal of Pharmacy Practice 35(6): 952-962
Corrao, S.; Prestileo, T.; Di Lorenzo, F. 2016: Antiretroviral Therapy in Early HIV Infection. New England Journal of Medicine 374(4): 393-394
Thet, D.; Siritientong, T. 2020: Antiretroviral Therapy-Associated Metabolic Complications: Review of the Recent Studies. Hiv/Aids 12: 507-524
Gebreagziabher, T.T.; Woldemariam, G.T. 2020: Antiretroviral Treatment Adherence and Determinant Factors Among Adult people Infected with Human Immunodeficiency Virus in Eastern Tigray General Hospitals, Northern Ethiopia, 2019. Hiv/Aids 12: 497-505
Ruiz-Mateos, E.; Poveda, E.; Lederman, M.M. 2020: Antiretroviral Treatment for HIV Elite Controllers?. Pathogens and Immunity 5(1): 121-133
Bertrand, L.; Dygert, L.; Toborek, M. 2016: Antiretroviral Treatment with Efavirenz Disrupts the Blood-Brain Barrier Integrity and Increases Stroke Severity. Scientific Reports 6: 39738
Foster, C.; Ayers, S.; Fidler, S. 2020: Antiretroviral adherence for adolescents growing up with HIV: understanding real life, drug delivery and forgiveness. Therapeutic Advances in Infectious Disease 7: 2049936120920177
Da Mata, E.C.G.; Ombredane, A.; Joanitti, G.A.; Kanzaki, L.I.B.; Schwartz, E.F. 2020: Antiretroviral and cytotoxic activities of Tityus obscurus synthetic peptide. Archiv der Pharmazie 353(11): E2000151
Copertino, D.C.; Casado Lima, B.C.; Duarte, R.R.R.; Powell, T.R.; Ormsby, C.E.; Wilkin, T.; Gulick, R.M.; de Mulder Rougvie, M.; Nixon, D.F. 2021: Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. Journal of Biomolecular Structure and Dynamics 2021: 1-14
Ferrara, M.; Bumpus, N.é N.; Ma, Q.; Ellis, R.J.; Soontornniyomkij, V.; Fields, J.A.; Bharti, A.; Achim, C.L.; Moore, D.J.; Letendre, S.L. 2020: Antiretroviral drug concentrations in brain tissue of adult decedents. Aids 34(13): 1907-1914
Obiako, O.R.; Murktar, H.M.; Ogoina, D. 2010: Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria 19(4): 352-360
Grant-McAuley, W.; Fogel, J.M.; Galai, N.; Clarke, W.; Breaud, A.; Marzinke, M.A.; Mbwambo, J.; Likindikoki, S.; Aboud, S.; Donastorg, Y.; Perez, M.; Barrington, C.; Davis, W.; Kerrigan, D.; Eshleman, S.H. 2020: Antiretroviral drug use and HIV drug resistance in female sex workers in Tanzania and the Dominican Republic. Plos one 15(10): E0240890
Kamau, F.; Strijdom, H.; Mwangi, P.; Blackhurst, D.; Imperial, E.; Salie, R. 2019: Antiretroviral drug-induced endothelial dysfunction is improved by dual PPARα/γ stimulation in obesity. Vascular Pharmacology 121: 106577
Rosenbloom, D.I.S.; Hill, A.L.; Rabi, S.Alireza.; Siliciano, R.F.; Nowak, M.A. 2012: Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nature Medicine 18(9): 1378-1385
Schumann, G.; Cannon, K.; Ma, W.P.; Crouch, R.J.; Boeke, J.D. 1997: Antiretroviral effect of a gag-RNase HI fusion gene. Gene Therapy 4(6): 593-599
Coovadia, H.M.; Coutsoudis, A.; Rollins, N.C. 2008: Antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. New England Journal of Medicine 359(17): 1846; Author Reply 1848
Mills, J. 2008: Antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. New England Journal of Medicine 359(17): 1846; Author Reply 1846-1847
Rodríguez-Gómez, F.J. 2020: Antiretroviral regimens for HIV and HBV co-infection in patients receiving rituximab. LANCET. Haematology 7(12): E857
Sharma, A.Lakhikumar.; Singh, T.Ramsing.; Singh, L.Shanjukumar. 2018: Antiretroviral resistance, genotypic characterization and origin of Human Immunodeficiency Virus among the infected wives of Intravenous drug users in Manipur. Scientific Reports 8(1): 15183
Reynes, J. 2007: Antiretroviral therapies: strategic perspectives for the future. Medecine Tropicale: Revue du Corps de Sante Colonial 67(4): 367
Denebayeva, A.; Abrahamyan, A.; Sargsyan, A.; Kentenyants, K.; Zhandybayeva, A.; Nugmanova, Z.; Nurkerimova, A.; Davtyan, K.; Tukeyev, M. 2020: Antiretroviral therapy among patients with HIV in Almaty, Kazakhstan: the implication for HIV-associated tuberculosis control. Journal of Infection in Developing Countries 14(11.1): 128s-132s
Wohlfeiler, M.; Mounzer, K.; Brunet, L.; Fusco, J.; Vannappagari, V.; Curtis, L.; Payvandi, N.; Aboud, M.; Hsu, R.; Lackey, P.; Fusco, G. 2020: Antiretroviral therapy and liver disorders in the OPERA® cohort. Therapeutic Advances in Drug Safety 11: 2042098620976953
Sibanda, E.; Taegtmeyer, M. 2021: Antiretroviral therapy dispensing for patients who are clinically stable. LANCET. Global Health 9(5): E565-E566
Ganatra, S.R.; Bucşan, A.N.; Alvarez, X.; Kumar, S.; Chatterjee, A.; Quezada, M.; Fish, A.; Singh, D.K.; Singh, B.; Sharan, R.; Lee, T.-H.; Shanmugasundaram, U.; Velu, V.; Khader, S.A.; Mehra, S.; Rengarajan, J.; Kaushal, D. 2020: Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV coinfection model. Journal of Clinical Investigation 130(10): 5171-5179
Plaçais, L.éo.; Boufassa, F.; Lécuroux, C.; Gardiennet, E.; Avettand-Fenoel, V.ér.; Saez-Cirion, A.; Lambotte, O.; Noël, N. 2021: Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. Eclinicalmedicine 37: 100963
Gao, C.; Meng, J.; Xiao, X.; Wang, M.; Williams, A.B.; Wang, H. 2020: Antiretroviral therapy improves neurocognitive impairment in people living with HIV? a meta-analysis. International Journal of Nursing Sciences 7(2): 238-247
Peters, P.J.; Moore, D.M.; Mermin, J.; Brooks, J.T.; Downing, R.; Were, W.; Kigozi, A.; Buchacz, K.; Weidle, P.J. 2008: Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney International 74(7): 925-929
Asieba, I.O.; Oqua, D.A.; Wutoh, A.A.; Agu, K.A.; Omeh, O.I.; Adeyanju, Z.A.; Adesina, A.; Agu, F.; Agada, P.; Achanya, A.; Ekechuwu, N.; Tofade, T. 2021: Antiretroviral therapy in community pharmacies - Implementation and outcomes of a differentiated drug delivery model in Nigeria. Research in Social and Administrative Pharmacy: Rsap 17(5): 842-849
Cordie, A.; El-Kotamy, M.-T.-A.; Esmat, G. 2020: Antiretroviral therapy optimisation in the time of COVID-19: Is it really different in North and South Africa?. Southern African Journal of HIV Medicine 21(1): 1118
Mburugu, P.; Muiruri, P.; Opiyo, N.; Simba, J.; Adunda, J.; Kawira, R.; Gachuno, O. 2021: Antiretroviral therapy outcomes among adolescents and young adults in a Tertiary hospital in Kenya. African Health Sciences 21(Suppl): 1-7
Márquez-Coello, M.; Montes de Oca Arjona, M.; Martín-Aspas, Aés.; Guerrero Sánchez, F.; Fernández-Gutiérrez Del Álamo, C.; Girón-González, Jé.A. 2019: Antiretroviral therapy partially improves the abnormalities of dendritic cells and lymphoid and myeloid regulatory populations in recently infected HIV patients. Scientific Reports 9(1): 11654
Temu, T.M.; Zifodya, J.S.; Polyak, S.J.; Wagoner, J.; Wanjalla, C.N.; Masyuko, S.; Nyabiage, J.; Kinuthia, J.; Bloomfield, G.S.; Page, S.T.; Farquhar, C. 2021: Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya. Aids 35(1): 45-51
Elsayed, H.; Hassany, M. 2020: Antiretroviral therapy under the wing of the COVID-19 epidemic: one look, and different solutions. Southern African Journal of HIV Medicine 21(1): 1167
Peters, R.P.H.; Joseph Davey, D.L.; Bekker, L.-G.; Myer, L.; Medina-Marino, A.; Klausner, J.D. 2021: Antiretroviral Therapy, Sexually Transmitted Infections, and Adverse Pregnancy Outcomes in South Africa. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 73(3): E851-E852
Selvaraj, S.; Ghebremichael, M.; Li, M.; Foli, Y.; Langs-Barlow, A.; Ogbuagu, A.; Barakat, L.; Tubridy, E.; Edifor, R.; Lam, W.; Cheng, Y-C.; Paintsil, E. 2014: Antiretroviral therapy-induced mitochondrial toxicity: potential mechanisms beyond polymerase-γ inhibition. Clinical Pharmacology and Therapeutics 96(1): 110-120
Parro-Torres, C.; Hernández-Huerta, D.; Ochoa-Mangado, E.; Pérez-Elías, Mía.Jesús.; Baca-García, E.; Madoz-Gúrpide, Aín. 2021: Antiretroviral treatment adherence and mental disorders: observational case-control study in people living with HIV in Spain. Aids Care 2021: 1-9
Pulido, F.; Rubio, R. 1996: Antiretroviral treatment against HIV. Medicina Clinica 106(20): 798-799
Birungi, N.; Fadnes, L.T.; Engebretsen, I.M.S.; Tumwine, J.K.; Åstrøm, A.N. 2020: Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children: a 6 year follow-up visit from the ANRS 12174 randomized trial. Medicine 99(39): E22352
Nega, J.; Taye, S.; Million, Y.; Rodrigo, C.; Eshetie, S. 2020: Antiretroviral treatment failure and associated factors among HIV patients on first-line antiretroviral treatment in Sekota, northeast Ethiopia. Aids Research and Therapy 17(1): 39
Moatti, J.P.; N'Doye, I.; Hammer, S.M.; Hale, P.; Kazatchkine, M. 2003: Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Nature Medicine 9(12): 1449-1452
Teruya, K. 2007: Antiretrovirals. Nihon Rinsho. Japanese Journal of Clinical Medicine 65 Suppl 2(Part 1): 384-389
Del Amo, J.; Polo, R.; Moreno, S.; Díaz, A.ón.; Martínez, E.; Arribas, J.é R.ón.; Jarrín, I.; Hernán, M.A. 2020: Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons. Epidemiology 31(6): E49-E51
Brocklehurst, P.; Volmink, J. 2002: Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database of Systematic Reviews 2: Cd003510
Marques, B.; Lederer, F.; Challet, C.; Christin, L. 2020: Antiretrovirals: drug and food interactions. Revue Medicale Suisse 16(705): 1606-1612
Valentini, M.; Zmerly, H. 2020: Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept. Journal of Population Therapeutics and Clinical Pharmacology 27(S Pt 1: E14-E25
Noferi, G. 1945: Antirheumatic therapy and devitaminizing action of drugs; Effect of sodium salicylate on ascorbinuria in humans. Rivista Critica di Clinica Medica 45(3-5): 335-341
Noferi, G. 1945: Antirheumatic therapy and devitaminizing action of drugs; Effects caused by pyramidone and antipyrine on urinary excretion of vitamin C and on the varenches (experimental research). Rivista Critica di Clinica Medica 45(3-5): 314-334
Noferi, G. 1945: Antirheumatic therapy and devitaminizing action of drugs; Effects of sodium salicylate on the ascorbic acid content of the various parenchymes and protective action of vitamin C against the onset of tissue lesions caused by the salicylic radical (experimental research). Rivista Critica di Clinica Medica 45(3-5): 289-313
Pascucci, F.; Noferi, G. 1945: Antirheumatic therapy and devitaminizing action of drugs; effects of rubrophen on the ascorbic acid content of various parenchymes and protective action of vitamin C against the onset of tissue lesions caused by the drug. Rivista Critica di Clinica Medica 45(6-9): 484-493
Nguyen, T.H.P.; Fagerland, M.W.; Deyab, G.; Hjeltnes, G.ør.; Hollan, I.; Feinberg, M.W.; Eilertsen, G.Ø; Mikkelsen, K.; Agewall, S. 2021: Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis. Plos one 16(6): E0253793
Deyab, G.; Reine, T.M.; Vuong, T.T.; Jenssen, T.; Hjeltnes, G.ør.; Agewall, S.; Mikkelsen, K.; Førre, Øy.; Fagerland, M.W.; Kolset, S.O.; Hollan, I. 2021: Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis. Plos one 16(7): E0253247
Seo, J.; Lee, J.; Yang, H.Y.; Ju, J. 2020: Antirrhinum majus L. flower extract inhibits cell growth and metastatic properties in human colon and lung cancer cell lines. Food Science and Nutrition 8(11): 6259-6268
Waldthaler, J.; Stock, L.; Sommerkorn, J.; Krüger-Zechlin, C.; Timmermann, L. 2021: Antisaccade Latency Is Sensitive to Longitudinal Change of Motor and Cognitive Symptoms in Parkinson's Disease. Movement Disorders: Official Journal of the Movement Disorder Society 36(1): 266-268
Huang, L.-Y.; Jackson, B.S.; Rodrigue, A.L.; Tamminga, C.A.; Gershon, E.S.; Pearlson, G.D.; Keshavan, M.S.; Keedy, S.S.; Hill, S.K.; Sweeney, J.A.; Clementz, B.A.; McDowell, J.E. 2022: Antisaccade error rates and gap effects in psychosis syndromes from bipolar-schizophrenia network for intermediate phenotypes 2 (B-SNIP2). Psychological Medicine 52(13): 2692-2701
Narayanaswamy, J.C.; Subramaniam, A.; Bose, A.; Agarwal, S.M.; Kalmady, S.V.; Jose, D.; Joseph, B.; Shivakumar, V.; Hutton, S.B.; Venkatasubramanian, G.; Reddy, Y.C.J. 2021: Antisaccade task performance in obsessive-compulsive disorder and its clinical correlates. Asian Journal of Psychiatry 57: 102508
Gallea, C.éc.; Wicki, B.; Ewenczyk, C.; Rivaud-Péchoux, S.; Yahia-Cherif, L.; Pouget, P.; Vidailhet, M.; Hainque, E. 2021: Antisaccade, a predictive marker for freezing of gait in Parkinson's disease and gait/gaze network connectivity. Brain: a Journal of Neurology 144(2): 504-514
Guerrero-Molina, M.ía.P.; Rodriguez-López, C.; Panadés-de Oliveira, L.; Uriarte-Pérez de Urabayen, D.; Garzo-Caldas, N.ás.; García-Cena, C.E.; Saiz-Díaz, R.A.; Benito-León, J.án.; Gonzalez de la Aleja, J.ús. 2021: Antisaccades and memory-guided saccades in genetic generalized epilepsy and temporal lobe epilepsy. Epilepsy and Behavior: E&b 123: 108236
Yu, W.; Song, D.; Chen, W.; Yang, H. 2020: Antiscalants in RO membrane scaling control. Water Research 183: 115985
Fadladdin, Y.A.J. 2021: Antischistosomal Activity of Origanum majorana, Ziziphus spina-christi, and Salvia fruticosa Plant Extracts on Hamster Infected with Schistosoma haematobium. Biomed Research International 2021: 5545331
Jaffe, J.J.; Meymarian, E.; Doremus, H.M. 1971: Antischistosomal action of tubercidin administered after absorption into red cells. Nature 230(5293): 408-409
Kalinić, J. 2017: Antiscience: Defend real science in the Balkans. Nature 547(7661): 32
Aguayo-Cerón, K.A.; Gutiérrez-Iglesias, G.; Parra-Barrera, A.; Ocharan-Hernández, M.ía.E.; Romero-Nava, R.; Jiménez-Zamarripa, C.A.; Calzada-Mendoza, C.C. 2021: Antisclerothic effect of tibolone by reducing proinflammatory cytokines expression, ROS production and LDL-ox uptake in THP-1 macrophages. Steroids 167: 108779
Banks, M.R.; Farthing, M.J.G.; Robberecht, P.; Burleigh, D.E. 2005: Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine. British Journal of Pharmacology 144(7): 994-1001
Romanowski, E.M.F. 2021: Antiseizure Medication Withdrawal Following Epilepsy Surgery. Seminars in Pediatric Neurology 38: 100898
Brown, C.S.; Rabinstein, A.A.; Nystrom, E.M.; Britton, J.W.; Singh, T.D. 2021: Antiseizure Medication use in Gastric Bypass Patients and other Post-Surgical Malabsorptive States. Epilepsy and Behavior Reports 16: 100439
Patel, T.; Grindrod, K.A. 2020: Antiseizure drugs and women: Challenges with contraception and pregnancy. Canadian Pharmacists Journal: Cpj 153(6): 357-360
Knudsen-Baas, K.M.; Storstein, A.M.; Zarabla, A.; Maialetti, A.; Giannarelli, D.; Beghi, E.; Maschio, M. 2021: Antiseizure medication in patients with Glioblastoma- a collaborative cohort study. Seizure 87: 107-113
Amha, H.; Memiah, P.; Getnet, A.; Mengist, B.; Gedfew, M.; Ayenew, T.; Akalu, T.Y.; Mulugeta, H.; Bewket, B.; Kebede, B.; Petrucka, P. 2021: Antiseizure medication nonadherence and its associated factors among Epileptic patients in Ethiopia, a systematic review and meta-analysis. Seizure 91: 462-475
Moores, G.; D'Souza, R.; Bui, E. 2021: Antiseizure medications and pregnancy. Cmaj: Canadian Medical Association Journal 193(32): E1253
Lopes, K.S.; Quintanilha, M.V.T.; de Souza, A.C.B.; Zamudio-Zuñiga, F.; Possani, L.D.; Mortari, M.ár.R. 2021: Antiseizure potential of peptides from the venom of social wasp Chartergellus communis against chemically-induced seizures. Toxicon: Official Journal of the International Society on Toxinology 194: 23-36
Guha, C.; Guha, U.; Tribius, S.; Alfieri, A.; Casper, D.; Chakravarty, P.; Mellado, W.; Pandita, T.K.; Vikram, B. 2000: Antisense ATM gene therapy: a strategy to increase the radiosensitivity of human tumors. Gene Therapy 7(10): 852-858
Morgan, E.S.; Tami, Y.; Hu, K.; Brambatti, M.; Mullick, A.E.; Geary, R.S.; Bakris, G.L.; Tsimikas, S. 2021: Antisense Inhibition of Angiotensinogen with IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies. JACC. Basic to Translational Science 6(6): 485-496
Cohn, D.M.; Viney, N.J.; Fijen, Lé.M.; Schneider, E.; Alexander, V.J.; Xia, S.; Kaeser, G.E.; Nanavati, C.; Baker, B.F.; Geary, R.S.; Levi, M.; Meijers, J.C.M.; Stroes, E.S.G. 2020: Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema. New England Journal of Medicine 383(13): 1242-1247
Philippen, L.E.; Dirkx, E.; Wit, J.B.M.; Burggraaf, K.; de Windt, L.J.; da Costa Martins, P.A. 2015: Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?. Molecular Therapy: the Journal of the American Society of Gene Therapy 23(12): 1810-1818
Das, D.; Das, A.; Panda, A.C. 2021: Antisense Oligo Pulldown of Circular RNA for Downstream Analysis. Bio-Protocol 11(14):E4088
Collin, R.Wj.; den Hollander, A.I.; van der Velde-Visser, S.D.; Bennicelli, J.; Bennett, J.; Cremers, F.Pm. 2012: Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290. Molecular Therapy. Nucleic Acids 1: E14
O'Callaghan, B.; Hofstra, B.; Handler, H.P.; Kordasiewicz, H.B.; Cole, T.; Duvick, L.; Friedrich, J.; Rainwater, O.; Yang, P.; Benneyworth, M.; Nichols-Meade, T.; Heal, W.; Ter Haar, R.; Henzler, C.; Orr, H.T. 2020: Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: a Safety Assessment. Molecular Therapy. Nucleic Acids 21: 1006-1016
Hill, S.F.; Meisler, M.H. 2021: Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders. Developmental Neuroscience 43(3-4): 247-252
Ferenchak, K.; Deitch, I.; Huckfeldt, R. 2021: Antisense Oligonucleotide Therapy for Ophthalmic Conditions. Seminars in Ophthalmology 2021: 1-6
Maruyama, R.; Yokota, T. 2021: Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting. Methods in Molecular Biology 2224: 203-214
Panagiotopoulos, A.-L.; Karguth, N.; Pavlou, M.; Böhm, S.; Gasparoni, G.; Walter, J.ör.; Graf, A.; Blum, H.; Biel, M.; Riedmayr, L.M.; Becirovic, E. 2020: Antisense Oligonucleotide- and CRISPR-Cas9-Mediated Rescue of mRNA Splicing for a Deep Intronic CLRN1 Mutation. Molecular Therapy. Nucleic Acids 21: 1050-1061
Matsuo, M. 2021: Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy. Jma Journal 4(3): 232-240
Valencia, A.; Bieber, V.L.R.; Bajrami, B.; Marsh, G.; Hamann, S.; Wei, R.; Ling, K.; Rigo, F.; Arnold, H.M.; Golonzhka, O.; Hering, H. 2021: Antisense Oligonucleotide-Mediated Reduction of HDAC6 Does not Reduce Tau Pathology in P301S Tau Transgenic Mice. Frontiers in Neurology 12: 624051
Bremer, J.; Bornert, O.; Nyström, A.; Gostynski, A.; Jonkman, M.F.; Aartsma-Rus, A.; van den Akker, P.C.; Pasmooij, A.Mg. 2016: Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa. Molecular Therapy. Nucleic Acids 5(10): E379
Clayton, N.P.; Nelson, C.A.; Weeden, T.; Taylor, K.M.; Moreland, R.J.; Scheule, R.K.; Phillips, L.; Leger, A.J.; Cheng, S.H.; Wentworth, B.M. 2014: Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease. Molecular Therapy. Nucleic Acids 3: E206
Nikravesh, A.; Dryselius, R.; Faridani, O.R.; Goh, S.; Sadeghizadeh, M.; Behmanesh, M.; Ganyu, A.; Klok, E.Jan.; Zain, R.; Good, L. 2007: Antisense PNA accumulates in Escherichia coli and mediates a long post-antibiotic effect. Molecular Therapy: the Journal of the American Society of Gene Therapy 15(8): 1537-1542
Weintraub, H.M. 1990: Antisense RNA and DNA. Scientific American 262(1): 40-46
Chadwick, D.R.; Lever, A.M. 2000: Antisense RNA sequences targeting the 5' leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle. Gene Therapy 7(16): 1362-1368
Gao, J.; Li, Z.; Chen, Z.; Shao, J.; Zhang, L.; Xu, G.; Tu, Z.; Gong, Y. 2006: Antisense Smo under the control of the PTCH1 promoter delivered by an adenoviral vector inhibits the growth of human pancreatic cancer. Gene Therapy 13(22): 1587-1594
Crooke, S.T.; Liang, X.-H.; Baker, B.F.; Crooke, R.M. 2021: Antisense technology: a review. Journal of Biological Chemistry 296: 100416
Shouman, M.M.; Abdelsalam, R.M.; Tawfick, M.M.; Kenawy, S.A.; El-Naa, M.M. 2021: Antisense Tissue Factor Oligodeoxynucleotides Protected Diethyl Nitrosamine/Carbon Tetrachloride-Induced Liver Fibrosis Through Toll like Receptor4-Tissue Factor-Protease Activated Receptor1 Pathway. Frontiers in Pharmacology 12: 676608
Savoret, J.; Mesnard, J.-M.; Gross, A.; Chazal, N. 2020: Antisense Transcripts and Antisense Protein: a new Perspective on Human Immunodeficiency Virus Type 1. Frontiers in Microbiology 11: 625941
Kim, R.; Emi, M.; Matsuura, K.; Tanabe, K. 2007: Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Therapy 14(1): 1-11
Sinha, G. 2013: Antisense battles small molecule for slice of rare lipid disorder market. Nature Biotechnology 31(3): 179-180
Simons, M.; Edelman, E.R.; DeKeyser, J.L.; Langer, R.; Rosenberg, R.D. 1992: Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359(6390): 67-70
Ferguson, P.J.; Collins, O.; Dean, N.M.; DeMoor, J.; Li, C.S.; Vincent, M.D.; Koropatnick, J. 1999: Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. British Journal of Pharmacology 127(8): 1777-1786
Tian, X-X.; Pang, J.C.S.; Zheng, J.; Chen, J.; To, S.S.T.; Ng, H-K. 2002: Antisense epidermal growth factor receptor RNA transfection in human glioblastoma cells down-regulates telomerase activity and telomere length. British Journal of Cancer 86(8): 1328-1332
Hirao, T.; Sawada, H.; Koyama, F.; Watanabe, A.; Yamada, Y.; Sakaguchi, T.; Tatsumi, M.; Fujimoto, H.; Emoto, K.; Narikiyo, M.; Oridate, N.; Nakano, H. 1999: Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer. Cancer Gene Therapy 6(5): 423-427
Ma, L.; Gauvillé, C.; Berthois, Y.; Millot, G.; Johnson, G.R.; Calvo, F. 1999: Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line. Oncogene 18(47): 6513-6520
Xu, Z.; Wei, W.; Gagneur, J.; Clauder-Münster, S.; Smolik, Młosz.; Huber, W.; Steinmetz, L.M. 2011: Antisense expression increases gene expression variability and locus interdependency. Molecular Systems Biology 7: 468
Good, L.; Nielsen, P.E. 1998: Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nature Biotechnology 16(4): 355-358
Phillips, M.I.; Wielbo, D.; Gyurko, R. 1994: Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes. Kidney International 46(6): 1554-1556
Sekhon, J.; Pereira, P.; Sabbaghian, N.; Schievella, A.R.; Rozen, R. 2002: Antisense inhibition of methylenetetrahydrofolate reductase reduces survival of methionine-dependent tumour lines. British Journal of Cancer 87(2): 225-230
Horwitz, G.D.; Callaway, E.M. 2004: Antisense inhibition of reward learning. Nature Neuroscience 7(10): 1023-1024
Bolland, D.J.; Wood, A.L.; Johnston, C.M.; Bunting, S.F.; Morgan, G.; Chakalova, L.; Fraser, P.J.; Corcoran, A.E. 2004: Antisense intergenic transcription in V(D)J recombination. Nature Immunology 5(6): 630-637
Reis, E.M.; Nakaya, H.I.; Louro, R.; Canavez, F.C.; Flatschart, A.V.F.; Almeida, G.T.; Egidio, C.M.; Paquola, Aã.C.; Machado, A.A.; Festa, F.; Yamamoto, D.; Alvarenga, R.; da Silva, C.C.; Brito, G.C.; Simon, Sérgio.D.; Moreira-Filho, C.A.; Leite, K.R.; Camara-Lopes, L.H.; Campos, F.S.; Gimba, E.; Vignal, G.M.; El-Dorry, H.; Sogayar, M.C.; Barcinski, M.A.; da Silva, A.M.; Verjovski-Almeida, S. 2004: Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer. Oncogene 23(39): 6684-6692
Dick, J.M.; Van Molle, W.; Libert, C.; Lefebvre, R.A. 2001: Antisense knockdown of inducible nitric oxide synthase inhibits the relaxant effect of VIP in isolated smooth muscle cells of the mouse gastric fundus. British Journal of Pharmacology 134(2): 425-433
Ghelardini, C.; Quattrone, A.; Galeotti, N.; Livi, S.; Banchelli, G.; Raimondi, L.; Pirisino, R. 2003: Antisense knockdown of the Shaker-like Kv1.1 gene abolishes the central stimulatory effects of amphetamines in mice and rats. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 28(6): 1096-1105
Mo, S.; Zhang, L.; Dai, W.; Han, L.; Wang, R.; Xiang, W.; Wang, Z.; Li, Q.; Yu, J.; Yuan, J.; Cai, S.; Cai, G. 2020: Antisense lncRNA LDLRAD4-AS1 promotes metastasis by decreasing the expression of LDLRAD4 and predicts a poor prognosis in colorectal cancer. Cell Death and Disease 11(2): 155
Araújo, D.; Mil-Homens, D.; Rodrigues, M.E.; Henriques, M.; Jørgensen, P.T.; Wengel, J.; Silva, S.ón. 2022: Antisense locked nucleic acid gapmers to control Candida albicans filamentation. Nanomedicine: Nanotechnology Biology and Medicine 39: 102469
Jiang, B.; Wang, R.; Lin, Z.; Ma, J.; Cui, J.; Wang, M.; Liu, R.; Wu, W.; Zhang, C.; Li, W.; Wang, S. 2020: Antisense long non‑coding RNA WEE2‑AS1 regulates human vascular endothelial cell viability via cell cycle G2/M transition in arteriosclerosis obliterans. Molecular Medicine Reports 22(6): 5069-5082
Mishra, N.; Friedson, L.; Hanin, G.; Bekenstein, U.; Volovich, M.; Bennett, E.R.; Greenberg, D.S.; Soreq, H. 2017: Antisense miR-132 blockade via the AChE-R splice variant mitigates cortical inflammation. Scientific Reports 7: 42755
Wang, D.; Wang, X.; Wang, L.; Zhang, J.; Ma, J.; Xia, G.; Hong, B. 2021: Antisense microRNA185 loaded liposome for efficient inhibition of the hepatic endogenous microRNA185 level. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 161: 105803
Al Husseini, L.B.; Maleki, A.; Al Marjani, M.F. 2021: Antisense mqsR-PNA as a putative target to the eradication of Pseudomonas aeruginosa persisters. New Microbes and new Infections 41: 100868
Sung, Y.Ying.; Cheung, E. 2013: Antisense now makes sense: dual modulation of androgen-dependent transcription by CTBP1-AS. EMBO Journal 32(12): 1653-1654
Walf, A.A.; Ciriza, I.; Garcia-Segura, L.Miguel.; Frye, C.A. 2008: Antisense oligodeoxynucleotides for estrogen receptor-beta and alpha attenuate estradiol's modulation of affective and sexual behavior, respectively. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 33(2): 431-440
Wang, H.Y.; Watkins, D.C.; Malbon, C.C. 1992: Antisense oligodeoxynucleotides to GS protein alpha-subunit sequence accelerate differentiation of fibroblasts to adipocytes. Nature 358(6384): 334-337
Wahlestedt, C.; Golanov, E.; Yamamoto, S.; Yee, F.; Ericson, H.; Yoo, H.; Inturrisi, C.E.; Reis, D.J. 1993: Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature 363(6426): 260-263
Hu, N.; Kim, E.; Antoury, L.; Li, J.; González-Pérez, P.; Rutkove, S.B.; Wheeler, T.M. 2021: Antisense oligonucleotide and adjuvant exercise therapy reverse fatigue in old mice with myotonic dystrophy. Molecular Therapy. Nucleic Acids 23: 393-405
Cao, Y.; Matsubara, T.; Zhao, C.; Gao, W.; Peng, L.; Shan, J.; Liu, Z.; Yuan, F.; Tang, L.; Li, P.; Guan, Z.; Fang, Z.; Lu, X.; Huang, H.; Yang, Q. 2017: Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment. Scientific Reports 7(1): 9307
Lidberg, K.A.; Annalora, A.J.; Jozic, M.; Elson, D.J.; Wang, L.; Bammler, T.K.; Ramm, S.; Monteiro, M.Beatriz.; Himmelfarb, J.; Marcus, C.B.; Iversen, P.L.; Kelly, E.J. 2021: Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease. Scientific Reports 11(1): 4722
Fyfe, I. 2020: Antisense oligonucleotide hope for childhood epilepsies. Nature Reviews. Neurology 16(3): 128
Hiraoka, H.; Shu, Z.; Tri Le, B.; Masuda, K.; Nakamoto, K.; Fangjie, L.; Abe, N.; Hashiya, F.; Kimura, Y.; Shimizu, Y.; Veedu, R.N.; Abe, H. 2021: Antisense Oligonucleotide Modified with Disulfide Units Induces Efficient Exon Skipping in mdx Myotubes through Enhanced Membrane Permeability and Nucleus Internalization. Chembiochem: a European Journal of Chemical Biology 22(24): 3437-3442
Lim, K.Huat.; Han, Z.; Jeon, H.Yong.; Kach, J.; Jing, E.; Weyn-Vanhentenryck, S.; Downs, M.; Corrionero, A.; Oh, R.; Scharner, J.; Venkatesh, A.; Ji, S.; Liau, G.; Ticho, B.; Nash, H.; Aznarez, I. 2020: Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression. Nature Communications 11(1): 3501
Lemprière, S. 2019: Antisense oligonucleotide reduces mutant protein in patients with HD. Nature Reviews. Neurology 15(8): 435
Xue, K.; MacLaren, R.E. 2020: Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. Expert Opinion on Investigational Drugs 29(10): 1163-1170
Scoles, D.R.; Meera, P.; Schneider, M.D.; Paul, S.; Dansithong, W.; Figueroa, K.P.; Hung, G.; Rigo, F.; Bennett, C.Frank.; Otis, T.S.; Pulst, S.M. 2017: Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 544(7650): 362-366
Yin, D.L.; Pu, L.; Pei, G. 1998: Antisense oligonucleotide to insulin-like growth factor II induces apoptosis in human ovarian cancer AO cell line. Cell Research 8(2): 159-165
Oren, Y.S.; Irony-Tur Sinai, M.; Golec, A.; Barchad-Avitzur, O.; Mutyam, V.; Li, Y.; Hong, J.; Ozeri-Galai, E.; Hatton, A.él.; Leibson, C.; Carmel, L.; Reiter, J.; Sorscher, E.J.; Wilton, S.D.; Kerem, E.; Rowe, S.M.; Sermet-Gaudelus, I.; Kerem, B. 2021: Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society 20(5): 865-875
Dean, N.M.; Bennett, C.Frank. 2003: Antisense oligonucleotide-based therapeutics for cancer. Oncogene 22(56): 9087-9096
Nakamura, A.; Ali, S.A.; Kapoor, M. 2020: Antisense oligonucleotide-based therapies for the treatment of osteoarthritis: Opportunities and roadblocks. Bone 138: 115461
Dulla, K.; Slijkerman, R.; van Diepen, H.C.; Albert, S.; Dona, M.; Beumer, W.; Turunen, J.J.; Chan, H.L.; Schulkens, I.A.; Vorthoren, L.; den Besten, C.; Buil, L.; Schmidt, I.; Miao, J.; Venselaar, H.; Zang, J.; Neuhauss, S.C.F.; Peters, T.; Broekman, S.; Pennings, R.; Kremer, H.; Platenburg, G.; Adamson, P.; de Vrieze, E.; van Wijk, E. 2021: Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Molecular Therapy: the Journal of the American Society of Gene Therapy 29(8): 2441-2455
Nomakuchi, T.T.; Rigo, F.; Aznarez, I.; Krainer, A.R. 2016: Antisense oligonucleotide-directed inhibition of nonsense-mediated mRNA decay. Nature Biotechnology 34(2): 164-166
Wilton, S.D.; Fall, A.M.; Harding, P.L.; McClorey, G.; Coleman, C.; Fletcher, S. 2007: Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Molecular Therapy: the Journal of the American Society of Gene Therapy 15(7): 1288-1296
McClorey, G.; Moulton, H.M.; Iversen, P.L.; Fletcher, S.; Wilton, S.D. 2006: Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Therapy 13(19): 1373-1381
Toonen, L.J.A.; Schmidt, I.; Luijsterburg, M.S.; van Attikum, H.; van Roon-Mom, W.M.C. 2016: Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3. Scientific Reports 6: 35200
Bell, T.A.; Liu, M.; Donner, A.J.; Lee, R.G.; Mullick, A.E.; Crooke, R.M. 2021: Antisense oligonucleotide-mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice. Journal of Lipid Research 62: 100101
Worley, B.L.; Auen, T.; Arnold, A.C.; Monia, B.P.; Hempel, N.; Czyzyk, T.A. 2021: Antisense oligonucleotide-mediated knockdown of Mpzl3 attenuates the negative metabolic effects of diet-induced obesity in mice. Physiological reports 9(9): e14853
Zaslavsky, A.; Adams, M.; Cao, X.; Yamaguchi, A.; Henderson, J.; Busch-Østergren, P.; Udager, A.; Pitchiaya, S.; Tourdot, B.; Kasputis, T.; Church, S.J.; Lee, S.K.; Ohl, S.; Patel, S.; Morgan, T.M.; Alva, A.; Wakefield, T.W.; Reichert, Z.; Holinstat, M.; Palapattu, G.S. 2021: Antisense oligonucleotides and nucleic acids generate hypersensitive platelets. Thrombosis Research 200: 64-71
Barton, C.M.; Lemoine, N.R. 1995: Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. British Journal of Cancer 71(3): 429-437
Mizuta, T.; Fujiwara, M.; Hatta, T.; Abe, T.; Miyano-Kurosaki, N.; Shigeta, S.; Yokota, T.; Takaku, H. 1999: Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Nature Biotechnology 17(6): 583-587
Haller, H.; Dragun, D.; Miethke, A.; Park, J.K.; Weis, A.; Lippoldt, A.; Gross, V.; Luft, F.C. 1996: Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney International 50(2): 473-480
Bajaj, A.; Rader, D.J. 2020: Antisense oligonucleotides for atherosclerotic disease. Nature Medicine 26(4): 471-472
Fyfe, I. 2018: Antisense oligonucleotides improve cognitive function in HD model. Nature Reviews. Neurology 14(12): 690-691
Yee, J-Kuan.; Lin, R-Jang. 2012: Antisense oligonucleotides shed new light on the pathogenesis and treatment of spinal muscular atrophy. Molecular Therapy: the Journal of the American Society of Gene Therapy 20(1): 8-10
Tian, L.; Chen, Y.; Chang, S.; Xu, L.; Zhou, X.; Mao, Q.; Liang, L. 2021: Antisense oligonucleotides targeting alternative splicing of Nrcam exon 10 suppress neurite outgrowth of ganglion sensory neurons in vitro. Neuroreport 32(7): 548-554
Li, M.; Ding, X.; Zhang, Y.; Li, X.; Zhou, H.; Yang, L.; Li, Y.; Yang, P.; Zhang, X.; Hu, J.; Nice, E.; Wu, H.; Xu, H. 2020: Antisense oligonucleotides targeting lncRNA AC104041.1 induces antitumor activity through Wnt2B/β-catenin pathway in head and neck squamous cell carcinomas. Cell Death and Disease 11(8): 672
Guinot, P.; Temsamani, J. 1998: Antisense oligonucleotides: a new therapeutic approach. Pathologie-Biologie 46(5): 347-354
Rinaldi, C.; Wood, M.J.A. 2018: Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nature Reviews. Neurology 14(1): 9-21
Yeh, C-Ting.; Lu, S-Chuan.; Tseng, I-Chu.; Lai, H-Yu.; Tsao, M-Lin.; Huang, S-Feng.; Liaw, Y-Fan. 2003: Antisense overexpression of BMAL2 enhances cell proliferation. Oncogene 22(34): 5306-5314
Esther da Silva, K.; Ribeiro, S.Meira.; Rossato, L.; Paes Dos Santos, C.; Preza, S.Espindola.; Cardoso, M.Henrique.; Franco, Oávio.Luiz.; Migliolo, L.; Simionatto, S. 2021: Antisense peptide nucleic acid inhibits the growth of KPC-producing Klebsiella pneumoniae strain. Research in Microbiology 2021: 103837
Caté, C.ém.; Larocque, Ém.; Peloponese, J.-M.; Mesnard, J.-M.; Rassart, Ér.; Barbeau, B.ît. 2018: Antisense proteins of HTLV viruses. Virologie 22(3): 183-191
Gokhale, P.C.; Soldatenkov, V.; Wang, F.H.; Rahman, A.; Dritschilo, A.; Kasid, U. 1997: Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer. Gene Therapy 4(12): 1289-1299
Märtens, B.; Manoharadas, S.; Hasenöhrl, D.; Manica, A.; Bläsi, U. 2013: Antisense regulation by transposon-derived RNAs in the hyperthermophilic archaeon Sulfolobus solfataricus. Embo Reports 14(6): 527-533
Frederickson 1999: Antisense scores a knockout. Nature Biotechnology 17(12): 1150
Naora, H.; Nishida, T.; Shindo, Y.; Adachi, M.; Naora, H. 1998: Antisense sequences of the nbl gene induce apoptosis in the human promyelocytic leukemia cell line HL-60. Leukemia 12(4): 532-541
Klausner, A. 1990: Antisense start-ups surveyed. Bio/Technology 8(4): 303-304
Carmichael, G.G. 2003: Antisense starts making more sense. Nature Biotechnology 21(4): 371-372
Scofield, G.N.; Hirose, T.; Gaudron, J.A.; Furbank, R.T.; Upadhyaya, N.M.; Ohsugi, R. 2002: Antisense suppression of the rice transporter gene, OsSUT1, leads to impaired grain filling and germination but does not affect photosynthesis. Functional Plant Biology: Fpb 29(7): 815-826
Beer-Romero, P.; Glass, S.; Rolfe, M. 1997: Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene 14(5): 595-602
Mourich, D.V.; Jendrzejewski, J.L.; Marshall, N.B.; Hinrichs, D.J.; Iversen, P.L.; Brand, R.M. 2009: Antisense targeting of cFLIP sensitizes activated T cells to undergo apoptosis and desensitizes responses to contact dermatitis. Journal of Investigative Dermatology 129(8): 1945-1953
Carter, G.; Lemoine, N.R. 1993: Antisense technology for cancer therapy: does it make sense?. British Journal of Cancer 67(5): 869-876
Stein, C.A. 2001: Antisense that comes naturally. Nature Biotechnology 19(8): 737-738
Clark, R.E. 2000: Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia 14(3): 347-355
Eperon, I. 2012: Antisense therapeutics: New ways to nudge splicing. Nature Chemical Biology 8(6): 507-508
Tse, M.Tsuey. 2012: Antisense therapeutics: Nuclear RNA more susceptible to knockdown. Nature Reviews. Drug Discovery 11(9): 674
Flemming, A. 2011: Antisense therapeutics: Systemic reawakening of a silent gene to improve survival in SMA. Nature Reviews. Drug Discovery 10(12): 900
Gleave, M.E.; Monia, B.P. 2005: Antisense therapy for cancer. Nature Reviews. Cancer 5(6): 468-479
Orr, R.M.; Monia, B.P. 1998: Antisense therapy for cancer. Idrugs: the Investigational Drugs Journal 1(2): 199-205
Masciarelli, S.; Mattioli, B.; Galletti, R.; Samoggia, P.; Chichiarelli, S.; Mearini, G.; Mattia, E. 2002: Antisense to Epstein Barr Virus-encoded LMP1 does not affect the transcription of viral and cellular proliferation-related genes, but induces phenotypic effects on EBV-transformed B lymphocytes. Oncogene 21(26): 4166-4170
Di Sano, F.; Di Bartolomeo, S.; Fazi, B.; Fiorentini, C.; Matarrese, P.; Spinedi, A.; Piacentini, M. 2002: Antisense to glucosylceramide synthase in human neuroepithelioma affects cell growth but not apoptosis. Cell Death and Differentiation 9(6): 693-695
Orfanelli, U.; Jachetti, E.; Chiacchiera, F.; Grioni, M.; Brambilla, P.; Briganti, A.; Freschi, M.; Martinelli-Boneschi, F.; Doglioni, C.; Montorsi, F.; Bellone, M.; Casari, G.; Pasini, D.; Lavorgna, G. 2015: Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. Oncogene 34(16): 2094-2102
Schwartz, J.C.; Younger, S.T.; Nguyen, N-Bich.; Hardy, D.B.; Monia, B.P.; Corey, D.R.; Janowski, B.A. 2008: Antisense transcripts are targets for activating small RNAs. Nature Structural and Molecular Biology 15(8): 842-848
Fyfe, I. 2018: Antisense treatment alleviates ALS in animals. Nature Reviews. Neurology 14(9): 508
Wu, S.; Liu, Y.; Lei, L.; Zhang, H. 2021: Antisense yycG modulates the susceptibility of Staphylococcus aureus to hydrogen peroxide via the sarA. Bmc Microbiology 21(1): 160
Potera, C. 2007: Antisense--down, but not out. Nature Biotechnology 25(5): 497-499
Ferguson, P.J.; DeMoor, J.M.; Vincent, M.D.; Koropatnick, J. 2001: Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells. British Journal of Pharmacology 134(7): 1437-1446
Kang, J.K.; Malerba, A.; Popplewell, L.; Foster, K.; Dickson, G. 2011: Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. Molecular Therapy: the Journal of the American Society of Gene Therapy 19(1): 159-164
Sud, R.; Geller, E.T.; Schellenberg, G.D. 2014: Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies. Molecular Therapy. Nucleic Acids 3: E180
Spear, J.M. 1896: Antisepsis. American Journal of Dental Science 29(11): 512-518
Schonbauer, L.; Semmelweis, I. 1947: Antisepsis and asepsis since Semmelweis. WienerKlinischeWochenschrift 50(34-35): 592
Pulaski, E.J. 1947: Antisepsis and disinfection in surgery. Surgery Gynecology and Obstetrics 84(2): 107-121
Chouhy Aguirre, S. 1948: Antisepsis of the operative field; Grossich's method. La Semana Medica 55(20): 806-809
Bose, G.C. 1936: Antiseptic Properties of Raw Cod-Liver Oil. Indian Medical Gazette 71(6): 370
Logan, W.H.G. 1900: Antiseptic Surgery of the Mouth and Face. Dental Register 54(12): 617-623
Pease, W.A. 1881: Antiseptic Treatment of Alveolar Abscesses. Dental Register 35(10): 399-411
Caujolle, F.; Delas, R.; Stanislas, E. 1948: Antiseptic action of sodium orthothymotate. Toulouse Medical 49(1): 41-44
Gonzalez, F.; Homar, R.D.; Ulloa, I.G. 1947: Antiseptic action of some drugs on the microbial flora of the second deep degrees in vivo and in vitro. Revista Dental de Chile 39(10): 390-401
Stickler, D.J.; Thomas, B.; Chawla, J.C. 1981: Antiseptic and antibiotic resistance in gram-negative bacteria causing urinary tract infection in spinal cord injured patients. Paraplegia 19(1): 50-58
Enria, G. 1947: Antiseptic arterio-therapy of inflammatory processes of the limbs. Minerva Medica 38(9): 244-250
Shin, Y.P.; Lee, J.H.; Choi, R.-Y.; Lee, H.J.; Baek, M.; Kim, I.-W.; Seo, M.; Kim, M.-A.; Kim, S.H.; Hwang, J.S. 2021: Antiseptic effect of antimicrobial peptide psacotheasin 2 derived from the yellow-spotted longicorn beetle (Psacothea hilaris). Developmental and Comparative Immunology 123: 104140
Wass, S.; Albrektsen, G.; Ødegård, M.Tjåland.; Sand, M.; Austeng, D. 2018: Antiseptic effect of low-concentration povidone-iodine applied with a depot device in the conjunctiva before cataract surgery. Eye 32(12): 1900-1907
Batista, R.I.M.; Nogueira, R.C.; Ferreira, G.C.; Oliveira-Paula, G.H.; Damacena-Angelis, C.él.; Pinheiro, L.C.; Tanus-Santos, J.E. 2021: Antiseptic mouthwash inhibits antihypertensive and vascular protective effects of L-arginine. European Journal of Pharmacology 907: 174314
Kalogiannides, T. 1970: Antiseptic properties of dental pulp capping materials. Stoma 2(3): 89-93
Gregorchuk, B.S.J.; Reimer, S.L.; Beniac, D.R.; Hiebert, S.L.; Booth, T.F.; Wuzinski, M.; Funk, B.E.; Milner, K.A.; Cartwright, N.H.; Doucet, A.N.; Mulvey, M.R.; Khajehpour, M.; Zhanel, G.G.; Bay, D.C. 2020: Antiseptic quaternary ammonium compound tolerance by gram-negative bacteria can be rapidly detected using an impermeant fluorescent dye-based assay. Scientific Reports 10(1): 20543
Lucarotti, M.E.; White, H.; Deas, J.; Silver, I.A.; Leaper, D.J. 1990: Antiseptic toxicity to breast carcinoma in tissue culture: an adjuvant to conservation therapy?. Annals of the Royal College of Surgeons of England 72(6): 388-392
Houwing, R.H.; de Wit, R.F. 1991: Antiseptic wound treatment agents; an overview. Nederlands Tijdschrift Voor Geneeskunde 135(41): 1908-1911
Salas Campos, L.; Gómez Ferrero, O.; Ramal Muñoz, I.; Villar Miranda, H.; Martínez de la Chica, A.M. 2000: Antiseptics. Revista de Enfermeria 23(7-8): 537-541
Hunt, G.E. 1896: Antiseptics. Dental Register 50(8): 365-369
Hayward, S.H. 1892: Antiseptics and Disinfectants Used in Dental Surgery. American Journal of Dental Science 25(10): 455-459
Marino, H. 1948: Antiseptics and other substances in the treatment of wounds. Prensa Medica Argentina 35(2): 79-90
Garrod, L.P. 1949: Antiseptics in surgery (transl.). Jornada Medica 3(24): 289-295
Roe, J.O. 1888: Antiseptics in the Mouth. Dental Register 42(4): 194-200
Løokken, P.; Borchegrevink, C.F. 1976: Antiseptics--sense organs--adverse effects. Den Norske Tannlaegeforenings Tidende 86(5): 224
Niman, H.L. 1984: Antisera to a synthetic peptide of the sis viral oncogene product recognize human platelet-derived growth factor. Nature 307(5947): 180-183
Mattes, M.J.; Steiner, L.A. 1978: Antisera to frog immunoglobulins cross-react with a periodate-sensitive cell surface determinant. Nature 273(5665): 761-763
Cresswell, P.; Geler, S.S. 1975: Antisera to human B-lymphocyte membrane glycoproteins block stimulation in mixed lymphocyte culture. Nature 257(5522): 147-149
Hruby, Z.W.; Shirota, K.; Jothy, S.; Lowry, R.P. 1991: Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce immune glomerular injury. Kidney International 40(1): 43-51
Wildy, P.; Watson, D.H. 1968: Antiserum production using minute quantities of viral antigens. Nature 219(5151): 299-300
Sanes, J.R.; Carlson, S.S.; Von Wedel, R.J.; Kelly, R.B. 1979: Antiserum specific for motor nerve terminals in skeletal muscle. Nature 280(5721): 403-404
Haravu, P.N.; Gottlieb, L.J.; Vrouwe, S.Q. 2021: Antishear Therapy for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a Follow-up Study. Journal of Burn Care and Research: Official Publication of the American Burn Association 42(6): 1152-1161
Kang, Y.-Q.; Yuan, X.-H.; Li, Z.-Z.; Wang, H.; Zhou, X.-F.; Wang, X.-X.; Zhang, Z.-W.; Feng, Y.-F.; Guo, J.-R. 2020: Antishock Characteristics of Erythrocyte-mediated Endoplasmic Reticulum Stress in Macrophages in Severe Hemorrhagic Shock Environment Based on TLR9-cGAS-STING-IFN Signal Axis. Cell Transplantation 29: 963689720950218
Nwankwo, H.C.; Idowu, A.A.; Muhammad, A.; Waziri, A.D.; Abubakar, Y.S.; Bashir, M.; Erukainure, O.L. 2021: Antisickling effect of chrysin is associated with modulation of oxygenated and deoxygenated haemoglobin via alteration of functional chemistry and metabolic pathways of human sickle erythrocytes. Human and Experimental Toxicology 40(12_suppl): S108-S124
He, Z.; Russell, J.Eric. 2004: Antisickling effects of an endogenous human alpha-like globin. Nature Medicine 10(4): 365-367
Shadike, Z.; Zhou, Y-Ning.; Chen, L-Li.; Wu, Q.; Yue, J-Li.; Zhang, N.; Yang, X-Qing.; Gu, L.; Liu, X-Song.; Shi, S-Qi.; Fu, Z-Wen. 2017: Antisite occupation induced single anionic redox chemistry and structural stabilization of layered sodium chromium sulfide. Nature Communications 8(1): 566
Hoffmann, M.; Zimmermann, B.; Müller, G.P.; Schürhoff, D.; Kiselev, N.S.; Melcher, C.; Blügel, S. 2017: Antiskyrmions stabilized at interfaces by anisotropic Dzyaloshinskii-Moriya interactions. Nature Communications 8(1): 308
Pandey, S.; Bolstad, I.; Lien, L.; Bramness, J.ør.G. 2021: Antisocial Personality Disorder Among Patients in Treatment for Alcohol use Disorder (AUD): Characteristics and Predictors of Early Relapse or Drop-Out. Substance Abuse and Rehabilitation 12: 11-22
Hovey, D.; Lindstedt, M.; Zettergren, A.; Jonsson, L.; Johansson, A.; Melke, J.; Kerekes, N.; Anckarsäter, H.; Lichtenstein, P.; Lundström, S.; Westberg, L. 2016: Antisocial behavior and polymorphisms in the oxytocin receptor gene: findings in two independent samples. Molecular Psychiatry 21(7): 983-988
Goldstein, R.B.; Powers, S.I.; McCusker, J.; Lewis, B.F.; Bigelow, C.; Mundt, K.A. 1999: Antisocial behavioral syndromes among residential drug abuse treatment clients. Drug and Alcohol Dependence 53(2): 171-187
Dos Santos, M.; Peña, J. 2017: Antisocial rewarding in structured populations. Scientific Reports 7(1): 6212
Zhu, C.; Yu, X.; Lv, J.; Zhang, J.; Yang, J.; Hao, N.; Feng, J. 2020: Antisoiling Performance of Lotus Leaf and other Leaves after Prolonged Outdoor Exposure. Acs Applied Materials and Interfaces 12(47): 53394-53402
Huang, Y.; Liu, T.; Wang, B.; Li, J.; Li, D.; Wang, G.; Lian, Q.; Amini, A.; Chen, S.; Cheng, C.; Xing, G. 2021: Antisolvent Engineering to Optimize Grain Crystallinity and Hole-Blocking Capability of Perovskite Films for High-Performance Photovoltaics. Advanced Materials 33(38): E2102816
Thakkar, M.; Islam, M.S.; Railkar, A.; Mitra, S. 2020: Antisolvent precipitative immobilization of micro and nanostructured griseofulvin on laboratory cultured diatom frustules for enhanced aqueous dissolution. Colloids and Surfaces. B Biointerfaces 196: 111308
Zhou, S.; Wang, Q.; Xu, Z.; Xu, S.; Yang, P.; Deng, H.; Li, B.; Dong, Y.; Han, P.; Su, Y. 2021: Antisolvent solvothermal synthesis of MAPbBr3 nanocrystals for efficient solar photodecomposition of methyl orange. Journal of Colloid and Interface Science 595: 98-106
Wang, Z.; Zhu, X.; Feng, J.; Wang, C.; Zhang, C.; Ren, X.; Priya, S.; Liu, S.F.; Yang, D. 2021: Antisolvent- and Annealing-Free Deposition for Highly Stable Efficient Perovskite Solar Cells via Modified ZnO. Advanced Science 8(13): 2002860
Mitchell, P. 2003: Antisoma-Roche deal--a new kind of buyout?. Nature Biotechnology 21(1): 3
Xu, X.; Xu, X.; Hao, Y.; Zhu, X.; Lu, J.; Ouyang, X.; Lu, Y.; Huang, X.; Li, Y.; Wang, J.; Shen, X. 2020: Antispasmodic Drug Drofenine as an Inhibitor of Kv2.1 Channel Ameliorates Peripheral Neuropathy in Diabetic Mice. Iscience 23(10): 101617
Bar, D.; Vanlerenberghe, J.; Erb 1956: Antispasmodic action of some amino alcohols. Therapie 11(6): 1114-1118
Roome, T.; Qasim, M.; Farooq, A.D.; Ilyas, Q.; Aziz, S.; Ali, S.F. 2021: Antispasmodic activity and mechanism of action of polyherbal formulation DCD-684 on rabbit jejunum. Pakistan Journal of Pharmaceutical Sciences 34(2 Supplary): 711-722
Lima, C.C.; de Holanda-Angelin-Alves, C.M.; Pereira-Gonçalves, Át.; Kennedy-Feitosa, E.; Evangelista-Costa, E.; Bezerra, M.A.C.; Coelho-de-Souza, A.N.; Leal-Cardoso, J.é H. 2020: Antispasmodic effects of the essential oil of Croton zehnteneri, anethole, and estragole, on tracheal smooth muscle. Heliyon 6(11): E05445
Pietrzak, A. 2021: Antispasmodics in irritable bowel syndrome - a hoary old chestnut?. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association 27(3): 113-114
Pandiyan, N.; Pandiyan, R. 1998: Antisperm antibodies and male subfertility. British Journal of Urology 82(1): 165
S Ferrer, M.; Palomares, R.; Hurley, D.; Bullington, A.-C.; Hoyos-Jaramillo, A.; H Bittar, J.ão. 2020: Antisperm antibodies and sperm function in bulls undergoing scrotal insulation. Reproduction 160(5): 783-792
Steen, E.; Schone, R. 1949: Antistafylolysinreaksjonen; a study of serum antistaphylolysin content of 533 blood donors. Nordisk Medicin 42(31): 1294-1297
Haghighat-Kharazi, S.; Reza Kasaai, M.; Milani, J.M.; Khajeh, K. 2020: Antistaling properties of encapsulated maltogenic amylase in gluten-free bread. Food Science and Nutrition 8(11): 5888-5897
Corsini Campioli, C.; Go, J.R.; Abu Saleh, O.; Challener, D.; Yetmar, Z.; Osmon, D.R. 2021: Antistaphylococcal Penicillin vs Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Spinal Epidural Abscesses. Open Forum Infectious Diseases 8(3): Ofab 071
Kourilsky, R.; Mercier, P. 1945: Antistaphylococcal immunization by specific toxoid. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 139: 248
Lefèvre, B.; Hoen, B.; Goehringer, F.; Sime, W.N.; Aissa, N.; Alauzet, C.; Jeanmaire, E.; Hénard, S.; Filippetti, L.; Selton-Suty, C.; Agrinier, N. 2021: Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study. European Journal of Clinical Microbiology and Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 40(12): 2605-2616
Abdelaal Ahmed Mahmoud M Alkhatip, A.; Yassin, H.M.; Farag, E.; Hamza, M.K.; Bahr, M.H.; Ahmed, A.G.; El Emady, M.F.; Sallam, A.M.; Elayashy, M.; Abdelhaq, M.; Kamal, A.M.; Elramely, M.A. 2020: Antistasis Retrograde Flow Vascular Catheter: a Novel Solution to Thrombogenicity: a Computational Fluid Dynamics Study. Anesthesia and Analgesia 131(4): 1281-1290
Robert 1973: Antistreptolysin O. L'Infirmiere Francaise 148: 20
Ratajczak, P.; Kus, K.; Zielińska-Przyjemska, M.łg.; Skórczewska, B.; Zaprutko, T.; Kopciuch, D.; Paczkowska, A.; Nowakowska, E.żb. 2020: Antistress and antidepressant properties of dapoxetine and vortioxetine. Acta Neurobiologiae Experimentalis 80(3): 217-224
Siegel, A.N.; Di Vincenzo, J.D.; Brietzke, E.; Gill, H.; Rodrigues, N.B.; Lui, L.M.W.; Teopiz, K.M.; Ng, J.; Ho, R.; McIntyre, R.S.; Rosenblat, J.D. 2021: Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: a systematic review. Journal of Psychiatric Research 137: 426-436
Du, Z.Xian.; Zhang, H.Yan.; Gao, D.Xin.; Wang, H.Qin.; Li, Y.Jun.; Liu, G.Liang. 2006: Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells. Experimental and Molecular Medicine 38(3): 230-240
Chai, C.; Guo, Y.; Huang, Z.; Zhang, Z.; Yang, S.; Li, W.; Zhao, Y.; Hao, J. 2020: Antiswelling and Durable Adhesion Biodegradable Hydrogels for Tissue Repairs and Strain Sensors. Langmuir 36(35): 10448-10459
Hu, G.; Zhu, Y.; Xiang, J.; Yang, T.-Y.; Huang, M.; Wang, Z.; Wang, Z.; Liu, P.; Zhang, Y.; Feng, C.; Hou, D.; Zhu, W.; Gu, M.; Hsu, C.-H.; Chuang, F.-C.; Lu, Y.; Xiang, B.; Chueh, Y.-L. 2020: Antisymmetric Magnetoresistance in a van der Waals Antiferromagnetic/Ferromagnetic Layered MnPS3/Fe3GeTe2 Stacking Heterostructure. Acs Nano 14(9): 12037-12044
Wang, Y.; Lee, P.A.; Silevitch, D.M.; Gomez, F.; Cooper, S.E.; Ren, Y.; Yan, J-Q.; Mandrus, D.; Rosenbaum, T.F.; Feng, Y. 2020: Antisymmetric linear magnetoresistance and the planar Hall effect. Nature Communications 11(1): 216
Liu, Y.; Dong, C.; Liu, X.; Dong, J. 2017: Antisymmetry of oceanic eddies across the Kuroshio over a shelfbreak. Scientific Reports 7(1): 6761
Raiteri, M.; Levi, G. 1973: Antisynaptosome antibodies affect synaptosomal permeability to neurotransmitters. Nature: new Biology 245(142): 89-91
Tzilas, V.; Sfikakis, P.P.; Bouros, D. 2021: Antisynthetase Syndrome Masquerading as Hypersensitivity Pneumonitis. Respiration; International Review of Thoracic Diseases 100(11): 1105-1113
Dumitrascu, C.I.; Olsen, D.A.; Arendt, K.W.; Rose, C.H.; Sharpe, E.E. 2021: Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy. Case Reports in Anesthesiology 2021: 1150394
Opinc, A.H.; Makowska, J.S. 2021: Antisynthetase syndrome - much more than just a myopathy. Seminars in Arthritis and Rheumatism 51(1): 72-83
Mirrakhimov, A.E. 2015: Antisynthetase syndrome: a review of etiopathogenesis, diagnosis and management. Current Medicinal Chemistry 22(16): 1963-1975
Ho, G.; Birgersdotter-Green, U. 2020: Antitachycardia pacing: a worthy cause?. Journal of Cardiovascular Electrophysiology 31(10): 2727-2729
Zuch de Zafra, C.L.; Ashkenazi, A.; Darbonne, W.C.; Cheu, M.; Totpal, K.; Ortega, S.; Flores, H.; Walker, M.D.; Kabakoff, B.; Lum, B.L.; Mounho-Zamora, B.J.; Marsters, S.A.; Dybdal, Nël.O. 2016: Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey. Cell Death and Disease 7(8): E2338
Quevauviller, A. 1945: Antithermal and antipyretic action of phenylcinchoninque acid, nor of cinchothienic acid and their sodium salt. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 139(11-12): 525-527
Iba, T.; Nakarai, E. 2011: Antithrombin. Rinsho Byori. Japanese Journal of Clinical Pathology Suppl 147: 167-170
Ehrhardt, J.D.; Boneva, D.; McKenney, M.; Elkbuli, A. 2020: Antithrombin Deficiency in Trauma and Surgical Critical Care. Journal of Surgical Research 256: 536-542
Ukita, M. 1987: Antithrombin IIi and heparin. Rinsho Byori. Japanese Journal of Clinical Pathology Spec no 70: 173-180
Chandika, P.; Heo, S.-Y.; Oh, G.-W.; Choi, I.-W.; Park, W.S.; Jung, W.-K. 2020: Antithrombin III-mediated blood coagulation inhibitory activity of chitosan sulfate derivatized with different functional groups. International Journal of Biological Macromolecules 161: 1552-1558
Wang, F.; Zhang, G.; Lu, Z.; Geurts, A.M.; Usa, K.; Jacob, H.J.; Cowley, A.W.; Wang, N.; Liang, M. 2015: Antithrombin III/SerpinC1 insufficiency exacerbates renal ischemia/reperfusion injury. Kidney International 88(4): 796-803
Sudo, M.; Xu, J.; Mitani, K.; Jimbo, M.; Tsutsui, H.; Hatano, E.; Fujimoto, J. 2021: Antithrombin Together with NETs Inhibitor Protected Against Postoperative Adhesion Formation in Mice. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology Biochemistry and Pharmacology 55(4): 400-412
Kean, W.F.; Kassam, Y.B.; Lock, C.J.; Buchanan, W.W.; Rischke, J.; Nablo, L. 1984: Antithrombin activity of gold sodium thiomalate. Clinical Pharmacology and Therapeutics 35(5): 627-632
Watanabe, K.; Chao, F.C.; Tullis, J.L. 1975: Antithrombin activity of intact human platelets. Thrombosis et Diathesis Haemorrhagica 34(1): 364
Okimoto, S.; Tashiro, H.; Iwako, H.; Kuroda, S.; Kobayashi, T.; Hinoi, T.; Ohdan, H. 2020: Antithrombin attenuates the progression of hepatocellular carcinoma by regulating neutrophil/interleukin-8 signaling. Hepatology Research: the Official Journal of the Japan Society of Hepatology 50(11): 1284-1296
Luengo-Gil, Gés.; Calvo, Mía.Inmaculada.; Martín-Villar, E.; Águila, S.; Bohdan, N.; Antón, A.I.; Espín, S.; Ayala de la Peña, F.; Vicente, V.; Corral, J.; Quintanilla, M.; Martínez-Martínez, I. 2016: Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase. Scientific Reports 6: 27544
Bravo-Pérez, C.; de la Morena-Barrio, M.E.; Vicente, V.; Corral, J. 2020: Antithrombin deficiency as a still underdiagnosed thrombophilia: a primer for internists. Polish Archives of Internal Medicine 130(10): 868-877
Smith, N.; Warren, B.B.; Smith, J.; Jacobson, L.; Armstrong, J.; Kim, J.; Di Paola, J.; Manco-Johnson, M. 2021: Antithrombin deficiency: a pediatric disorder. Thrombosis Research 202: 45-51
Schmid, J. 1946: Antithrombin effect in typhus patients. Wiener Klinische Wochenschrift 58(2): 34
Madhok, J.; Ruoss, S.J. 2021: Antithrombin in Extracorporeal Membrane Oxygenation: to Replenish or not to Replenish?. Critical Care Medicine 49(4): E480-E481
Taniguchi, K.; Ohbe, H.; Yamakawa, K.; Matsui, H.; Fushimi, K.; Yasunaga, H. 2020: Antithrombin use and mortality in patients with stage IV solid tumor-associated disseminated intravascular coagulation: a nationwide observational study in Japan. Bmc Cancer 20(1): 867
Mungmungpuntipantip, R.; Wiwanitkit, V. 2021: Antithrombin, COVID-19, and Fresh Frozen Plasma Treatment. Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology 38(2): 157-159
Morris, J.D.; Harris, R.E.; Hashmi, R.; Sambrano, J.E.; Gruppo, R.A.; Becker, A.T.; Morris, C.L. 1997: Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplantation 20(10): 871-878
Johnson, D.J.D.; Li, W.; Adams, T.E.; Huntington, J.A. 2006: Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO Journal 25(9): 2029-2037
Haraguchi, K.; Takehisa, T.; Mizuno, T.; Kubota, K. 2015: Antithrombogenic Properties of Amphiphilic Block Copolymer Coatings: Evaluation of Hemocompatibility Using Whole Blood. Acs Biomaterials Science and Engineering 1(6): 352-362
Guglielmone, H.A.; Agnese, A.M.; Nuñez-Montoya, S.C.; Cabrera, J.é L.; Cuadra, G.R. 2020: Antithrombotic "in vivo" effects of quercetin 3,7,3',4'-tetrasulfate isolated from Flaveria bidentis in an experimental thrombosis model in mice. Thrombosis Research 195: 190-192
Meade, M.J.; Tumati, A.; Chantachote, C.; Huang, E.C.; Rutigliano, D.N.; Rubano, J.A.; Vosswinkel, J.A.; Jawa, R.S. 2021: Antithrombotic Agent use in Elderly Patients Sustaining Low-Level Falls. Journal of Surgical Research 258: 216-223
Ye, Y.; Zhang, F.-T.; Wang, X.-Y.; Tong, H.-X.; Zhu, Y.-T. 2020: Antithrombotic Agents for tPA-Induced Cerebral Hemorrhage: a Systematic Review and Meta-Analysis of Preclinical Studies. Journal of the American Heart Association 9(24): E017876
Meah, M.N.; Raftis, J.; Wilson, S.J.; Perera, V.; Garonzik, S.M.; Murthy, B.; Everlof, J.G.; Aronson, R.; Luettgen, J.; Newby, D.E. 2020: Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition. Arteriosclerosis Thrombosis and Vascular Biology 40(11): 2678-2685
Das, S.; Deb, A.; Pal, T. 2021: Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas. Medical Principles and Practice: International Journal of the Kuwait University Health Science Centre 30(5): 412-421
Capranzano, P.; Angiolillo, D.J. 2021: Antithrombotic Management of Elderly Patients with Coronary Artery Disease. JACC. Cardiovascular Interventions 14(7): 723-738
Renner, E.; Barnes, G.D. 2020: Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar. Journal of the American College of Cardiology 76(18): 2142-2154
Fanaroff, A.C.; Lopes, R.D. 2021: Antithrombotic Regimens in Low-Risk Patients Undergoing Transcatheter Aortic Valve Replacement: Trials Evaluating Patient-Centered Outcomes Needed. Circulation. Cardiovascular Interventions 14(1): E010331
Cotoban, A.G.; Udroiu, C.A.; Vina, R.; Vinereanu, D. 2021: Antithrombotic Strategies in Invasively Managed Patients with Non-ST Elevation Acute Coronary Syndromes and Non-Valvular Atrial Fibrillation in Romania. Maedica 16(1): 6-15
Kwak, S.; Yang, H.-M. 2019: Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Journal of Lipid and Atherosclerosis 8(1): 8-14
Maldonado, E.; Tao, D.; Mackey, K. 2020: Antithrombotic Therapies in COVID-19 Disease: a Systematic Review. Journal of General Internal Medicine 35(9): 2698-2706
Godino, C.; Pivato, C.A.; Rubino, C.; Russi, A.; Cera, M.; Margonato, A. 2020: Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation. American Journal of Cardiology 129: 122-124
Capodanno, D.; Collet, J.-P.; Dangas, G.; Montalescot, G.; Ten Berg, J.M.; Windecker, S.; Angiolillo, D.J. 2021: Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. JACC. Cardiovascular Interventions 14(15): 1688-1703
Bittl, J.A. 2021: Antithrombotic Therapy after Acute Coronary Syndromes. New England Journal of Medicine 384(19): 1872-1873
Parada Barcia, J.; Raposeiras Roubin, S.; Abu-Assi, E. 2021: Antithrombotic Therapy after Acute Coronary Syndromes. New England Journal of Medicine 384(19): 1873
Zimarino, M.; Angiolillo, D.J.; Dangas, G.; Capodanno, D.; Barbato, E.; Hahn, J.-Y.; Giustino, G.; Watanabe, H.; Costa, F.; Cuisset, T.; Rossini, R.; Sibbing, D.; Burzotta, F.; Louvard, Y.; Shehab, A.; Renda, G.; Kimura, T.; Gwon, H.-C.; Chen, S.-L.; Costa, R.A.; Koo, B.-K.; Storey, R.F.; Valgimigli, M.; Mehran, R.; Stankovic, G. 2021: Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. Eurointervention: Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 17(1): 59-66
Capodanno, D.; Angiolillo, D.J. 2020: Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. Circulation 142(22): 2172-2188
Matsuzawa, Y.; Kimura, K.; Yasuda, S.; Kaikita, K.; Akao, M.; Ako, J.; Matoba, T.; Nakamura, M.; Miyauchi, K.; Hagiwara, N.; Hirayama, A.; Matsui, K.; Ogawa, H. 2021: Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients with Prior Atherothrombotic Disease: a Post Hoc Analysis of the AFIRE Trial. Journal of the American Heart Association 10(21): E020907
Patti, G.; De Caterina, R. 2019: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. New England Journal of Medicine 381(25): 2480
Gremmel, T. 2019: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. New England Journal of Medicine 381(25): 2480-2481
Lee, K.-H.; Ou, S.-M.; Chu, Y.-C.; Lin, Y.-P.; Tsai, M.-T.; Tarng, D.-C. 2021: Antithrombotic Therapy for Chronic Kidney Disease Patients with Concomitant Atrial Fibrillation and Coronary Artery Disease. Frontiers in Cardiovascular Medicine 8: 751359
Fernando, H.; McFadyen, J.D.; Palasubramaniam, J.; Shaw, J.; Wang, X.; Stub, D.; Peter, K. 2020: Antithrombotic Therapy in Myocardial Infarction: Historic Perils and Current Challenges-A 70-Year Journey. Thrombosis and Haemostasis 120(10): 1352-1356
Calabrò, P.; Gragnano, F.; Niccoli, G.; Marcucci, R.; Zimarino, M.; Spaccarotella, C.; Renda, G.; Patti, G.; Andò, G.; Moscarella, E.; Mancone, M.; Cesaro, A.; Giustino, G.; De Caterina, R.; Mehran, R.; Capodanno, D.; Valgimigli, M.; Windecker, S.; Dangas, G.D.; Indolfi, C.; Angiolillo, D.J. 2021: Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. Circulation 144(16): 1323-1343
Darius, H. 2020: Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation. Deutsche Medizinische Wochenschrift 145(14): 978-986
Camaj, A.; Miller, M.S.; Halperin, J.L.; Giustino, G. 2020: Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiology Clinics 38(4): 551-561
Hand, K.R.; Hale, G.M. 2021: Antithrombotic Therapy in Peripheral Artery Disease: Stepping in the Right Direction. American Journal of Cardiovascular Drugs: Drugs Devices and other Interventions 21(5): 523-534
Halperin, J.L.; Chen, H.; Olin, J.W. 2021: Antithrombotic Therapy to Reduce Mortality in Patients with Atherosclerosis: 2 Pathways to a Single Goal. Journal of the American College of Cardiology 78(1): 24-26
Verstraete, A.; Herregods, M.C.; Verbrugghe, P.; Lamberigts, M.; Vanassche, T.; Meyns, B.; Oosterlinck, W.; Rega, F.; Adriaenssens, T.; Van Hoof, L.; Keuleers, S.; Vandenbriele, C.; Sinnaeve, P.; Janssens, S.; Dubois, C.; Meuris, B.; Verhamme, P. 2021: Antithrombotic Treatment After Surgical and Transcatheter Heart Valve Repair and Replacement. Frontiers in Cardiovascular Medicine 8: 702780
Diener, H.-C.; Sacco, R.L.; Easton, J.D.; Granger, C.B.; Bar, M.; Bernstein, R.A.; Brainin, M.; Brueckmann, M.; Cronin, L.; Donnan, G.; Gdovinová, Z.; Grauer, C.; Kleine, E.; Kleinig, T.J.; Lyrer, P.; Martins, S.; Meyerhoff, J.; Milling, T.; Pfeilschifter, W.; Poli, S.; Reif, M.; Rose, D.Z.; Šaňák, D.; Schäbitz, W.-R.üd. 2020: Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups. Stroke 51(6): 1758-1765
Ebner, M.; Lankeit, M. 2020: Antithrombotic Treatment of Pulmonary Embolism. Deutsche Medizinische Wochenschrift 145(14): 970-977
Bauersachs, R.; Wu, O.; Briere, J.-B.; Bowrin, K.; Borkowska, K.; Jakubowska, A.; Taieb, V.; Toumi, M.; Huelsebeck, M. 2020: Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: a Systematic Review of Randomised Controlled Trials. Cardiovascular Therapeutics 2020: 3057168
Berry, C.N.; Lunven, C.; Lechaire, I.; Girardot, C.; O'Connor, S.E. 1998: Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis. British Journal of Pharmacology 125(1): 29-34
Broersma, R.J.; Kutcher, L.W.; Heminger, E.F.; Krstenansky, J.L.; Marshall, F.N. 1991: Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals. Thrombosis and Haemostasis 65(4): 377-381
Cardillo, G.; Viggiano, G.V.; Russo, V.; Mangiacapra, S.; Cavalli, A.; Castaldo, G.; Agrusta, F.; Bellizzi, A.; Amitrano, M.; Iannuzzo, M.; Sacco, C.; Lodigiani, C.; Fontanella, A.; Di Micco, P. 2021: Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: the FONDENOXAVID Study. Journal of Blood Medicine 12: 69-75
Liss, D.B.; Mullins, M.E. 2021: Antithrombotic and Antiplatelet Drug Toxicity. Critical Care Clinics 37(3): 591-604
Huang, J.; Song, W.; Hua, H.; Yin, X.; Huang, F.; Alolga, R.N. 2021: Antithrombotic and anticoagulant effects of a novel protein isolated from the venom of the Deinagkistrodon acutus snake. Biomedicine and PharmacoTherapy 138: 111527
Lee, W.; Lee, J.; Kulkarni, R.; Kim, M-Ae.; Hwang, J.Sam.; Na, M.; Bae, J-Sup. 2016: Antithrombotic and antiplatelet activities of small-molecule alkaloids from Scolopendra subspinipes mutilans. Scientific Reports 6: 21956
Ku, J.C.; Priola, S.M.; Mathieu, F.; Taslimi, S.; Pasarikovski, C.R.; Zeiler, F.A.; Machnowska, M.; Nathens, A.; Yang, V.X.D.; da Costa, L. 2021: Antithrombotic choice in blunt cerebrovascular injuries: Experience at a tertiary trauma center, systematic review, and meta-analysis. Journal of Trauma and Acute Care Surgery 91(1): E1-E12
Dub, A.M.; Dugani, A.M. 2013: Antithrombotic effect of repeated doses of the ethanolic extract of local olive (Olea europaea L.) leaves in rabbits. Libyan Journal of Medicine 8(1): 20947
Liu, H.; Chen, X.; Liu, Y.; Fang, C.; Chen, S. 2021: Antithrombotic effects of Huanglian Jiedu decoction in a rat model of ischaemia-reperfusion-induced cerebral stroke. Pharmaceutical Biology 59(1): 823-827
Sato, K.; Kawasaki, T.; Hisamichi, N.; Taniuchi, Y.; Hirayama, F.; Koshio, H.; Matsumoto, Y. 1998: Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. British Journal of Pharmacology 123(1): 92-96
Sakamoto, T.; Kudoh, T.; Sakamoto, K.; Matsui, K.; Ogawa, H. 2014: Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study. Hypertension Research: Official Journal of the Japanese Society of Hypertension 37(6): 513-518
Rebello, S.S.; Bentley, R.G.; Morgan, S.R.; Kasiewski, C.J.; Chu, V.; Perrone, M.H.; Leadley, R.J. 2001: Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. British Journal of Pharmacology 133(7): 1190-1198
De Luca, L.; Rubboli, A.; Bolognese, L.; Gonzini, L.; Urbinati, S.; Murrone, A.; Scotto di Uccio, F.; Ferrari, F.; Lucà, F.; Caldarola, P.; Lucci, D.; Gabrielli, D.; Di Lenarda, A.; Gulizia, M.M. 2020: Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study. Bmj Open 10(12): E041044
Chu, G.; Seelig, J.; Trinks-Roerdink, E.M.; Geersing, G.J.; Rutten, F.H.; de Groot, J.R.; Huisman, M.V.; Hemels, M.E.W. 2020: Antithrombotic management of patients with atrial fibrillation-Dutch anticoagulant initiatives anno 2020. Netherlands Heart Journal: Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 28(Suppl 1): 19-24
Scheers, H.; Nawrot, T.S.; Nemery, B.; De Troeyer, K.; Callens, M.; De Smet, F.; Van Nieuwenhuyse, A.; Casas, L. 2020: Antithrombotic medication and endovascular interventions associated with short-term exposure to particulate air pollution: a nationwide case-crossover study. Environmental Pollution 266(Part 1): 115130
Lee, W.; Lee, S.; Choi, J.; Park, J-Hyeong.; Kim, K-Min.; Jee, J-Goo.; Bae, J-Sup. 2017: Antithrombotic properties of JJ1, a potent and novel thrombin inhibitor. Scientific Reports 7(1): 14862
Nyansah, W.B.; Koffuor, G.A.; Ben, I.O.; Gyanfosu, L.; Ehigiator, B.E. 2021: Antithrombotic property of an aqueous extract from Pseudocedrela kotschyi and Adenia cissampeloides. Research in Pharmaceutical Sciences 16(4): 436-446
Karimi, M.; Bozorgi, H.; Zarei, T.; Bordbar, M.; Amanati, A.; Safaei, A.; De Sanctis, V. 2020: Antithrombotic prophylaxis in children and adolescents' patients with SARS-CoV-2 (COVID-19) infection: A practical guidance for clinicians. ActaBio-Medica:AteneiParmensis 91(4):E2020170
Robinson, D.; Pyle, L.; Foreman, B.; Ngwenya, L.B.; Adeoye, O.; Woo, D.; Kreitzer, N. 2021: Antithrombotic regimens and need for critical care interventions among patients with subdural hematomas. American Journal of Emergency Medicine 47: 6-12
Strauss, S.A.; Jetty, P.; Kobewka, D.; Carrier, M. 2021: Antithrombotic regimens in females with symptomatic lower extremity peripheral arterial disease: protocol for a systematic review and meta-analysis. Bmj Open 11(5): E042980
Urbanowicz, T.; Olasińska-Wiśniewska, A.; Cassadei, V.; Straburzyńska-Migaj, E.; Buczkowski, P.; Jemielity, M. 2020: Antithrombotic regimens in patients awaiting heart transplant: a single-center experience. Kardiologia Polska 78(7-8): 753-755
Lim, G.B. 2020: Antithrombotic therapy after TAVI. Nature Reviews. Cardiology 17(6): 323
Wohl, V.R.; Hecht, E.; Shaughnessy, K. 1999: Antithrombotic therapy after coronary-artery stenting. New England Journal of Medicine 340(17): 1366; Author Reply 1367-1368
Zhong, W.; Lou, Y.; Qiu, C.; Li, D.; Zhang, H. 2020: Antithrombotic therapy after iliac vein stenting. Zhejiang da Xue Xue Bao. Yi Xue Ban 49(1): 131-136
Hoefnagels, W.A.J. 2005: Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives. Nederlands Tijdschrift Voor Geneeskunde 149(9): 498; Author Reply 498
Espinola-Klein, C. 2021: Antithrombotic therapy after peripheral revascularization. Deutsche Medizinische Wochenschrift 146(3): 136-140
Spyropoulos, A.C.; Ortel, T.L. 2013: Antithrombotic therapy and invasive procedures. New England Journal of Medicine 369(11): 1078
Bomzer, C.A. 2013: Antithrombotic therapy and invasive procedures. New England Journal of Medicine 369(11): 1078-1079
Grzybowski, A.; Ascaso, F.J. 2013: Antithrombotic therapy and invasive procedures. New England Journal of Medicine 369(11): 1079
Kakkar, A.K.; Macbeth, F. 2010: Antithrombotic therapy and survival in patients with malignant disease. British Journal of Cancer 102 Suppl. 1: S24-S29
Kahale, L.A.; Matar, C.F.; Tsolakian, I.; Hakoum, M.B.; Yosuico, V.E.; Terrenato, I.; Sperati, F.; Barba, M.; Hicks, L.K.; Schünemann, H.; Akl, E.A. 2021: Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents. Cochrane Database of Systematic Reviews 9: Cd014739
Ihle-Hansen, H.åk.; Sandset, E.C.; Hagberg, G.; Ihle-Hansen, H. 2020: Antithrombotic therapy for established cerebrovascular disease. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 140(12)
Franchi, F.; Rollini, F.; Angiolillo, D.J. 2017: Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nature Reviews. Cardiology 14(6): 361-379
De Stefano, V.; Finazzi, G.; Barbui, T. 2018: Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. Blood Cancer Journal 8(7): 65
Fareed, J. 2015: Antithrombotic therapy in 2014: Making headway in anticoagulant and antiplatelet therapy. Nature Reviews. Cardiology 12(2): 70-71
Bhatt, D.L. 2018: Antithrombotic therapy in 2017: Advances in atherosclerosis, atrial fibrillation, and valvular disease. Nature Reviews. Cardiology 15(2): 71-72
Saeed, S.; Bleie, Øy. 2021: Antithrombotic therapy in COVID-19. Pakistan Journal of Medical Sciences 37(4): 931-932
Uchiyama, S. 2006: Antithrombotic therapy in acute ischemic stroke. Rinsho Shinkeigaku 46(11): 844-846
Turpie, A.G.; Connolly, S.J. 1996: Antithrombotic therapy in atrial fibrillation. Canadian Family Physician Medecin de Famille Canadien 42: 1341-1345
Farré, J.; Navarro, F.; Romero, J.; Rivas, D.; Manuel Rubio, J.; Sanziani, L. 1996: Antithrombotic therapy in atrial fibrillation. Revista Espanola de Cardiologia 49(Suppl 2): 42-49
Da Costa, J.T. 1999: Antithrombotic therapy in atrial fibrillation. Acta Medica Portuguesa 12(7-11): 245-254
Chin, B.; Lip, G.Y. 2000: Antithrombotic therapy in atrial fibrillation. Journal of the Royal Society of Medicine 93(5): 278-279
Kiraç, F.Suna. 2007: Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?. Anadolu Kardiyoloji Dergisi: Akd 7(2): 214-5; Author Reply 218-9
Tandoğan, I. 2007: Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?. Anadolu Kardiyoloji Dergisi: Akd 7(2): 216; Author Reply 218-9
Marx, N. 2020: Antithrombotic therapy in cardiovascular diseases. Deutsche Medizinische Wochenschrift 145(14): 947
Calvert, P.; Gupta, D.; Lip, G.Y.H. 2021: Antithrombotic therapy in chronic liver disease: to clot or not to clot. Lancet Regional Health. Europe 10: 100226
Wei, L.; Su, E.; Liu, W.; Xing, W.; Liu, X.; Zhang, Y.; Wang, S.; Cheng, Q.; Qi, D.; Gao, C. 2020: Antithrombotic therapy in coronary artery disease patients with atrial fibrillation. Bmc Cardiovascular Disorders 20(1): 323
Felmeden, D.C.; Lip, G.Y.H. 2005: Antithrombotic therapy in hypertension: a Cochrane Systematic review. Journal of Human Hypertension 19(3): 185-196
Marijon, E. 2020: Antithrombotic therapy in patients with atrial fibrillation. La Revue du Praticien 70(8): 903-909
Mihajlovic, M.; Marinkovic, M.; Kozieł, M.; Mujovic, N.; Lip, G.Y.H.; Potpara, T.S. 2020: Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention. Kardiologia Polska 78(6): 512-519
Procházka, M.; Procházková, J.; Slavík, L. 2010: Antithrombotic therapy in pregnancy. Vnitrni Lekarstvi 56(2): 130-137
Mélon, P. 2000: Antithrombotic therapy of atrial fibrillation. Revue Medicale de Liege 55(4): 297-301
Colleran, R.ói.ín.; Byrne, R.A.; Ndrepepa, G.; Alvarez-Covarrubias, H.A.; Mayer, K.; Kuna, C.; Rai, H.; Kastrati, A.; Cassese, S. 2022: Antithrombotic Therapy with or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: a Meta-Analysis and Network Analysis of Randomized Controlled Trials. Cardiovascular Revascularization Medicine: Including Molecular Interventions 36: 99-106
Pellegrini, C.; Xhepa, E.; Ndrepepa, G.; Alvarez-Covarrubias, H.; Kufner, S.; Lahmann, A.L.; Rheude, T.; Rai, H.; Mayr, N.P.; Schunkert, H.; Kastrati, A.; Joner, M.; Cassese, S. 2022: Antithrombotic therapy with or without clopidogrel after transcatheter aortic valve replacement. a meta-analysis of randomized controlled trials. Clinical Research in Cardiology: Official Journal of the German Cardiac Society 111(1): 14-22
Lim, G.B. 2017: Antithrombotic therapy: Dual therapy after PCI in AF. Nature Reviews. Cardiology 14(11): 634
Myrvang, H. 2010: Antithrombotic therapy: Is combination antithrombotic therapy safe for patients with atrial fibrillation?. Nature Reviews. Cardiology 7(12): 665
Bornstein, N.M.; Auriel, E. 2007: Antithrombotic treatment and stroke severity in patients with atrial fibrillation. Nature Clinical Practice. Neurology 3(5): 252-253
Lip, G.Y.H.; Boos, C.J. 2008: Antithrombotic treatment in atrial fibrillation. Postgraduate Medical Journal 84(991): 252-258
Huisman, M.V. 2021: Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention. Netherlands Heart Journal: Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 29(3): 119-120
Vitolo, M.; Javed, S.; Capodanno, D.; Rubboli, A.; Boriani, G.; Lip, G.Y.H. 2020: Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. Expert Review of Cardiovascular Therapy 18(9): 587-600
Sagris, D.; Georgiopoulos, G.; Leventis, I.; Pateras, K.; Pearce, L.A.; Korompoki, E.; Makaritsis, K.; Vemmos, K.; Milionis, H.; Ntaios, G. 2020: Antithrombotic treatment in patients with stroke and supracardiac atherosclerosis. Neurology 95(5): E499-E507
Migliore, F.; Providencia, R.; Farkowski, M.M.; Dan, G.A.; Daniel, S.; Potpara, T.S.; Jubele, K.; Chun, J.K.R.; de Asmundis, C.; Zorzi, A.; Boveda, S. 2021: Antithrombotic treatment management in low stroke risk patients undergoing cardioversion of atrial fibrillation <48 h duration: results of an EHRA survey. Europace: European Pacing Arrhythmias and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing Arrhythmias and Cardiac Cellular Electrophysiology of the European Society of Cardiology 23(9): 1502-1507
Patrono, C.; Malliani, A. 2001: Antithrombotic treatment of acute coronary syndromes. Recenti Progressi in Medicina 92(11 Suppl): 3a-7a
Gresele, P.; Paciullo, F.; Migliacci, R. 2020: Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma. Internal and Emergency Medicine 15(7): 1169-1181
Ibeh, C.; Tirschwell, D.L.; Mahr, C.; Creutzfeldt, C.J. 2020: Antithrombotics after Intracranial Hemorrhage in Patients with Left Ventricular Assist Devices. Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation 39(4s): S149
Ni, H. 2020: Antithrombotics from Frog Skin Secretions. Thrombosis and Haemostasis 120(10): 1351
Van Rijckevorsel, V.A.J.I.M.; Roukema, G.R.; Klem, T.M.A.L.; Kuijper, T.M.; de Jong, L. 2021: Antithrombotics in Patients with a Femoral Neck Fracture: Evaluating Daily Practice in an Observational Cohort Study. Geriatric Orthopaedic Surgery and Rehabilitation 12: 21514593211037755
Van Minnen, B.; Piersma-Wichers, M.; Rooijers, W.; van Diermen, D.E.; Rozema, F.R. 2020: Antithrombotics: backgrounds with haemostasis and antithrombotic therapy. Nederlands Tijdschrift Voor Tandheelkunde 127(11): 617-624
Hintz, B.; Webber, M.M. 1965: Antithymic antibody localization in the mouse. Nature 208(5012): 797-798
Bae, S.; Durand, C.M.; Garonzik-Wang, J.M.; Chow, E.K.H.; Kucirka, L.M.; McAdams-DeMarco, M.A.; Massie, A.B.; Al Ammary, F.; Coresh, J.; Segev, D.L. 2020: Antithymocyte Globulin Versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients with Hepatitis C Virus. Transplantation 104(6): 1294-1303
Shibusawa, M.; Tanimoto, T. 2020: Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients with Hematologic Malignancies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 38(35): 4223-4224
Chang, Y.-J.; Wu, D.-P.; Lai, Y.-R.; Liu, Q.-F.; Sun, Y.-Q.; Hu, J.; Hu, Y.; Zhou, J.-F.; Li, J.; Wang, S.-Q.; Li, W.; Du, X.; Lin, D.-J.; Ren, H.-Y.; Chen, F.-P.; Li, Y.-H.; Zhang, X.; Huang, H.; Song, Y.-P.; Jiang, M.; Hu, J.-D.; Liang, Y.-M.; Wang, J.-B.; Xiao, Y.; Huang, X.-J. 2020: Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients with Hematologic Malignancies: a Multicenter, Open-Label, Randomized Controlled Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 38(29): 3367-3376
Khouzam, S.; Narula, T.; Alvarez, F.; Elrefaei, M. 2020: Antithymocyte Globulin is Associated with a Lower Incidence of De Novo Donor-Specific Antibody Detection in Lung Transplant Recipients: A Single-Center Experience. Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation 39(4s): S324
Von Stein, L.; Leino, A.D.; Pesavento, T.; Rajab, A.; Winters, H. 2021: Antithymocyte induction dosing and incidence of opportunistic viral infections using steroid-free maintenance immunosuppression. Clinical Transplantation 35(1): E14102
Yazji, S.; Giles, F.J.; Tsimberidou, A-M.; Estey, E.H.; Kantarjian, H.M.; O'Brien, S.A.; Kurzrock, R. 2003: Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 17(11): 2101-2106
Jullien, M.; Guillaume, T.; Peterlin, P.; Garnier, A.; Le Bourgeois, A.; Debord, C.; Mahe, B.; Dubruille, V.; Wuilleme, S.; Blin, N.; Touzeau, C.; Gastinne, T.; Tessoulin, B.; Le Bris, Y.; Eveillard, M.; Duquesne, A.; Moreau, P.; Le Gouill, S.; Bene, M.C.; Chevallier, P. 2020: Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. Scientific Reports 10(1): 15399
Shiratori, S. 2021: Antithymocyte globulin for GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation. Japanese Journal of Clinical Hematology 62(8): 1265-1274
Kumar, A.; Mhaskar, A.R.; Reljic, T.; Mhaskar, R.S.; Kharfan-Dabaja, M.A.; Anasetti, C.; Mohty, M.; Djulbegovic, B. 2012: Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia 26(4): 582-588
Luo, Y.; Jin, M.; Tan, Y.; Zhao, Y.; Shi, J.; Zhu, Y.; Zheng, W.; Lai, X.; Yu, J.; Huang, H. 2019: Antithymocyte globulin improves GVHD-free and relapse-free survival in unrelated hematopoietic stem cell transplantation. Bone Marrow Transplantation 54(10): 1668-1675
Wang, H.; Liu, H.; Zhou, J-Yi.; Zhang, T-Tong.; Jin, S.; Zhang, X.; Chen, S-Ning.; Li, W-Yang.; Xu, Y.; Miao, M.; Wu, D-Pei. 2017: Antithymocyte globulin improves the survival of patients with myelodysplastic syndrome undergoing HLA-matched unrelated donor and haplo-identical donor transplants. Scientific Reports 7: 43488
Kreis, H.; Mansouri, R.; Descamps, J.M.; Dandavino, R.; N'Guyen, A.T.; Bach, J.F.; Crosnier, J. 1981: Antithymocyte globulin in cadaver kidney transplantation: a randomized trial based on T-cell monitoring. Kidney International 19(3): 438-444
Jin, F.; He, J.; Jin, C.; Fan, W.; Shan, Y.; Zhang, Z.; Sun, L.; Hu, Z.; Yang, Y-Guang. 2017: Antithymocyte globulin treatment at the time of transplantation impairs donor hematopoietic stem cell engraftment. Cellular and Molecular Immunology 14(5): 443-450
Sirvent-von Bueltzingsloewen, A.; Gratecos, N.; Legros, L.; Fuzibet, J.G.; Cassuto, J.P. 2001: Antithymocyte-associated reticulonodular pneumonitis during a conditioning regimen of reduced intensity for genoidentical bone marrow transplantation. Bone Marrow Transplantation 27(8): 891-892
Nishino, M.; Murakami, M. 2005: Antithyroglobulin antibodies and antimicrosomal antibodies. Nihon Rinsho. Japanese Journal of Clinical Medicine 63(Suppl 8): 280-283
Beernaert, L.; Vanderhulst, J. 2020: Antithyroid Drug-Induced Lupus Erythematosus and Immunoglobulin a Deficiency. American Journal of Case Reports 21: E927929
Rabiee, A.; Salman, M.; Tourky, M.; Ameen, M.; Hussein, A.; Salman, A.; Labib, S.; Soliman, A.A.Z.A.; Shaaban, H.E.-D.; GabAllah, G.; Abouelregal, T. 2021: Antithyroid Peroxidase Antibodies and Histopathological Outcomes in Egyptian Patients Subjected to Total Thyroidectomy for Non-Malignant Nodular Goiter. International Journal of General Medicine 14: 2421-2425
Nizet, A. 1948: Antithyroid and young red blood cells in vitro. Archives Internationales de Pharmacodynamie et de Therapie 77(2): 141-144
Ghosh, R.; Dubey, S.; Sarkar, A.; Biswas, D.; Ray, A.; Roy, D.; Chatterjee, S.; Benito-León, J.án. 2021: Antithyroid arthritis syndrome in a case of post-COVID-19 subacute thyroiditis. Diabetes and Metabolic Syndrome 15(3): 683-686
Bliddal, S.; Rasmussen, A.Krogh.; Sundberg, K.; Brocks, V.; Feldt-Rasmussen, U. 2011: Antithyroid drug-induced fetal goitrous hypothyroidism. Nature Reviews. Endocrinology 7(7): 396-406
Andersen, S.L.; Andersen, S. 2020: Antithyroid drugs and birth defects. Thyroid Research 13: 11
Korevaar, T.I.M.; Peeters, R.P. 2018: Antithyroid drugs and congenital malformations. Nature Reviews. Endocrinology 14(6): 328-329
Glock, G.E. 1946: Antithyroid drugs and cytochrome oxidase activity. Nature 158: 169
Kilgour, J.M. 1947: Antithyroid drugs in the treatment of hyperthyroidism. Treatment Services Bulletin. Canada. DePartment of Veterans' Affairs 2(7): 88
Kilgour, J.M. 1947: Antithyroid drugs in the treatment of hyperthyroidism. Canadian Medical Association Journal 57(6): 585-588
Caeiro, J.A. 1952: Antithyroid drugs; advantages and hazards. Boletines y Trabajos de la Academia Argentina de Cirugia. Academia Argentina de Cirugia 36(23): 644-645
Busacchi, V.; Galuppi, G. 1948: Antithyroid drugs; clinical research on aminomethylthiazole hydrochloride. Minerva Medica 39(49 Part 2): 646-649
Faienza, M.Felicia.; Palmieri, V.Valeria.; Chiarito, M.; Lassandro, G.; Giordano, P. 2020: Antithyroid treatment improves thrombocytopenia in a young patient with graves' disease. ActaBio-Medica:AteneiParmensis 91(4):E2020194
Langer, P. 1960: Antithyroidal effect of some fresh plants on guinea pigs. Nature 185: 174-175
Sbravati, F.; Cosentino, A.; Lenzi, J.; Fiorentino, M.; Ambrosi, F.; Salerno, A.; Di Biase, A.; Righi, B.; Brusa, S.; Valin, P.S.; Bruni, L.; Battistini, B.; Pagano, S.; Grondona, A.G.; Labriola, F.; Alvisi, P. 2022: Antitissue transglutaminase antibodies' normalization after starting a gluten-free diet in a large population of celiac children-a real-life experience. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 54(3): 336-342
Salera, A.M. 1945: Antitoxic factor in melancholy; Clinical case. Prensa Medica Argentina 32: 1973
Lemetayer, E.; Nicol, L. 1947: Antitoxic immunity transmitted from Mare to foal; Particular case of the immunity of mares vaccinated against tetanus. Annales de l'Institut Pasteur 73(4): 297-322
Binet, L.; Wellers, G. 1947: Antitoxic power of glutathione. Schweizerische Medizinische Wochenschrift 77(1-2): 8-11
Soo, V.W.C.; Wood, T.K. 2013: Antitoxin MqsA represses curli formation through the master biofilm regulator CsgD. Scientific Reports 3: 3186
Beck, I.N.; Usher, B.; Hampton, H.G.; Fineran, P.C.; Blower, T.R. 2020: Antitoxin autoregulation of M. tuberculosis toxin-antitoxin expression through negative cooperativity arising from multiple inverted repeat sequences. Biochemical Journal 477(12): 2401-2419
Scott, A.B. 1988: Antitoxin reduces botulinum side effects. Eye 2: 29-32
Rainey, G.Jonah.A.; Young, J.A.T. 2004: Antitoxins: novel strategies to target agents of bioterrorism. Nature Reviews. Microbiology 2(9): 721-726
Hadjifrangiskou, M.; Kostakioti, M.; Hultgren, S.J. 2011: Antitoxins: therapy for stressed bacteria. Nature Chemical Biology 7(6): 345-347
Becker, Y. 1971: Antitrachoma activity of rifamycin B and 8-O-acetylrifamycin S. Nature 231(5298): 115-116
Jones, R.J.; Mansfield, T.A. 1971: Antitranspirant activity of the methyl and phenyl esters of abscisic acid. Nature 231(5301): 331-332
Boland, J.M. 1981: Antitrust in health care. Medical Group Management 28(6): 18-20; 26
Taylor, M.; Majoras, D.Platt. 2006: Antitrust watchdog. FTC Chairman Majoras says healthcare remains an important priority for her agency. Modern Healthcare 36(26): 28-30
Urbanski, T.; Slopek, S.; Venulet, J. 1951: Antitubercular activity of some 8-hydroxyquinoline derivatives. Nature 168(4262): 29
Priyadarshini, N.; Veeramani, A. 2020: Antitubercular compounds isolated and characterized in Tithonia diversifolia and Couroupita guianensis. International Journal of Mycobacteriology 9(2): 195-199
Song, Z.; Liu, Y.; Gao, J.; Hu, J.; He, H.; Dai, S.; Wang, L.; Dai, H.; Zhang, L.; Song, F. 2021: Antitubercular metabolites from the marine-derived fungus strain Aspergillus fumigatus MF029. Natural Product Research 35(16): 2647-2654
Nizi, M.G.; Desantis, J.; Nakatani, Y.; Massari, S.; Mazzarella, M.A.; Shetye, G.; Sabatini, S.; Barreca, M.L.; Manfroni, G.; Felicetti, T.; Rushton-Green, R.; Hards, K.; Latacz, G.; Satała, G.; Bojarski, A.J.; Cecchetti, V.; Kolář, M.H.; Handzlik, J.; Cook, G.M.; Franzblau, S.G.; Tabarrini, O. 2020: Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors. European Journal of Medicinal Chemistry 201: 112420
Trotsko, N. 2021: Antitubercular properties of thiazolidin-4-ones - a review. European Journal of Medicinal Chemistry 215: 113266
Prentice, S.; Dockrell, H.M. 2020: Antituberculosis BCG vaccination: more reasons for varying innate and adaptive immune responses. Journal of Clinical Investigation 130(10): 5121-5123
Raju, A.; De, S.S.; Ray, M.K.; Degani, M.S. 2021: Antituberculosis activity of polyphenols of Areca catechu. International Journal of Mycobacteriology 10(1): 13-18
Le Hir, M. 1956: Antituberculosis campaign in Morocco. Semaine Medicale Professionelle et Medico-Sociale 32(46): 1445-1456
Wilson, R.; Kumar, P.; Parashar, V.; Vilchèze, C.; Veyron-Churlet, R.; Freundlich, J.S.; Barnes, S.Whitney.; Walker, J.R.; Szymonifka, M.J.; Marchiano, E.; Shenai, S.; Colangeli, R.; Jacobs, W.R.; Neiditch, M.B.; Kremer, L.; Alland, D. 2013: Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. Nature Chemical Biology 9(8): 499-506
Cornforth, J.W.; Hart, P.D.; Rees, R.J.W.; Stock, J.A. 1951: Antituberculous effect of certain surface-active polyoxyethylene ethers in mice. Nature 168(4265): 150-153
Franc, Z.; Hais, I.M.; Horesovsky, O. 1958: Antituberculous factors of milk. Nature 182(4639): 884-885
McKeon, J.; Patel, A.M. 1995: Antituberculous therapy and acute liver failure. Lancet 345(8958): 1170-1171
Caplin, M.; Thompson, N.; Hamilton, M.; McIntyre, N.; Burroughs, A. 1995: Antituberculous therapy and acute liver failure. Lancet 345(8958): 1171
Janes, S.L.; Behrens, J. 1995: Antituberculous therapy and acute liver failure. Lancet 345(8953): 867
FitzGerald, J.M. 1995: Antituberculous therapy and acute liver function. Lancet 345(8958): 1172
Bourke, S.J.; White, J.; Stenton, S.C.; Hendrick, D.J. 1995: Antituberculous therapy and acute liver function. Lancet 345(8958): 1171-1172
Foshay, L.; Ruchman, I.; Nicholes, P.S. 1947: Antitularense serum; correlation between protective capacity for white rats and precipitable antibody content. Journal of Laboratory and Clinical Medicine 32(3): 332
Chang, J.-C.; Chang, H.-S.; Wu, Y.-C.; Cheng, W.-L.; Lin, T.-T.; Chang, H.-J.; Chen, S.-T.; Liu, C.-S. 2020: Antitumor Actions of Intratumoral Delivery of Membrane-Fused Mitochondria in a Mouse Model of Triple-Negative Breast Cancers. Oncotargets and Therapy 13: 5241-5255
Hou, Y.; Pi, C.; Feng, X.; Wang, Y.; Fu, S.; Zhang, X.; Zhao, L.; Wei, Y. 2020: Antitumor Activity In Vivo and Vitro of new Chiral Derivatives of Baicalin and Induced Apoptosis via the PI3K/Akt Signaling Pathway. Molecular Therapy Oncolytics 19: 67-78
Wu, X.-L.; Liu, L.; Wang, Q.-C.; Wang, H.-F.; Zhao, X.-R.; Lin, X.-B.; Lv, W.-J.; Niu, Y.-B.; Lu, T.-L.; Mei, Q.-B. 2020: Antitumor Activity and Mechanism Study of Riluzole and its Derivatives. Iranian Journal of Pharmaceutical Research: Ijpr 19(3): 217-230
Yun, J.; Lee, S.-H.; Kim, S.-Y.; Jeong, S.-Y.; Kim, J.-H.; Pyo, K.-H.; Park, C.-W.; Heo, S.G.; Yun, M.R.; Lim, S.; Lim, S.M.; Hong, M.H.; Kim, H.R.; Thayu, M.; Curtin, J.C.; Knoblauch, R.E.; Lorenzi, M.V.; Roshak, A.; Cho, B.C. 2020: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discovery 10(8): 1194-1209
Qiu, Y.; Sun, J.; Qiu, J.; Chen, G.; Wang, X.; Mu, Y.; Li, K.; Wang, W. 2020: Antitumor Activity of Cabazitaxel and MSC-TRAIL Derived Extracellular Vesicles in Drug-Resistant Oral Squamous Cell Carcinoma. Cancer Management and Research 12: 10809-10820
Ko, E.; Baek, S.; Kim, J.; Park, D.; Lee, Y. 2020: Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells. Development and Reproduction 24(2): 113-123
Niwa, Y.; Asano, M.; Nakagawa, T.; France, D.; Semba, T.; Funahashi, Y. 2020: Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models. Anticancer Research 40(12): 6699-6712
Khalil, M.; Khalifeh, H.; Baldini, F.; Serale, N.; Parodi, A.; Voci, A.; Vergani, L.; Daher, A. 2020: Antitumor Activity of Ethanolic Extract from Thymbra Spicata L. aerial Parts: Effects on Cell Viability and Proliferation, Apoptosis Induction, STAT3, and NF-kB Signaling. Nutrition and Cancer 2020: 1-14
Zhong, L.; Gan, L.; Deng, Z.; Liu, X.; Peng, H.; Tang, H.; Liu, X.; Fang, F.; Yao, F.; Li, W.; Liu, Z.; Hou, W.; Cui, C.; Zhao, Y.; Tan, W.; Shi, W.; He, J. 2020: Antitumor Activity of Lipid-DNA Aptamer Modified T Lymphocytes in Carcinoma. Journal of Biomedical Nanotechnology 16(7): 1110-1118
Yang, K.; Shen, J.; Tan, F.-Q.; Zheng, X.-Y.; Xie, L.-P. 2021: Antitumor Activity of Small Activating RNAs Induced PAWR Gene Activation in Human Bladder Cancer Cells. International Journal of Medical Sciences 18(13): 3039-3049
Yang, T.; Zhu, A.-J.; Wang, J.-S.; Jin, Z. 2020: Antitumor Activity of TRAIL-Mu3 Protein in vitro and in vivo and the Mechanisms. Sichuan da Xue Xue Bao. Yi Xue Ban 51(3): 304-311
Xu, Y.; Jin, X.; Zhang, J.; Wang, K.; Jin, X.; Xu, D.; Tian, X.; Liu, L. 2020: Antitumor Activity of a Novel Double-Targeted System for Folate Receptor-Mediated Delivery of Mitomycin C. Acs Omega 5(41): 26864-26870
Dyrkheeva, N.S.; Zakharenko, A.L.; Novoselova, E.S.; Chepanova, A.A.; Popova, N.A.; Nikolin, V.P.; Luzina, O.A.; Salakhutdinov, N.F.; Ryabchikova, E.I.; Lavrik, O.I. 2021: Antitumor Activity of the Combination of Topotecan and Tyrosyl-DNA-Phosphodiesterase 1 Inhibitor on Model Krebs-2 Mouse Ascite Carcinoma. Molekuliarnaia Biologiia 55(2): 312-317
Lu, L.; Sun, J.; Su, H.; Luo, S.; Chen, J.; Qiu, S.; Chi, Y.; Lin, J.; Xu, X.; Zheng, D. 2021: Antitumor CD8 T cell responses in glioma patients are effectively suppressed by T follicular regulatory cells. Experimental Cell Research 407(2): 112808
Zhao, J.; Chen, S.; Zhu, L.; Zhang, L.; Liu, J.; Xu, D.; Tian, G.; Jiang, T.'a. 2020: Antitumor Effect and Immune Response of Nanosecond Pulsed Electric Fields in Pancreatic Cancer. Frontiers in Oncology 10: 621092
Gong, G.; Jiao, Y.; Pan, Q.; Tang, H.; An, Y.; Yuan, A.; Wang, K.; Huang, C.; Dai, W.; Lu, Y.; Wang, S.; Zhang, J.; Su, H. 2019: Antitumor Effect and Toxicity of an Albumin-Paclitaxel Nanocarrier System Constructed via Controllable Alkali-Induced Conformational Changes. Acs Biomaterials Science and Engineering 5(4): 1895-1906
Dupertuis, Y.M.; Boulens, N.; Angibaud, E.; Briod, A.-S.; Viglione, A.; Allémann, E.; Delie, F.; Pichard, C. 2021: Antitumor Effect of 5-Fluorouracil-Loaded Liposomes Containing n-3 Polyunsaturated Fatty Acids in two Different Colorectal Cancer Cell Lines. Aaps Pharmscitech 22(1): 36
Yang, Z.; Li, Z.; Guo, Z.; Ren, Y.; Zhou, T.; Xiao, Z.; Duan, J.; Han, C.; Cheng, Y.; Xu, F. 2021: Antitumor Effect of Fluoxetine on Chronic Stress-Promoted Lung Cancer Growth via Suppressing Kynurenine Pathway and Enhancing Cellular Immunity. Frontiers in Pharmacology 12: 685898
Feng, Y.; Qin, G.; Chang, S.; Jing, Z.; Zhang, Y.; Wang, Y. 2021: Antitumor Effect of Hyperoside Loaded in Charge Reversed and Mitochondria-Targeted Liposomes. International Journal of Nanomedicine 16: 3073-3089
Lee, E.; Kwon, Y.; Kim, J.; Park, D.; Lee, Y. 2021: Antitumor Effect of Metformin in Combination with Binimetinib on Melanoma Cells. Development and Reproduction 25(2): 93-104
Cheng, T.; Ying, M. 2021: Antitumor Effect of Saikosaponin a on Human Neuroblastoma Cells. Biomed Research International 2021: 5845554
Teratani, M.; Nakamura, S.; Sakagami, H.; Fujise, M.; Hashimoto, M.; Okudaira, N.; Bandow, K.; Iijima, Y.; Nagai, J.; Uesawa, Y.; Wakabayashi, H. 2020: Antitumor Effects and Tumor-specificity of Guaiazulene-3-Carboxylate Derivatives Against Oral Squamous Cell Carcinoma in Vitro. Anticancer Research 40(9): 4885-4894
Cui, L.; Li, Z.; Xu, F.; Tian, Y.; Chen, T.; Li, J.; Guo, Y.; Lyu, Q. 2021: Antitumor Effects of Astaxanthin on Esophageal Squamous Cell Carcinoma by up-Regulation of PPARγ. Nutrition and Cancer 2021: 1-12
Yu, G.; Chen, L.; Hu, Y.; Yuan, Z.; Luo, Y.; Xiong, Y. 2021: Antitumor Effects of Baicalein and Its Mechanism via TGF β Pathway in Cervical Cancer HeLa Cells. Evidence-BasedComplementaryandAlternativeMedicine:Ecam 2021: 5527190
Sampaio, L.A.; Pina, L.íc.T.S.; Serafini, M.R.; Tavares, D.éb.D.S.; Guimarães, A.G. 2021: Antitumor Effects of Carvacrol and Thymol: a Systematic Review. Frontiers in Pharmacology 12: 702487
Yang, Y.; Zhang, L.; Chen, Q.; Lu, W.-L.; Li, N. 2020: Antitumor Effects of Extract of the Oak Bracket Medicinal Mushroom, Phellinus baumii (Agaricomycetes), on Human Melanoma Cells A375 in Vitro and in Vivo. International Journal of Medicinal Mushrooms 22(2): 197-209
Nigra, A.én.D.; de Almeida Bauer Guimarães, D.; Prucca, C.és.G.; Freitas-Silva, O.; Teodoro, A.J.; Gil, G.án.A. 2021: Antitumor Effects of Freeze-Dried Robusta Coffee (Coffea canephora) Extracts on Breast Cancer Cell Lines. Oxidative Medicine and Cellular Longevity 2021: 5572630
Chantree, P.; Surarak, T.; Sangpairoj, K.; Aguilar, P.; Hitakomate, E. 2020: Antitumor Effects of Fucoidan Via Apoptotic and Autophagic Induction on HSC-3 Oral Squamous CellCarcinoma. Asian Pacific Journal of Cancer Prevention: Apjcp 21(8): 2469-2477
Niu, K.; Liu, Y.; Zhou, Z.; Wu, X.; Wang, H.; Yan, J. 2021: Antitumor Effects of Paeoniflorin on Hippo Signaling Pathway in Gastric Cancer Cells. Journal of Oncology 2021: 4724938
Wei, W.; Tang, J.; Li, H.; Huang, Y.; Yin, C.; Li, D.; Tang, F. 2021: Antitumor Effects of Self-Assembling Peptide-Emodin in situ Hydrogels in vitro and in vivo. International Journal of Nanomedicine 16: 47-60
Lai, K.-C.; Chia, Y.-T.; Yih, L.-H.; Lu, Y.-L.; Chang, S.-T.; Hong, Z.-X.; Chen, T.-L.; Hour, M.-J. 2021: Antitumor Effects of the Novel Quinazolinone Holu-12: Induction of Mitotic Arrest and Apoptosis in Human Oral Squamous Cell Carcinoma CAL27 Cells. Anticancer Research 41(1): 259-268
Ben Taleb, A.; Karakuş, S.; Tan, E.; Ilgar, M.; Kutlu, Öz.; Gözüaçık, D.; Kutlu, H.M.; Kilislioğlu, A. 2021: Antitumor Efficacy of Ceranib-2 with Nano-Formulation of PEG and Rosin Esters. Methods in Molecular Biology 2207: 199-220
Liu, S.; Liu, F.; Zhao, M.; Zhang, J. 2020: Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts. Cancer Management and Research 12: 11803-11812
Kagamu, H. 2021: Antitumor Immunity Evaluated via the Peripheral Blood. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 48(3): 315-319
Cañete, F.; Mañosa, M.ír.; Pérez-Martínez, I.; Barreiro-de Acosta, M.; González-Sueyro, R.C.; Nos, P.; Iglesias-Flores, E.; Gutiérrez, A.; Bujanda, L.; Gordillo, J.; Ríos León, R.; Casanova, M.ía.J.é; Villoria, A.; Rodríguez-Lago, I.; López Serrano, P.; García-Herola, A.; Ramírez-de la Piscina, P.; Navarro-Llavat, M.è; Taxonera, C.; Barrio, J.ús.; Ramos, L.; Navarro, P.; Benítez-Leiva, O.; Calafat, M.; Domènech, E. 2020: Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: a Nationwide Study with Propensity-Matched Score Analysis. Clinical and Translational Gastroenterology 11(8): E00218
Lorenzo, D.; Vullierme, M.P.; Rebours, V. 2020: Antitumor Necrosis Factor Therapy Is Effective for Autoimmune Pancreatitis Type 2. American Journal of Gastroenterology 115(7): 1133-1134
Fonseca, A.; Sunny, J.; Felipez, L.M. 2021: Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn's Disease. Case Reports in Pediatrics 2021: 9989729
Abbas, M.; Xing, R.; Zhang, N.; Zou, Q.; Yan, X. 2018: Antitumor Photodynamic Therapy Based on Dipeptide Fibrous Hydrogels with Incorporation of Photosensitive Drugs. Acs Biomaterials Science and Engineering 4(6): 2046-2052
Farias, K.; da Costa, R.F.; Meira, A.S.; Diniz-Filho, J.; Bezerra, E.M.; Freire, V.N.; Guest, P.; Nikahd, M.; Ma, X.; Gardiner, M.G.; Banwell, M.G.; de Oliveira, M.d.C.F.; de Moraes, M.O.; do Ó Pessoa, C. 2020: Antitumor Potential of the Isoflavonoids (+)- and (-)-2,3,9-Trimethoxypterocarpan: Mechanism-of-Action Studies. Acs Medicinal Chemistry Letters 11(6): 1274-1280
Romero, Y.; Castillejos-López, M.; Romero-García, S.; Aguayo, A.S.; Herrera, I.; Garcia-Martin, M.O.; Torres-Espíndola, L.M.; Negrete-García, M.C.; Olvera, A.C.; Huerta-Cruz, J.C.; Cruz, R.V.; Cisneros, J.é; Soto, E.F.; Solís-Chagoyán, H.éc.; Mendoza-Milla, C.; Cabello-Gutiérrez, C.; Ruiz, V.íc.; Aquino-Gálvez, A. 2020: Antitumor Therapy under Hypoxic Microenvironment by the Combination of 2-Methoxyestradiol and Sodium Dichloroacetate on Human Non-Small-Cell Lung Cancer. Oxidative Medicine and Cellular Longevity 2020: 3176375
Xie, S.; Jiang, H.; Zhai, X-Wen.; Wei, F.; Wang, S-Dong.; Ding, J.; Chen, Y. 2016: Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacologica Sinica 37(11): 1481-1489
Chirigos, M.A. 1981: Antitumor action of interferon: animal systems. Texas Reports on Biology and Medicine 41: 610-613
Nguyen, H.M.; Nguyen, H.T.; Seephan, S.; Do, H.B.; Nguyen, H.T.; Ho, D.V.; Pongrakhananon, V. 2021: Antitumor activities of Aspiletrein A, a steroidal saponin from Aspidistra letreae, on non-small cell lung cancer cells. Bmc Complementary Medicine and Therapies 21(1): 87
Zhao, F.; Guo, Z.; Ma, Z-Ren.; Ma, L-Li.; Zhao, J. 2021: Antitumor activities of Grifola frondosa (Maitake) polysaccharide: A meta-analysis based on preclinical evidence and quality assessment. Journal of Ethnopharmacology 280:: 114395
Yan, M.; Dongmei, B.; Jingjing, Z.; Xiaobao, J.; Jie, W.; Yan, W.; Jiayong, Z. 2017: Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma. Scientific Reports 7(1): 14074
Pairoj, S.; Damrongsak, P.; Damrongsak, B.; Jinawath, N.; Kaewkhaw, R.; Ruttanasirawit, C.; Leelawattananon, T.; Locharoenrat, K. 2021: Antitumor activities of carboplatin-doxorubicin-ZnO complexes in different human cancer cell lines (breast, cervix uteri, colon, liver and oral) under UV exposition. Artificial Cells Nanomedicine and Biotechnology 49(1): 120-135
Musil, J.; Kutinova, L.; Zurkova, K.; Hainz, P.; Babiarova, K.; Krystofova, J.; Nemeckova, S. 2014: Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3. Cancer Gene Therapy 21(3): 115-125
Lee, J.; Hampl, M.; Albert, P.; Fine, H.A. 2002: Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 4(4): 312-323
Parker, W.B.; Allan, P.W.; Hassan, A.E.A.; Secrist, J.A.; Sorscher, E.J.; Waud, W.R. 2003: Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Therapy 10(1): 23-29
Jiménez, J.A.; Li, X.; Zhang, Y-P.; Bae, K.H.; Mohammadi, Y.; Pandya, P.; Kao, C.; Gardner, T.A. 2010: Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL. Cancer Gene Therapy 17(3): 180-191
Kavitha, C.N.; Raja, K.D.; Rao, S.K. 2021: Antitumor activity of Albizia lebbeck L. against Ehrlich ascites carcinoma in vivo and Hela and A549 cell lines in vitro. Journal of Cancer Research and Therapeutics 17(2): 491-498
Crossland, D.L.; Denning, W.L.; Ang, S.; Olivares, S.; Mi, T.; Switzer, K.; Singh, H.; Huls, H.; Gold, K.S.; Glisson, B.S.; Cooper, L.J.; Heymach, J.V. 2018: Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene 37(27): 3686-3697
Li, H.; Huang, Y.; Jiang, D-Qing.; Cui, L-Zhen.; He, Z.; Wang, C.; Zhang, Z-Wei.; Zhu, H-Li.; Ding, Y-Mei.; Li, L-Fang.; Li, Q.; Jin, H-Jun.; Qian, Q-Jun. 2018: Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice. Cell Death and Disease 9(2): 177
Ding, Y.; Wang, L.; Su, L-Kuo.; Frey, J.A.; Shao, R.; Hunt, K.K.; Yan, D-Hwa. 2004: Antitumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer. Oncogene 23(26): 4556-4566
Yun, H-M.; Oh, J.H.; Shim, J-H.; Ban, J.O.; Park, K-R.; Kim, J-H.; Lee, D.H.; Kang, J-W.; Park, Y.H.; Yu, D.; Kim, Y.; Han, S.B.; Yoon, D-Y.; Hong, J.T. 2013: Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals. Cell Death and Disease 4: E640
Patriota, L.L.d.S.; Ramos, D.d.B.M.; Dos Santos, A.C.L.A.; Silva, Y.A.új.; Gama E Silva, M.; Torres, D.J.é L.; Procópio, T.F.; de Oliveira, A.M.ár.; Coelho, L.C.B.B.; Pontual, E.V.; da Silva, D.C.és.N.; Paiva, P.íc.M.G.; de Lorena, V.ír.M.B.; Mendes, R.L.; Napoleão, T.H. 2020: Antitumor activity of Moringa oleifera (drumstick tree) flower trypsin inhibitor (MoFTI) in sarcoma 180-bearing mice. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 145: 111691
Jayaraman, S.; Hou, X.; Kuffel, M.J.; Suman, V.J.; Hoskin, T.L.; Reinicke, K.E.; Monroe, D.G.; Kalari, K.R.; Tang, X.; Zeldenrust, M.A.; Cheng, J.; Bruinsma, E.S.; Buhrow, S.A.; McGovern, R.M.; Safgren, S.L.; Walden, C.A.; Carter, J.M.; Reid, J.M.; Ingle, J.N.; Ames, M.M.; Hawse, J.R.; Goetz, M.P. 2020: Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Research: Bcr 22(1): 51
Muscella, A.; Vetrugno, C.; Migoni, D.; Biagioni, F.; Fanizzi, F.P.; Fornai, F.; De Pascali, S.A.; Marsigliante, S. 2014: Antitumor activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in mouse xenograft model of breast cancer. Cell Death and Disease 5: E1014
Monia, B.P.; Johnston, J.F.; Geiger, T.; Muller, M.; Fabbro, D. 1996: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Medicine 2(6): 668-675
Huertas, D.; Soler, M.; Moreto, J.; Villanueva, A.; Martinez, A.; Vidal, A.; Charlton, M.; Moffat, D.; Patel, S.; McDermott, J.; Owen, J.; Brotherton, D.; Krige, D.; Cuthill, S.; Esteller, M. 2012: Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene 31(11): 1408-1418
Chin, E.N.; Yu, C.; Vartabedian, V.F.; Jia, Y.; Kumar, M.; Gamo, A.M.; Vernier, W.; Ali, S.H.; Kissai, M.; Lazar, D.C.; Nguyen, N.; Pereira, L.E.; Benish, B.; Woods, A.K.; Joseph, S.B.; Chu, A.; Johnson, K.A.; Sander, P.N.; Martínez-Peña, F.; Hampton, E.N.; Young, T.S.; Wolan, D.W.; Chatterjee, A.K.; Schultz, P.G.; Petrassi, H.M.; Teijaro, J.R.; Lairson, L.L. 2020: Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science 369(6506): 993-999
Kim, J.W.; Marquez, C.P.; Kostyrko, K.; Koehne, A.L.; Marini, K.; Simpson, D.R.; Lee, A.G.; Leung, S.G.; Sayles, L.C.; Shrager, J.; Ferrer, I.; Paz-Ares, L.; Gephart, M.Hayden.; Vicent, S.; Cochran, J.R.; Sweet-Cordero, E.Alejandro. 2019: Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma. Nature Medicine 25(11): 1783-1795
Iizuka, K.; Shoji, K.; Fujiyuki, T.; Moritoh, K.; Tamura, K.; Yoshida, A.; Sato, H.; Yoneda, M.; Asano, K.; Kai, C. 2020: Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells. Research in Veterinary Science 133: 313-317
Lim, J.; Kim, J.; Duong, T.; Lee, G.; Kim, J.; Yoon, J.; Kim, J.; Kim, H.; Ruley, H.Earl.; El-Rifai, W.; Jo, D. 2012: Antitumor activity of cell-permeable p18(INK4c) with enhanced membrane and tissue penetration. Molecular Therapy: the Journal of the American Society of Gene Therapy 20(8): 1540-1549
Drilon, A.; Clark, J.W.; Weiss, J.; Ou, S-Hong.Ignatius.; Camidge, D.Ross.; Solomon, B.J.; Otterson, G.A.; Villaruz, L.C.; Riely, G.J.; Heist, R.S.; Awad, M.M.; Shapiro, G.I.; Satouchi, M.; Hida, T.; Hayashi, H.; Murphy, D.A.; Wang, S.C.; Li, S.; Usari, T.; Wilner, K.D.; Paik, P.K. 2020: Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nature Medicine 26(1): 47-51
Murphy, A.; Westwood, J.A.; Brown, L.E.; Teng, M.W.L.; Moeller, M.; Xu, Y.; Smyth, M.J.; Hwu, P.; Darcy, P.K.; Kershaw, M.H. 2007: Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Therapy 14(5): 499-508
Subbiah, V.; Paz-Ares, L.; Besse, B.; Moreno, V.; Peters, S.; Sala, M.ía.A.; López-Vilariño, J.é A.; Fernández, C.; Kahatt, C.; Alfaro, V.; Siguero, M.; Zeaiter, A.; Zaman, K.; López, R.; Ponce, S.; Boni, V.; Arrondeau, J.; Delord, J.-P.; Martínez, M.; Wannesson, L.; Antón, A.; Valdivia, J.; Awada, A.; Kristeleit, R.; Olmedo, M.E.; Rubio, M.ía.J.ús.; Sarantopoulos, J.; Chawla, S.P.; Mosquera-Martinez, J.ín.; D' Arcangelo, M.; Santoro, A.; Villalobos, V.M.; Sands, J.; Trigo, J.é 2020: Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer 150: 90-96
Sun, V.; Zhou, W.B.; Nosrati, M.; Majid, S.; Thummala, S.; de Semir, D.; Bezrookove, V.; de Feraudy, S.; Chun, L.; Schadendorf, D.; Debs, R.; Kashani-Sabet, M.; Dar, A.A. 2015: Antitumor activity of miR-1280 in melanoma by regulation of Src. Molecular Therapy: the Journal of the American Society of Gene Therapy 23(1): 71-78
Santodonato, L.; Ferrantini, M.; Palombo, F.; Aurisicchio, L.; Delmastro, P.; La Monica, N.; Di Marco, S.; Ciliberto, G.; Du, M.X.; Taylor, M.W.; Belardelli, F. 2001: Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells. Cancer Gene Therapy 8(1): 63-72
Salah, R.; Salama, M.F.; Mahgoub, H.A.; El-Sherbini, E.-S. 2021: Antitumor activity of sitagliptin and vitamin B12 on Ehrlich ascites carcinoma solid tumor in mice. Journal of Biochemical and Molecular Toxicology 35(2): E22645
Furtado, R.Andrade.; Ozelin, S.Duarte.; Ferreira, Nália.Helen.; Miura, Bárbara.Ayumi.; Almeida Junior, S.; Magalhães, Górgia.Modé.; Nassar, E.José.; Miranda, M.Abreu.; Bastos, J.Kenupp.; Tavares, D.Crispim. 2021: Antitumor activity of solamargine in mouse melanoma model: relevance to clinical safety. Journal of Toxicology and Environmental Health. Part a 2021: 1-12
Auclair, D.; Miller, D.; Yatsula, V.; Pickett, W.; Carter, C.; Chang, Y.; Zhang, X.; Wilkie, D.; Burd, A.; Shi, H.; Rocks, S.; Gedrich, R.; Abriola, L.; Vasavada, H.; Lynch, M.; Dumas, J.; Trail, P.A.; Wilhelm, S.M. 2007: Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 21(3): 439-445
Jeon, G-Che.; Park, M-Soon.; Yoon, D-Young.; Shin, C-Ho.; Sin, H-Sig.; Um, S-Jong. 2005: Antitumor activity of spinasterol isolated from Pueraria roots. Experimental and Molecular Medicine 37(2): 111-120
Spriano, F.; Gaudio, E.; Cascione, L.; Tarantelli, C.; Melle, F.; Motta, G.; Priebe, V.; Rinaldi, A.; Golino, G.; Mensah, A.A.; Aresu, L.; Zucca, E.; Pileri, S.; Witcher, M.; Brown, B.; Wahlestedt, C.; Giles, F.; Stathis, A.; Bertoni, F. 2020: Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood Advances 4(17): 4124-4135
Ribeiro, M.L.; Reyes-Garau, D.; Vinyoles, M.; Profitós Pelejà, N.úr.; Santos, J.C.; Armengol, M.; Fernández-Serrano, M.; Sedó Mor, A.íc.; Bech-Serra, J.J.; Blecua, P.; Musulen, E.; De La Torre, C.; Miskin, H.; Esteller, M.; Bosch, F.; Menéndez, P.; Normant, E.; Roué, G.ël. 2021: Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 27(23): 6591-6601
An, Z.; Hu, Y.; Bai, Y.; Zhang, C.; Xu, C.; Kang, X.; Yang, S.; Li, W.; Zhong, X. 2021: Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1. Oncoimmunology 10(1): 1960728
Flores-Cortez, D.; Villalobos-Pacheco, E.; Chávez-Rojas, D.; Rodriguez-Tafur Dávila, J.; Palomino-Yamamoto, M. 2020: Antitumor activity of vibrio sp. isolated biopolymers in induced breast cancer in rats. Revista Peruana de Medicina Experimental y Salud Publica 37(2): 246-252
Xie, F.-L.; Huang, Z.-T.; Bai, L.; Zhu, J.-W.; Xu, H.-H.; Long, Q.-Q.; Guo, Q.-F.; Wu, Y.; Liu, S.-H. 2021: Antitumor activity studies of iridium (III) polypyridine complexes-loaded liposomes against gastric tumor cell in vitro. Journal of Inorganic Biochemistry 225: 111603
Terra, W.d.S.; Bull, Ér.S.; Morcelli, S.R.; Moreira, R.R.; Maciel, L.L.F.; Almeida, J.ão.C.d.A.; Kanashiro, M.M.; Fernandes, C.; Horn, A. 2021: Antitumor activity via apoptotic cell death pathway of water soluble copper(II) complexes: effect of the diamino unit on selectivity against lung cancer NCI-H460 cell line. Biometals: An International Journal on the Role of Metal Ions in Biology Biochemistry and Medicine 34(3): 661-674
Petronijević, J.; Joksimović, N.; Milović, E.; Crnogorac, M.Đorđić.; Petrović, N.; Stanojković, T.; Milivojević, Dšan.; Janković, N. 2021: Antitumor activity, DNA and BSA interactions of novel copper(II) complexes with 3,4-dihydro-2(1H)-quinoxalinones. Chemico-BiologicalInteractions 2021: 109647
El-Azab, A.S.; Abdel-Aziz, A.A.-M.; AlSaif, N.A.; Alkahtani, H.M.; Alanazi, M.M.; Obaidullah, A.J.; Eskandrani, R.O.; Alharbi, A. 2020: Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis. Bioorganic Chemistry 104: 104345
Nakshatri, H.; Rice, S.E.; Bhat-Nakshatri, P. 2004: Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23(44): 7330-7344
Gajate, C.; Matos-da-Silva, M.; Dakir, e-H.; Fonteriz, R.I.; Alvarez, J.; Mollinedo, F. 2012: Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum. Oncogene 31(21): 2627-2639
Liu, X.; Lan, T.; Mo, F.; Yang, J.; Wei, Y.; Wei, X. 2021: Antitumor and Radiosensitization Effects of a CXCR2 Inhibitor in Nasopharyngeal Carcinoma. Frontiers in Cell and Developmental Biology 9: 689613
Mishra, S.; Alhodieb, F.Saad.; Barkat, M.Abul.; Hassan, M.Zaheen.; Barkat, H.Abul.; Ali, R.; Alam, P.; Alam, O. 2022: Antitumor and hepatoprotective effect of Cuscuta reflexa Roxb. in a murine model of colon cancer. Journal of Ethnopharmacology 282:: 114597
Othman, G.A.; Ahmed, D.A.E.M. 2020: Antitumor and immunomodulatory effects of thymosin against tumor growth in mice. Pakistan Journal of Pharmaceutical Sciences 33(6): 2611-2616
Song, H.; Xing, W.; Shi, X.; Zhang, T.; Lou, H.; Fan, P. 2021: Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP+) as a carrier. Bioorganic and Medicinal Chemistry 50: 116466
Mishra, R.Kumar.; Maganti, L. 2021: Antitumor drugs effect on the stability of double-stranded DNA: steered molecular dynamics analysis. Journal of Biomolecular Structure and Dynamics 2021: 1-10
Natsume, A.; Mizuno, M.; Ryuke, Y.; Yoshida, J. 1999: Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Therapy 6(9): 1626-1633
Chen, X.; Sun, L.; Wei, X.; Lu, H.; Tan, Y.; Sun, Z.; Jiang, J. 2021: Antitumor effect and molecular mechanism of fucoidan in NSCLC. Bmc Complementary Medicine and Therapies 21(1): 25
Pibuel, Mías.Arturo.; Poodts, D.; Díaz, Mángeles.; Molinari, Y.Azul.; Franco, P.Gabriela.; Hajos, S.Elvira.; Lompardía, S.Laura. 2021: Antitumor effect of 4MU on glioblastoma cells is mediated by senescence induction and CD44, RHAMM and p-ERK modulation. Cell Death Discovery 7(1): 280
Botella-Estrada, R.; Malet, G.; Revert, F.; Dasí, F.; Crespo, A.; Sanmartín, O.; Guillén, C.; Aliño, S.F. 2001: Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor rnasin. Cancer Gene Therapy 8(4): 278-284
Bartholomeusz, C.; Itamochi, H.; Nitta, M.; Saya, H.; Ginsberg, M.H.; Ueno, N.T. 2006: Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 25(1): 79-90
Wu, J.; Xie, S.; Li, H.; Zhang, Y.; Yue, J.; Yan, C.; Liu, K.; Liu, Y.; Xu, R.; Zheng, G. 2021: Antitumor effect of IL-12 gene-modified bone marrow mesenchymal stem cells combined with Fuzheng Yiliu decoction in an in vivo glioma nude mouse model. Journal of Translational Medicine 19(1): 143
Solbach, C.; Sterner-Kock, A.; Roller, M.; Schnürch, H.Georg.; Stegmüller, M.; Caspar-Bell, G.; Schumm-Draeger, P.Maria.; Kaufmann, M.; Knecht, R. 2002: Antitumor effect of MAb EMD 55900 depends on EGF-R expression and histopathology. Neoplasia 4(3): 237-242
Di Martile, M.; Garzoli, S.; Sabatino, M.; Valentini, E.; D'Aguanno, S.; Ragno, R.; Del Bufalo, D. 2021: Antitumor effect of Melaleuca alternifolia essential oil and its main component terpinen-4-ol in combination with target therapy in melanoma models. Cell Death Discovery 7(1): 127
Ha, D-Hyeon.; Min, A.; Kim, S.; Jang, H.; Kim, S.Hyeon.; Kim, H-Jun.; Ryu, H.Suk.; Ku, J-Lok.; Lee, K-Hun.; Im, S-Ah. 2020: Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. Scientific Reports 10(1): 9930
Abula, A.; Zhao, J.; Xu, G.; Li, Y.; Sun, S. 2020: Antitumor effect of a pyrazolone-based-complex [Cu(PMPP-SAL)(EtOH)] against murine melanoma B16 cell in vitro and in vivo. Acta Pharmaceutica 70(4): 561-575
Secondino, S.; Pedrazzoli, P.; Schiavetto, I.; Basilico, V.; Bramerio, E.; Massimino, M.; Gambacorta, M.; Siena, S. 2008: Antitumor effect of allogeneic hematopoietic SCT in metastatic medulloblastoma. Bone Marrow Transplantation 42(2): 131-133
Drozdzik, M.; Qian, C.; Lasarte, J.J.; Bilbao, R.; Prieto, J. 1998: Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL). Gene Therapy 5(12): 1622-1630
Lampreht Tratar, U.; Kos, S.; Kamensek, U.; Ota, M.; Tozon, N.; Sersa, G.; Cemazar, M. 2018: Antitumor effect of antibiotic resistance gene-free plasmids encoding interleukin-12 in canine melanoma model. Cancer Gene Therapy 25(9-10): 260-273
Zhang, Y.; Liu, X.X.; Zhang, B.; Hu, H.Y.; Gong, L. 2005: Antitumor effect of antisense ODC adenovirus on human prostate cancer cells. Prostate Cancer and Prostatic Diseases 8(3): 280-286
Ma, Y-Heng.; Wang, S-Yuan.; Ren, Y-Peng.; Li, J.; Guo, T-Jie.; Lu, W.; Zhou, T-Yan. 2019: Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft. Acta Pharmacologica Sinica 40(2): 243-256
De Menezes, F.C.; Cabral, L.G.d.S.; Petrellis, M.C.; Neto, C.F.; Maria, D.A. 2020: Antitumor effect of cell therapy with mesenchymal stem cells on murine melanoma B16-F10. Biomedicine and PharmacoTherapy 128: 110294
Hayashi, K.; Nakazato, Y.; Ouchi, M.; Fujita, T.; Endou, H.; Chida, M. 2021: Antitumor effect of dimethyl itaconate on thymic carcinoma by targeting LDHA-mTOR axis. Life Sciences 282: 119847
Nakamura, K.; Ito, Y.; Kawano, Y.; Kurozumi, K.; Kobune, M.; Tsuda, H.; Bizen, A.; Honmou, O.; Niitsu, Y.; Hamada, H. 2004: Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Therapy 11(14): 1155-1164
Masuda, T.; Ohba, S.; Kawada, M.; Osono, M.; Ikeda, D.; Esumi, H.; Kunimoto, S. 2006: Antitumor effect of kigamicin D on mouse tumor models. Journal of Antibiotics 59(4): 209-214
Seino, K.; Kayagaki, N.; Okumura, K.; Yagita, H. 1997: Antitumor effect of locally produced CD95 ligand. Nature Medicine 3(2): 165-170
Fiori, M.E.; Barbini, C.; Haas, T.L.; Marroncelli, N.; Patrizii, M.; Biffoni, M.; De Maria, R. 2014: Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death and Differentiation 21(5): 774-782
Lee, S-H.; Shen, G-N.; Jung, Y.S.; Lee, S-J.; Chung, J-Y.; Kim, H-S.; Xu, Y.; Choi, Y.; Lee, J-W.; Ha, N-C.; Song, G.Y.; Park, B-J. 2010: Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells. Oncogene 29(32): 4576-4587
Dong, J.; Bohinski, R.J.; Li, Y-Qin.; Van Waes, C.; Hendler, F.; Gleich, L.; Stambrook, P.J. 2003: Antitumor effect of secreted Flt3-ligand can act at distant tumor sites in a murine model of head and neck cancer. Cancer Gene Therapy 10(2): 96-104
Jia, X.; Guo, J.; Guo, S.; Zhao, T.; Liu, X.; Cheng, C.; Wang, L.; Zhang, B.; Meng, C.; Jia, H.; Luo, E. 2021: Antitumor effects and mechanisms of CpG ODN combined with attenuated Salmonella-delivered si RNAs against PD-1. International Immunopharmacology 90: 107052
Yan, Y.-B.; Tian, Q.; Zhang, J.-F.; Xiang, Y. 2020: Antitumor effects and molecular mechanisms of action of natural products in ovarian cancer. Oncology Letters 20(5): 141
Zhang, T.; Shen, H.; Dong, W.; Qu, X.; Liu, Q.; Du, J. 2014: Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma. Scientific Reports 4: 6855
Liao, H.; Wang, Y.; Xu, X.; Zhou, C.; Zhang, J.; Zhong, K.; Yang, D. 2021: Antitumor effects of AZD2014, a dual mTORC1/2 inhibitor, against human hepatocellular carcinoma xenograft in nude mice. Nan Fang Yi Ke da Xue Xue Bao 41(7): 1056-1061
Ma, R.; Shimura, T.; Yin, C.; Okugawa, Y.; Kitajima, T.; Koike, Y.; Okita, Y.; Ohi, M.; Uchida, K.; Goel, A.; Yao, L.; Zhang, X.; Toiyama, Y. 2021: Antitumor effects of Andrographis via ferroptosis-associated genes in gastric cancer. Oncology Letters 22(1): 523
Lathrop, M.J.; Sage, E.K.; Macura, S.L.; Brooks, E.M.; Cruz, F.; Bonenfant, N.R.; Sokocevic, D.; MacPherson, M.B.; Beuschel, S.L.; Dunaway, C.W.; Shukla, A.; Janes, S.M.; Steele, C.; Mossman, B.T.; Weiss, D.J. 2015: Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma. Cancer Gene Therapy 22(1): 44-54
Wang, X.; Lin, Y.; Zheng, Y. 2020: Antitumor effects of aconitine in A2780 cells via estrogen receptor β‑mediated apoptosis, DNA damage and migration. Molecular Medicine Reports 22(3): 2318-2328
Fang, J.-B.; Zhu, G.-Z.; Zhu, Y.-L.; Li, Y.-Q.; Shang, C.; Bai, B.; Jin, N.-Y.; Li, X. 2020: Antitumor effects of apoptin expressed by the dual cancer-specific oncolytic adenovirus - a review. European Review for Medical and Pharmacological Sciences 24(21): 11334-11343
Fujihira, A.; Suzuki, T.; Chang, M.O.; Moriyama, T.; Kitajima, M.; Takaku, H. 2014: Antitumor effects of baculovirus-infected dendritic cells against human pancreatic carcinoma. Gene Therapy 21(9): 849-854
Itashiki, Y.; Harada, K.; Takenawa, T.; Ferdous, T.; Ueyama, Y.; Mishima, K. 2021: Antitumor effects of bevacizumab in combination with fluoropyrimidine drugs on human oral squamous cell carcinoma. Oncology Letters 22(4): 730
Zhai, Z.; Wang, Z.; Fu, S.; Lu, J.; Wang, F.; Li, R.; Zhang, H.; Li, S.; Hou, Z.; Wang, H.; Rodriguez, R. 2012: Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer. Gene Therapy 19(11): 1065-1074
An, J.; Sun, Y.; Fisher, M.; Rettig, M.B. 2004: Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 18(10): 1699-1704
Kakarla, S.; Chow, K.K.H.; Mata, M.; Shaffer, D.R.; Song, X-Tong.; Wu, M-Fen.; Liu, H.; Wang, L.L.; Rowley, D.R.; Pfizenmaier, K.; Gottschalk, S. 2013: Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Molecular Therapy: the Journal of the American Society of Gene Therapy 21(8): 1611-1620
Fauzi, Y.R.; Nakahata, S.; Chilmi, S.; Ichikawa, T.; Nueangphuet, P.; Yamaguchi, R.; Nakamura, T.; Shimoda, K.; Morishita, K. 2021: Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-κB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells. Plos one 16(8): E0256320
Xiang, L.; He, B.; Liu, Q.; Hu, D.; Liao, W.; Li, R.; Peng, X.; Wang, Q.; Zhao, G. 2020: Antitumor effects of curcumin on the proliferation, migration and apoptosis of human colorectal carcinoma HCT‑116 cells. Oncology Reports 44(5): 1997-2008
Wang, P.; Wang, C.; Liu, C. 2021: Antitumor effects of dioscin in A431 cells via adjusting ATM/p53-mediated cell apoptosis, DNA damage and migration. Oncology Letters 21(1): 59
Hua, R.; Pei, Y.; Gu, H.; Sun, Y.; He, Y. 2021: Antitumor effects of flavokawain-B flavonoid in gemcitabine-resistant lung cancer cells are mediated via mitochondrial-mediated apoptosis, ROS production, cell migration and cell invasion inhibition and blocking of PI3K/AKT Signaling pathway. Journal of Buon: Official Journal of the Balkan Union of Oncology 26(2): 645
Gallo, R.C.; Bryant, J.; Lundardi-Iskandar, Y. 1998: Antitumor effects of hCG in KS. Nature Biotechnology 16(3): 218
Liu, J.; Zhao, Y.; Shi, Z.; Bai, Y. 2021: Antitumor effects of helenalin in doxorubicin-resistant leukemia cells are mediated via mitochondrial mediated apoptosis, loss of mitochondrial membrane potential, inhibition of cell migration and invasion and downregulation of PI3-kinase/AKT/m-TOR signalling pathway. Journal of Buon: Official Journal of the Balkan Union of Oncology 26(1): 292
Zhang, C.; Sui, X.; Jiang, Y.; Wang, X.; Wang, S. 2020: Antitumor effects of icaritin and the molecular mechanisms. Discovery Medicine 29(156): 5-16
Juarez, M.; Schcolnik-Cabrera, A.; Dominguez-Gomez, G.; Chavez-Blanco, A.; Diaz-Chavez, J.; Duenas-Gonzalez, A. 2020: Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Cancer ChemoTherapy and Pharmacology 85(6): 1153-1163
Kaushik, V.; Azad, N.; Yakisich, J.Sebastian.; Iyer, A.Krishnan.V. 2017: Antitumor effects of naturally occurring cardiac glycosides convallatoxin and peruvoside on human ER+ and triple-negative breast cancers. Cell Death Discovery 3: 17009
Berto, E.; Bozac, A.; Volpi, I.; Lanzoni, I.; Vasquez, F.; Melara, N.; Manservigi, R.; Marconi, P. 2007: Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth. Cancer Gene Therapy 14(9): 791-801
Yang, Y-F.; Xue, S-Y.; Lu, Z-Z.; Xiao, F-J.; Yin, Y.; Zhang, Q-W.; Wu, C-T.; Wang, H.; Wang, L-S. 2014: Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer. Gene Therapy 21(8): 723-731
Ou, X.; Tan, T.; He, L.; Li, Y.; Li, J.; Kuang, A. 2005: Antitumor effects of radioiodinated antisense oligonuclide mediated by VIP receptor. Cancer Gene Therapy 12(3): 313-320
Ochiai, Y.; Sumi, K.; Sano, E.; Yoshimura, S.; Yamamuro, S.; Ogino, A.; Ueda, T.; Suzuki, Y.; Nakayama, T.; Hara, H.; Katayama, Y.; Yoshino, A. 2020: Antitumor effects of ribavirin in combination with TMZ and IFN-β in malignant glioma cells. Oncology Letters 20(5): 178
Siddiqa, A.; Munir, R.; Faisal, M. 2021: Antitumor effects of sodium selenite on acute lymphocytic leukemia. Journal of Cancer Research and Therapeutics 17(1): 266-268
Dorvignit, D.; Boligan, K.F.; Relova-Hernández, E.; Clavell, M.; López, A.; Labrada, M.; Simon, H-Uwe.; López-Requena, A.; Mesa, C.; von Gunten, S. 2019: Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells. Scientific Reports 9(1): 9921
Tominaga, M.; Iwashita, Y.; Ohta, M.; Shibata, K.; Ishio, T.; Ohmori, N.; Goto, T.; Sato, S.; Kitano, S. 2007: Antitumor effects of the MIG and IP-10 genes transferred with poly [D,L-2,4-diaminobutyric acid] on murine neuroblastoma. Cancer Gene Therapy 14(8): 696-705
Lasek, W.; Mackiewicz, A.; Czajka, A.; Switaj, T.; Goł b, J.; Wiznerowicz, M.; Korczak-Kowalska, G.; Bakowiec-Iskra, E.Z.; Gryska, K.; Izycki, D.; Jakóbisiak, M. 2000: Antitumor effects of the combination therapy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice. Cancer Gene Therapy 7(12): 1581-1590
Santoni, M.; Iacovelli, R.; Colonna, V.; Klinz, S.; Mauri, G.; Nuti, M. 2021: Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. Expert Review of Anticancer Therapy 2021: 1-26
Wang, S.; Qi, J.; Smith, M.; Link, C.J. 2002: Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir. Cancer Gene Therapy 9(1): 1-8
Ryan, P.C.; Jakubczak, J.L.; Stewart, D.A.; Hawkins, L.K.; Cheng, C.; Clarke, L.M.; Ganesh, S.; Hay, C.; Huang, Y.; Kaloss, M.; Marinov, A.; Phipps, S.S.; Reddy, P.Seshidhar.; Shirley, P.S.; Skripchenko, Y.; Xu, L.; Yang, J.; Forry-Schaudies, S.; Hallenbeck, P.L. 2004: Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Therapy 11(8): 555-569
Yoo, J.Young.; Haseley, A.; Bratasz, A.; Chiocca, E.Antonio.; Zhang, J.; Powell, K.; Kaur, B. 2012: Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Molecular Therapy: the Journal of the American Society of Gene Therapy 20(2): 287-297
Streck, C.J.; Dickson, P.V.; Ng, C.Y.C.; Zhou, J.; Hall, M.M.; Gray, J.T.; Nathwani, A.C.; Davidoff, A.M. 2006: Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Therapy 13(1): 99-106
Dong, Z.; Cheng, W.A.; Smith, D.L.; Huang, B.; Zhang, T.; Chang, W.-C.; Wang, X.; Forman, S.J.; Kwak, L.W.; Qin, H. 2020: Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. Cancer Immunology Immunotherapy: Cii 69(10): 2139-2145
Rosen, J.C.; Weiss, J.; Pham, N.-A.; Li, Q.; Martins-Filho, S.N.; Wang, Y.; Tsao, M.-S.; Moghal, N. 2021: Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts. Translational Oncology 14(10): 101179
Hess, S.D.; Egilmez, N.K.; Shiroko, J.; Bankert, R.B. 2001: Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model. Cancer Gene Therapy 8(5): 371-377
Lione, L.; Salvatori, E.; Petrazzuolo, A.; Massacci, A.; Maggio, R.; Confroti, A.; Compagnone, M.; Aurisicchio, L.; Ciliberto, G.; Palombo, F. 2021: Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition. Oncoimmunology 10(1): 1898832
Ding, Y.; Fan, J.; Deng, L.; Huang, B.; Zhou, B. 2020: Antitumor efficacy of cytosine deaminase-armed vaccinia virus plus 5-fluorocytosine in colorectal cancers. Cancer Cell International 20: 243
Shi, X.; Sun, J.; Li, H.; Lin, H.; Xie, W.; Li, J.; Tan, W. 2020: Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer. Prostate 80(11): 811-823
Liu, S.; Zhang, J.; Fang, S.; Su, X.; Zhang, Q.; Zhu, G.; Zhu, L.; Zhao, M.; Liu, F. 2020: Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft. Cancer Letters 495: 123-134
Kanzaki, A.; Kasuya, H.; Yamamura, K.; Sahin, T.T.; Nomura, N.; Shikano, T.; Shirota, T.; Tan, G.; Fukuda, S.; Misawa, M.; Nishikawa, Y.; Yamada, S.; Fujii, T.; Sugimoto, H.; Nomoto, S.; Takeda, S.; Kodera, Y.; Nakao, A. 2012: Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes. Cancer Gene Therapy 19(4): 292-298
Rosery, V.; Reis, H.; Savvatakis, K.; Kowall, B.; Stuschke, M.; Paul, A.; Dechêne, A.; Yang, J.; Zhao, B.; Borgers, A.; Kasper, S.; Schuler, M.; Cheung, P.F.; Siveke, J.T. 2021: Antitumor immune response is associated with favorable survival in GEP-NEN G3. Endocrine-Related Cancer 28(10): 683-693
Djeha, H.A.; Todryk, S.M.; Pelech, S.; Wrighton, C.J.; Irvine, A.S.; Mountain, A.; Lipinski, K.S. 2005: Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70. Cancer Gene Therapy 12(6): 560-571
Kimura, T.; Ohashi, T.; Kikuchi, T.; Kiyota, H.; Eto, Y.; Ohishi, Y. 2003: Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector. Cancer Gene Therapy 10(11): 833-839
Brossart, P. 2020: Antitumor immunity and T-cell avidity. Blood 136(4): 378-380
Hayashi, Y.; Goyama, S.; Liu, X.; Tamura, M.; Asada, S.; Tanaka, Y.; Fukuyama, T.; Wunderlich, M.; O'Brien, E.; Mizukawa, B.; Yamazaki, S.; Matsumoto, A.; Yamasaki, S.; Shibata, T.; Matsuda, K.; Sashida, G.; Takizawa, H.; Kitamura, T. 2019: Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Nature Communications 10(1): 4869
Matsumoto, A.; Asuka, M.; Takahashi, Y.; Takakura, Y. 2020: Antitumor immunity by small extracellular vesicles collected from activated dendritic cells through effective induction of cellular and humoral immune responses. Biomaterials 252: 120112
Mozaffari Nejad, A.S.; Fotouhi, F.; Mehrbod, P.; Alikhani, M.Y. 2021: Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: a promising method to treat tumors. Saudi Journal of Biological Sciences 28(10): 5833-5840
Zhang, Y.; Ng, D.K.P.; Fong, W-Ping. 2019: Antitumor immunity induced by the photodynamic action of BAM-SiPc, a silicon (IV) phthalocyanine photosensitizer. Cellular and Molecular Immunology 16(7): 676-678
Chang, M-Ra.; Lee, W-Hee.; Choi, J-Wha.; Park, S-Ok.; Paik, S-Gi.; Kim, Y.Sang. 2005: Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2. Experimental and Molecular Medicine 37(3): 240-249
Xie, J.; Yuan, S.; Peng, L.; Li, H.; Niu, L.; Xu, H.; Guo, X.; Yang, M.; Duan, F. 2020: Antitumor immunity targeting fibroblast activation protein-α in a mouse Lewis lung carcinoma model. Oncology Letters 20(1): 868-876
Fitzgerald, D.J. 1997: Antitumor immunotoxin secretion by T cells: ABSolutely FABulous?. Nature Biotechnology 15(1): 18-19
Zhu, L.; Lu, Z.; Zhao, H. 2015: Antitumor mechanisms when pRb and p53 are genetically inactivated. Oncogene 34(35): 4547-4557
Han, X.; Zhang, X.; Wang, Q.; Wang, L.; Yu, S. 2020: Antitumor potential of Hedyotis diffusa Willd: a systematic review of bioactive constituents and underlying molecular mechanisms. Biomedicine and PharmacoTherapy 130: 110735
Jiménez Charris, Eécer.; Lopes, D.Silva.; Gimenes, S.Natalie.Cirilo.; Teixeira, S.Cota.; Montealegre Sánchez, L.; Solano-Redondo, L.; Fierro, L.; de Melo Rodrigues Ávila, V. 2020: Antitumor potential of Pllans-II, an acidic Asp49-PLA2 from Porthidium lansbergii lansbergii snake venom on human cervical carcinoma HeLa cells. Toxicon: Official Journal of the International Society on Toxinology 177 Suppl. 1: S22
Chen, J.; Yang, B.; Zhang, S.; Ling, Y.; Ye, J.; Jia, Z.; Cao, J. 2012: Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma. Cancer Gene Therapy 19(5): 328-335
Yin, H.; Chen, N.; Guo, R.; Wang, H.; Li, W.; Wang, G.; Cui, J.; Jin, H.; Hu, J-Fan. 2015: Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells. Scientific Reports 5: 16975
Noratto, G.; Layosa, M.A.; Lage, N.N.; Atienza, L.; Ivanov, I.; Mertens-Talcott, S.U.; Chew, B.P. 2020: Antitumor potential of dark sweet cherry sweet (Prunus avium) phenolics in suppressing xenograft tumor growth of MDA-MB-453 breast cancer cells. Journal of Nutritional Biochemistry 84: 108437
Matuszewska, A.; Stefaniuk, D.; Jaszek, M.; Pięt, M.; Zając, A.; Matuszewski, Łukasz.; Cios, I.; Grąz, M.; Paduch, R.; Bancerz, R. 2019: Antitumor potential of new low molecular weight antioxidative preparations from the white rot fungus Cerrena unicolor against human colon cancer cells. Scientific Reports 9(1): 1975
Ren, Y.; Kinghorn, A.D. 2021: Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives. Bioorganic and Medicinal Chemistry 32: 116012
Hseu, Y-Cheng.; Tsai, T-Jung.; Korivi, M.; Liu, J-Yuh.; Chen, H-Jye.; Lin, C-Ming.; Shen, Y-Chun.; Yang, H-Ling. 2017: Antitumor properties of Coenzyme Q 0 against human ovarian carcinoma cells via induction of ROS-mediated apoptosis and cytoprotective autophagy. Scientific Reports 7(1): 8062
Duan, X.; Li, H.; Han, X.; Ren, J.; Li, F.; Ju, S.; Wang, M.; Wang, W. 2020: Antitumor properties of arsenic trioxide-loaded CalliSpheres® microspheres by transarterial chemoembolization in VX2 liver tumor rabbits: suppression of tumor growth, angiogenesis, and metastasis and elongation of survival. American Journal of Translational Research 12(9): 5511-5524
Thoren, F.B.; Aurelius, J.; Martner, A. 2011: Antitumor properties of histamine in vivo. Nature Medicine 17(5): 537; Author Reply 537-8
Penthala, N.R.; Balasubramaniam, M.; Dachavaram, S.S.; Morris, E.J.; Bhat-Nakshatri, P.; Ponder, J.; Jordan, C.T.; Nakshatri, H.; Crooks, P.A. 2021: Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD). European Journal of Medicinal Chemistry 224: 113675
Sánchez-Melgar, A.; Muñoz-López, S.; Albasanz, J.é L.; Martín, M. 2021: Antitumoral Action of Resveratrol Through Adenosinergic Signaling in C6 Glioma Cells. Frontiers in Neuroscience 15: 702817
Korff, J.M.; Menke, K.; Schwermer, M.; Falke, K.; Schramm, A.; Längler, A.; Zuzak, T.J. 2021: Antitumoral Effects of Curcumin (Curcuma longa L.) and Thymoquinone (Nigella sativa L.) on Neuroblastoma Cell Lines. Complementary Medicine Research 28(2): 164-168
Chequin, A.; Costa, L.E.; de Campos, F.F.; Moncada, A.D.B.; de Lima, L.T.F.; Sledz, L.R.; Picheth, G.F.; Adami, E.R.; Acco, A.; Gonçalves, M.B.; Manica, G.C.M.; Valdameri, Gáucio.; de Noronha, L.; Telles, Jé.E.Q.; Jandrey, E.H.F.; Costa, E.T.; Costa, F.F.; de Souza, E.M.; Ramos, E.A.S.; Klassen, G. 2021: Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chemico-BiologicalInteractions 2021: 109641
Creasey, W.A. 1969: Antitumoral activity of the fern Cibotium schiedei. Nature 222(5200): 1281-1282
Duque, P.M.; Alonso, C.; Sanchez-Prieto, R.; Quintanilla, M.; Ramón, S.; Ramon y Cajal, S. 1998: Antitumoral effect of E1B defective adenoviruses in human malignant cells. Gene Therapy 5(2): 286-287
Bishop, J.S.; Thull, N.M.; Matar, M.; Quezada, A.; Munger, W.E.; Batten, T.L.; Muller, S.; Pericle, F. 2000: Antitumoral effect of a nonviral interleukin-2 gene therapy is enhanced by combination with 5-fluorouracil. Cancer Gene Therapy 7(8): 1165-1171
Sanches, R.; Kuiper, M.; Penault-Llorca, F.; Aunoble, B.; D'Incan, C.; Bignon, Y.J. 2000: Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy. Cancer Gene Therapy 7(5): 707-720
Brú, A.; Bosch, R.; Céspedes, M.V.; Carmona-Güedes, S.; Pascual, E.; Brú, I.; Souto, J.C. 2019: Antitumoral effect of maintained neutrophilia induced by rhG-CSF in a murine model of pancreatic cancer. Scientific Reports 9(1): 2879
Vitiello, M.; Evangelista, M.; Di Lascio, N.; Kusmic, C.; Massa, A.; Orso, F.; Sarti, S.; Marranci, A.; Rodzik, K.; Germelli, L.; Chandra, D.; Salvetti, A.; Pucci, A.; Taverna, D.; Faita, F.; Gravekamp, C.; Poliseno, L. 2019: Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma. Oncogene 38(19): 3756-3762
Hoshi, M.; Harada, A.; Kawase, T.; Uyemura, K.; Yazaki, T. 2000: Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy. Cancer Gene Therapy 7(5): 799-805
García-Quiroz, J.; Cárdenas-Ochoa, N.í; García-Becerra, R.ío.; Morales-Guadarrama, G.; Méndez-Pérez, E.A.; Santos-Cuevas, C.; Ramírez-Nava, G.J.; Segovia-Mendoza, M.; Prado-García, H.; Avila, E.; Larrea, F.; Díaz, L. 2021: Antitumoral effects of dovitinib in triple-negative breast cancer are synergized by calcitriol in vivo and in vitro. Journal of Steroid Biochemistry and Molecular Biology 214: 105979
Rothemund, M.; Bär, S.I.; Rehm, T.; Kostrhunova, H.; Brabec, V.; Schobert, R. 2020: Antitumoral effects of mitochondria-targeting neutral and cationic cis-[bis(1,3-dibenzylimidazol-2-ylidene)Cl(L)]Pt(ii) complexes. Dalton Transactions 49(26): 8901-8910
Gimenes, S.N.C.; Lopes, D.S.; Alves, Pícia.T.; Azevedo, F.V.P.V.; Vecchi, L.; Goulart, L.R.; Rodrigues, T.C.S.; Santos, Aé.L.Q.; Brites, V.L.de.C.; Teixeira, T.L.; da Silva, Cáudio.V.; Dias, M.H.; Teixeira, S.C.; Rodrigues, R.S.; Yoneyama, K.A.G.; Oliveira, R.A.; Rodrigues, V.de.M. 2017: Antitumoral effects of γCdcPLI, a PLA 2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell. Scientific Reports 7(1): 7077
Okada, M.; Kudo, S.; Miyazaki, O.; Saino, T.; Ekimoto, H.; Iguchi, H.; Hirano, S.; Kuboki, H.; Kadosawa, H.; Takeuchi, T. 1995: Antitumoral efficacy and pharmacokinetic properties of pirarubicin upon hepatic intra-arterial injection in the rabbit V x 2 tumour model. British Journal of Cancer 71(3): 518-524
De la Rosa, Á.J.; Rodríguez-Hernández, Á.; González, R.; Romero-Brufau, S.; Navarro-Villarán, E.; Barrera-Pulido, L.; Pereira, S.; Marín, L.M.; López-Bernal, F.; Álamo, J.M.; Gómez-Bravo, M.A.; Padillo, F.J.; Muntané, J. 2016: Antitumoral gene-based strategy involving nitric oxide synthase type III overexpression in hepatocellular carcinoma. Gene Therapy 23(1): 67-77
Coënon, L.ïs.; Battistoni, A.; Poupée-Beaugé, A.; Germon, S.ép.; Dimier-Poisson, I. 2021: Antitumoral microorganisms: the Swiss army knife of immunotherapy. Medecine Sciences: M/S 37(1): 47-52
Mariani, D.; Ghasemishahrestani, Z.; Freitas, W.; Pezzuto, P.; Costa-da-Silva, A.C.; Tanuri, A.; Kanashiro, M.M.; Fernandes, C.; Horn, A.; Pereira, M.D. 2021: Antitumoral synergism between a copper(II) complex and cisplatin improves in vitro and in vivo anticancer activity against melanoma, lung and breast cancer cells. Biochimica et Biophysica Acta. General Subjects 1865(10): 129963
Lechanteur, C.; Moutschen, M.; Princen, F.; Lopez, M.; Franzen, E.; Gielen, J.; Bours, V.; Merville, M.P. 2000: Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells. Cancer Gene Therapy 7(5): 676-682
Nan, C.; Zheng, Y.; Fan, H.; Sun, H.; Huang, S.; Li, N. 2020: Antitumorigenic Effect of Hsp90 Inhibitor SNX-2112 on Tongue Squamous Cell Carcinoma is Enhanced by Low-Intensity Ultrasound. Oncotargets and Therapy 13: 7907-7919
Liang, Q.; Kong, L.; Du, Y.; Zhu, X.; Tian, J. 2019: Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging. Experimental and Molecular Medicine 51(7): 76
Han, D.; Cho, J.Hyoung.; Lee, R.Ham.; Bang, W.; Park, K.; Kim, M.S.; Shim, J-Hyun.; Chae, J-Il.; Moon, S.Youn. 2017: Antitumorigenic effect of atmospheric-pressure dielectric barrier discharge on human colorectal cancer cells via regulation of Sp1 transcription factor. Scientific Reports 7: 43081
Ray, J.E.; Ralff, M.D.; Jhaveri, A.; Zhou, L.; Dicker, D.T.; Ross, E.A.; El-Deiry, W.S. 2021: Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo. Cancer Biology and Therapy 2021: 1-10
Lee, R.Ham.; Oh, J-Don.; Hwang, J.Sam.; Lee, H-Kyo.; Shin, D. 2021: Antitumorigenic effect of insect-derived peptide poecilocorisin-1 in human skin cancer cells through regulation of Sp1 transcription factor. Scientific Reports 11(1): 18445
Leong, C-O.; Gaskell, M.; Martin, E.A.; Heydon, R.T.; Farmer, P.B.; Bibby, M.C.; Cooper, P.A.; Double, J.A.; Bradshaw, T.D.; Stevens, M.F.G. 2003: Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. British Journal of Cancer 88(3): 470-477
Jeyamogan, S.; Khan, N.A.; Siddiqui, R. 2021: Antitumour Activities of Selected Pure Compounds Identified from the Serum of Crocodylus porosus, Malayopython reticulatus, Varanus salvator and Cuora kamaroma amboinensis. Asian Pacific Journal of Cancer Prevention: Apjcp 22(S1): 97-106
Huang, H.; Yang, W.; Hu, J.; Jiang, Y.; Wang, J.; Shi, C.; Kang, Y.; Wang, D.; Wang, C.; Yang, G. 2021: Antitumour metastasis and the antiangiogenic and antitumour effects of a Eimeria stiedae soluble protein. Parasite Immunology 43(6): E12825
Akhouri, V.; Kumar, A.; Kumari, M. 2020: Antitumour Property of Pterocarpus santalinus Seeds Against DMBA-Induced Breast Cancer in Rats. Breast Cancer: Basic and Clinical Research 14: 1178223420951193
Reina-Campos, M.; Goldrath, A.W. 2019: Antitumour T cells stand the test of time. Nature 576(7787): 392-393
Parker, B.S.; Rautela, J.; Hertzog, P.J. 2016: Antitumour actions of interferons: implications for cancer therapy. Nature Reviews. Cancer 16(3): 131-144
Kamoun, W.S.; Kirpotin, D.B.; Huang, Z.Richard.; Tipparaju, S.K.; Noble, C.O.; Hayes, M.E.; Luus, L.; Koshkaryev, A.; Kim, J.; Olivier, K.; Kornaga, T.; Oyama, S.; Askoxylakis, V.; Pien, C.; Kuesters, G.; Dumont, N.; Lugovskoy, A.A.; Schihl, S.A.; Wilton, J.H.; Geddie, M.L.; Suchy, J.; Grabow, S.; Kohli, N.; Reynolds, C.Patrick.; Blaydes, R.; Zhou, Y.; Sawyer, A.J.; Marks, J.D.; Drummond, D.C. 2019: Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nature Biomedical Engineering 3(4): 264-280
Creighton, A.M.; Hellmann, K.; Whitecross, S. 1969: Antitumour activity in a series of bisdiketopiperazines. Nature 222(5191): 384-385
Lamon, E.W.; Wigzell, H.; Andersson, B.; Klein, E. 1973: Antitumour activity in vitro dependent on immune B lymphocytes. Nature: new Biology 244(137): 209-211
Régina, A.; Demeule, M.; Ché, C.; Lavallée, I.; Poirier, J.; Gabathuler, R.; Béliveau, R.; Castaigne, J-P. 2008: Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. British Journal of Pharmacology 155(2): 185-197
Hahn, M.A.; Botkin, C.C.; Adamson, R.H. 1966: Antitumour activity of N-hydroxyurethane. Nature 211(5052): 984-985
Hu, M.; Ning, J.; Mao, L.; Yu, Y.; Wu, Y. 2021: Antitumour activity of TH1579, a novel MTH1 inhibitor, against castration-resistant prostate cancer. Oncology Letters 21(1): 62
Loriot, Y.; Bianchini, D.; Ileana, E.; Sandhu, S.; Patrikidou, A.; Pezaro, C.; Albiges, L.; Attard, G.; Fizazi, K.; De Bono, J.S.; Massard, C. 2013: Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of Oncology: Official Journal of the European Society for Medical Oncology 24(7): 1807-1812
Omlin, A.; Pezaro, C.J.; Zaidi, S.; Lorente, D.; Mukherji, D.; Bianchini, D.; Ferraldeschi, R.; Sandhu, S.; Dearnaley, D.; Parker, C.; Van As, N.; de Bono, J.S.; Attard, G. 2013: Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. British Journal of Cancer 109(5): 1079-1084
Mezynski, J.; Pezaro, C.; Bianchini, D.; Zivi, A.; Sandhu, S.; Thompson, E.; Hunt, J.; Sheridan, E.; Baikady, B.; Sarvadikar, A.; Maier, G.; Reid, A.H.M.; Mulick Cassidy, A.; Olmos, D.; Attard, G.; de Bono, J. 2012: Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. Annals of Oncology: Official Journal of the European Society for Medical Oncology 23(11): 2943-2947
Voltti, H.; Piha, R.S.; Alavaikko, M.; Palva, I.P. 1973: Antitumour activity of iodine in acidic medium with calcium. Nature 246(5428): 98-100
Everse, K.E.; Lin, H.; Stuyt, E.L.; Brady, J.C.; Buddingh, F.; Everse, J. 1985: Antitumour activity of peroxidases. British Journal of Cancer 51(5): 743-746
Sawada, M.; Matsui, Y.; Okudaira, Y. 1986: Antitumour activity of platinum analogues against human yolk sac tumours heterotransplanted in nude mice. British Journal of Cancer 53(3): 415-417
Martínez-Pérez, C.; Ward, C.; Turnbull, A.K.; Mullen, P.; Cook, G.; Meehan, J.; Jarman, E.J.; Thomson, P.I.T.; Campbell, C.J.; McPhail, D.; Harrison, D.J.; Langdon, S.P. 2016: Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models. British Journal of Cancer 114(8): 905-916
Yang, Q.; Zhang, F.; Ding, Y.; Huang, J.; Chen, S.; Wu, Q.; Wang, Z.; Wang, Z.; Chen, C. 2014: Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer. British Journal of Cancer 110(5): 1288-1297
Romano, M.; Della Porta, M.Giovanni.; Gallì, A.; Panini, Nò.; Licandro, S.Andrea.; Bello, E.; Craparotta, I.; Rosti, V.; Bonetti, E.; Tancredi, R.; Rossi, M.; Mannarino, L.; Marchini, S.; Porcu, L.; Galmarini, C.M.; Zambelli, A.; Zecca, M.; Locatelli, F.; Cazzola, M.; Biondi, A.; Rambaldi, A.; Allavena, P.; Erba, E.; D'Incalci, M. 2017: Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. British Journal of Cancer 116(3): 335-343
Caers, J.; Menu, E.; De Raeve, H.; Lepage, D.; Van Valckenborgh, E.; Van Camp, B.; Alvarez, E.; Vanderkerken, K. 2008: Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. British Journal of Cancer 98(12): 1966-1974
Torrisi, R.; Bagnardi, V.; Pruneri, G.; Ghisini, R.; Bottiglieri, L.; Magni, E.; Veronesi, P.; D'Alessandro, C.; Luini, A.; Dellapasqua, S.; Viale, G.; Goldhirsch, A.; Colleoni, M. 2007: Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. British Journal of Cancer 97(6): 802-808
Harari, A.; Graciotti, M.; Bassani-Sternberg, M.; Kandalaft, L.E. 2020: Antitumour dendritic cell vaccination in a priming and boosting approach. Nature Reviews. Drug Discovery 19(9): 635-652
Koster, D.A.; Palle, K.; Bot, E.S.M.; Bjornsti, M-Ann.; Dekker, N.H. 2007: Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 448(7150): 213-217
Komata, T.; Kanzawa, T.; Takeuchi, H.; Germano, I.M.; Schreiber, M.; Kondo, Y.; Kondo, S. 2003: Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells. British Journal of Cancer 88(8): 1277-1280
Chernyakhovskaya, I.Y.; Slavina, E.G.; Svet-Moldavsky, G.J. 1970: Antitumour effect of lymphoid cells activated by interferon. Nature 228(5266): 71-72
Ogata, A.; Yanagie, H.; Ishikawa, E.; Morishita, Y.; Mitsui, S.; Yamashita, A.; Hasumi, K.; Takamoto, S.; Yamase, T.; Eriguchi, M. 2008: Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models. British Journal of Cancer 98(2): 399-409
Katterle, Y.; Brandt, B.H.; Dowdy, S.F.; Niggemann, B.; Zänker, K.S.; Dittmar, T. 2004: Antitumour effects of PLC-gamma1-(SH2)2-TAT fusion proteins on EGFR/c-erbB-2-positive breast cancer cells. British Journal of Cancer 90(1): 230-235
Monini, P.; Sgadari, C.; Toschi, E.; Barillari, G.; Ensoli, B. 2004: Antitumour effects of antiretroviral therapy. Nature Reviews. Cancer 4(11): 861-875
Morgillo, F.; Cascone, T.; D'Aiuto, E.; Martinelli, E.; Troiani, T.; Saintigny, P.; De Palma, R.; Heymach, J.V.; Berrino, L.; Tuccillo, C.; Ciardiello, F. 2011: Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. British Journal of Cancer 105(3): 382-392
Dev, I.K.; Dornsife, R.E.; Hopper, T.M.; Onori, J.A.; Miller, C.G.; Harrington, L.E.; Dold, K.M.; Mullin, R.J.; Johnson, J.H.; Crosby, R.M.; Truesdale, A.T.; Epperly, A.H.; Hinkle, K.W.; Cheung, M.; Stafford, J.A.; Luttrell, D.K.; Kumar, R. 2004: Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. British Journal of Cancer 91(7): 1391-1398
Goddard, C.; Slack, J.A.; Stevens, M.F. 1985: Antitumour imidazotetrazines, Part IX. The pharmacokinetics of mitozolomide in mice. British Journal of Cancer 52(1): 37-41
Tisdale, M.J. 1985: Antitumour imidazotetrazines--XI: Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism. British Journal of Cancer 52(5): 789-792
Oliva Arguelles, B.; Riera-Romo, M.; Guerra Vallespi, M. 2020: Antitumour peptide based on a protein derived from the horseshoe crab: CIGB-552 a promising candidate for cancer therapy. British Journal of Pharmacology 177(16): 3625-3634
Mahale, S.; Bharate, S.B.; Manda, S.; Joshi, P.; Jenkins, P.R.; Vishwakarma, R.A.; Chaudhuri, B. 2015: Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization. Cell Death and Disease 6: E1743
Burgess, D.J. 2012: Antitumour potential of catalytic DNA. Nature Reviews. Cancer 12(8): 508-509
Los, G.; Kop, W.; Deurloo, M.J. 1991: Antitumour response and nephrotoxicity following intraperitoneal administration of a slow release formulation of cisplatin to rats bearing cancers restricted to the peritoneal cavity. British Journal of Cancer 64(1): 90-92
James, K.; Cullen, R.T.; Milne, I.; Norval, M. 1978: Antitumour responses induced by short-term pretreatment with tumour cells. British Journal of Cancer 37(2): 269-281
Ching, L.M.; Joseph, W.R.; Baguley, B.C. 1992: Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. British Journal of Cancer 66(1): 128-130
Nosáľová, G.; Capek, P.; Matáková, T.; Nosáľ, S.ír.; Flešková, D.; Jureček, Ľu.ít. 2012: Antitussive activity of an extracellular Rhodella grisea proteoglycan on the mechanically induced cough reflex. Carbohydrate Polymers 87(1): 752-756
Brown, C.; Fezoui, M.; Selig, W.M.; Schwartz, C.E.; Ellis, J.L. 2004: Antitussive activity of sigma-1 receptor agonists in the guinea-pig. British Journal of Pharmacology 141(2): 233-240
Hur, M.; Kim, J.Y.; Kim, D.H.; Yoo, J.Y.; Shin, H.-B.; Park, B.; Kim, M.; Park, E.; Park, S.Y. 2020: Antitussive effect of a magnesium infusion during anesthetic emergence in patients with double-lumen endotracheal tube: a randomized controlled trial. Journal of Thoracic Disease 12(10): 5691-5699
Yu, L.; Tsuji, K.; Ujihara, I.; Liu, Q.; Pavelkova, N.; Tsujimura, T.; Inoue, M.; Meeker, S.; Nisenbaum, E.; McDermott, J.S.; Krajewski, J.; Undem, B.J.; Kollarik, M.; Canning, B.J. 2021: Antitussive effects of NaV 1.7 blockade in Guinea pigs. European Journal of Pharmacology 907: 174192
Kumar, N.; Awasthi, A.; Kumari, A.; Sood, D.; Jain, P.; Singh, T.; Sharma, N.; Grover, A.; Chandra, R. 2020: Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis. Journal of Biomolecular Structure and Dynamics 2020: 1-16
Bickerman, H.A. 1963: Antitussives. American Journal of Nursing 63: 61-64
Cass, L.J.; Frederik, W.S. 1963: Antitussives. Current Therapeutic Research 5: 87-91
Onyeka, I.P.; Bako, S.P.; Suleiman, M.M.; Onyegbule, F.A.; Morikwe, U.C.; Ogbue, C.O. 2020: Antiulcer Effects of Methanol Extract of Euphorbia hirta and Honey Combination in Rats. Biomed Research International 2020: 6827504
Ofusori, A.E.; Moodley, R.; Jonnalagadda, S.B. 2020: Antiulcerogenic effects of Celosia trigyna plant extracts on ethanol-induced gastric ulcer in adult Wistar rats. Journal of Traditional and Complementary Medicine 10(6): 586-593
Reich, E.Samuel. 2011: Antiuniverse here we come. Nature 473(7345): 13-14
Mandal, B.; Madan, S.; Ahmad, S.; Sharma, A.K.; Ansari, M.H.R. 2021: Antiurolithic efficacy of a phenolic rich ethyl acetate fraction of the aerial parts of Aerva lanata (Linn) Juss. ex Schult. in ethylene glycol induced urolithic rats. Journal of Pharmacy and Pharmacology 73(4): 560-572
Wadman, M. 2020: Antivaccine forces gaining online. Science 368(6492): 699
Durand, G.; Joseph; Darnaud 1947: Antivenereal statistics 1946. Annales de Dermatologie et de Syphiligraphie 7(4): 132
Straight, R.; Glenn, J.L.; Snyder, C.C. 1976: Antivenom activity of rattlesnake blood plasma. Nature 261(5557): 259-260
Murphy, J.C. 2010: Antivenoms administered properly and swiftly save lives. Nature Medicine 16(7): 747
Hutson, S. 2010: Antivenoms needed, say officials, but companies won't bite. Nature Medicine 16(6): 615
Zheng, X.; Fahlgren, N.; Abbasi, A.; Berry, J.C.; Carrington, J.C. 2019: Antiviral ARGONAUTEs Against Turnip Crinkle Virus Revealed by Image-Based Trait Analysis. Plant Physiology 180(3): 1418-1435
Adamek, M.; Davies, J.; Beck, A.; Jordan, L.; Becker, A.M.; Mojzesz, M.; Rakus, K.; Rumiac, T.; Collet, B.; Brogden, G.; Way, K.; Bergmann, S.M.; Zou, J.; Steinhagen, D. 2021: Antiviral Actions of 25-Hydroxycholesterol in Fish Vary with the Virus-Host Combination. Frontiers in Immunology 12: 581786
Lujan, R.A.; Vrba, S.M.; Hickman, H.D. 2022: Antiviral Activities of Group i Innate Lymphoid Cells. Journal of Molecular Biology 434(6): 167266
Sun, L.; Zhang, X.; Xu, S.; Hou, C.; Xu, J.; Zhao, D.; Chen, Y. 2021: Antiviral Activities of a Medicinal Plant Extract Against Sacbrood Virus in Honeybees. Virology Journal 18(1): 83
Zhang, H.; Wang, F.; Zhu, X.; Chen, Y.; Chen, H.; Li, X.; Wu, M.; Li, C.; Liu, J.; Zhang, Y.; Ding, Y.; Niu, J. 2021: Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients with Chronic HBV Infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 73(2): 175-182
Chen, J.; Xia, L.; Liu, L.; Xu, Q.; Ling, Y.; Huang, D.; Huang, W.; Song, S.; Xu, S.; Shen, Y.; Lu, H. 2020: Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19. Open Forum Infectious Diseases 7(7): Ofaa 241
Kumar, S.; Maurya, V.K.; Kabir, R.; Nayak, D.; Khurana, A.; Manchanda, R.K.; Gadugu, S.; Shanker, K.; Saxena, S.K. 2020: Antiviral Activity of Belladonna During Japanese Encephalitis Virus Infection via Inhibition of Microglia Activation and Inflammation Leading to Neuronal Cell Survival. Acs Chemical Neuroscience 11(21): 3683-3696
Elkousy, R.H.; Said, Z.N.A.; Abd El-Baseer, M.A.; Abu El Wafa, S.A. 2021: Antiviral activity of castor oil plant (Ricinus communis) leaf extracts. Journal of Ethnopharmacology 271:: 113878
Qu, M.; Wang, W.; Li, W.; Cao, J.; Zhang, X.; Wang, C.; Wu, J.; Yu, B.; Zhang, H.; Wu, H.; Kong, W.; Yu, X. 2020: Antiviral Activity of Feline BCA2 Is Mainly Dependent on its Interference with Proviral Transcription Rather than Degradation of FIV Gag. Frontiers in Microbiology 11: 1230
Ullah, H.; Sajid, M.; Yan, K.; Feng, J.; He, M.; Shereen, M.A.; Li, Q.; Xu, T.; Hao, R.; Guo, D.; Chen, Y.; Zhou, L.; Zhou, L. 2021: Antiviral Activity of Interferon Alpha-Inducible Protein 27 Against Hepatitis B Virus Gene Expression and Replication. Frontiers in Microbiology 12: 656353
Lai, Y.; Han, T.; Zhan, S.; Jiang, Y.; Liu, X.; Li, G. 2021: Antiviral Activity of Isoimperatorin Against Influenza a Virus in vitro and its Inhibition of Neuraminidase. Frontiers in Pharmacology 12: 657826
Muhammad, W.; Zhai, Z.; Gao, C. 2020: Antiviral Activity of Nanomaterials against Coronaviruses. Macromolecular Bioscience 20(10): E2000196
Carrouel, F.; Gonçalves, L.S.; Conte, M.P.; Campus, G.; Fisher, J.; Fraticelli, L.; Gadea-Deschamps, E.; Ottolenghi, L.; Bourgeois, D. 2021: Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2. Journal of Dental Research 100(2): 124-132
Li, L.; Wang, X.; Wang, R.; Hu, Y.; Jiang, S.; Lu, X. 2020: Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. Drug Design Development and Therapy 14: 3001-3013
Mochulskaya, N.N.; Nosova, E.V.; Charushin, V.N. 2021: Antiviral Agents - Benzazine Derivatives. Chemistry of Heterocyclic Compounds 57(4): 374-382
Chiu, C.; Openshaw, P.J. 2015: Antiviral B cell and T cell immunity in the lungs. Nature Immunology 16(1): 18-26
Jurado, K.A.; Yockey, L.J.; Wong, P.W.; Lee, S.; Huttner, A.J.; Iwasaki, A. 2018: Antiviral CD8 T cells induce Zika-virus-associated paralysis in mice. Nature Microbiology 3(2): 141-147
De Clercq, E.; Brancale, A.; Hodge, A.Vere.; Field, H.J. 2006: Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2006 (1st edition). Antiviral Chemistry and ChemoTherapy 17(3): 113-166
Silva, J.B.; Bosco, E.; Quilliam, D.N.; Gravenstein, S.; Zullo, A.R. 2020: Antiviral Chemoprophylaxis use During Influenza Outbreaks in Rhode Island Long-Term Care Facilities. Journal of the American Medical Directors Association 21(9): 1354-1356
Panda, P.K.; Singh, B.O.; Moirangthem, B.; Bahurupi, Y.A.; Saha, S.; Saini, G.; Dhar, M.; Bairwa, M.; Pai, V.S.; Agarwal, A.; Sindhwani, G.; Handu, S.; Kant, R. 2021: Antiviral Combination Clinically Better than Standard Therapy in Severe but not in Non-Severe COVID-19. Clinical Pharmacology: Advances and Applications 13: 185-195
Chaijamorn, W.; Rungkitwattanakul, D.; Nuchtavorn, N.; Charoensareerat, T.; Pattharachayakul, S.; Sirikun, W.; Srisawat, N. 2020: Antiviral Dosing Modification for Coronavirus Disease 2019-Infected Patients Receiving Extracorporeal Therapy. Critical Care Explorations 2(10): E0242
Chen, R.; Wang, T.; Song, J.; Pu, D.; He, D.; Li, J.; Yang, J.; Li, K.; Zhong, C.; Zhang, J. 2021: Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics. International Journal of Nanomedicine 16: 4959-4984
Piret, J.; Boivin, G. 2021: Antiviral Drugs Against Herpesviruses. Advances in Experimental Medicine and Biology 1322: 1-30
Won, S-Young.; Seol, I-Chan.; Yoo, H-Ryong.; Kim, Y-Sik. 2021: Antiviral Effect of Hyunggaeyungyo-Tang on A549 Cells Infected with Human Coronavirus. Evidence-BasedComplementaryandAlternativeMedicine:Ecam 2021: 4494389
Galli, A.; Mens, H.; Gottwein, J.M.; Gerstoft, J.; Bukh, J. 2018: Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model. Scientific Reports 8(1): 4619
Zhang, W.; Deng, H.; Liu, Y.; Chen, S.; Liu, Y.; Zhao, Y. 2021: Antiviral Effectivity of Favipiravir Against Peste des Petits Ruminants Virus Is Mediated by the JAK/STAT and PI3K/AKT Pathways. Frontiers in Veterinary Science 8: 722840
Nielsen, J.R.; Lazear, H.M. 2020: Antiviral Effector RTP4 Bats against Flaviviruses. Immunity 53(6): 1133-1135
Shukla, D.A.K.; Misra, D.S. 2021: Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible?. International Journal of Infectious Diseases: Ijid: Official Publication of the International Society for Infectious Diseases 109: 91
Newman, R.A.; Sastry, K.J.; Arav-Boger, R.; Cai, H.; Matos, R.; Harrod, R. 2020: Antiviral Effects of Oleandrin. Journal of Experimental Pharmacology 12: 503-515
Shen, T.-J.; Chen, C.-L.; Jhan, M.-K.; Tseng, P.-C.; Satria, R.D.; Hsing, C.-H.; Lin, C.-F. 2021: Antiviral Efficacy of the Anesthetic Propofol against Dengue Virus Infection and Cellular Inflammation. Journal of Immunology Research 2021: 6680913
Yadalam, P.K.; Varatharajan, K.; Rajapandian, K.; Chopra, P.; Arumuganainar, D.; Nagarathnam, T.; Sohn, H.; Madhavan, T. 2021: Antiviral Essential Oil Components Against SARS-CoV-2 in Pre-procedural Mouth Rinses for Dental Settings During COVID-19: a Computational Study. Frontiers in Chemistry 9: 642026
Roy, E.R.; Cao, W. 2020: Antiviral Immune Response in Alzheimer's Disease: Connecting the Dots. Frontiers in Neuroscience 14: 577744
Hasan, J.; Pyke, A.; Nair, N.; Yarlagadda, T.; Will, G.; Spann, K.; Yarlagadda, P.K.D.V. 2020: Antiviral Nanostructured Surfaces Reduce the Viability of SARS-CoV-2. Acs Biomaterials Science and Engineering 6(9): 4858-4861
Chowdhury, S.M.; Talukder, S.A.; Khan, A.M.; Afrin, N.; Ali, M.A.; Islam, R.; Parves, R.; Al Mamun, A.; Sufian, M.A.; Hossain, M.N.; Hossain, M.A.; Halim, M.A. 2020: Antiviral Peptides as Promising Therapeutics against SARS-CoV-2. Journal of Physical Chemistry. B 124(44): 9785-9792
Agarwal, G.; Gabrani, R. 2021: Antiviral Peptides: Identification and Validation. International Journal of Peptide Research and Therapeutics 27(1): 149-168
Lam, S.; Chen, H.; Chen, C.Karen.; Min, N.; Chu, J.Jang.Hann. 2015: Antiviral Phosphorodiamidate Morpholino Oligomers are Protective against Chikungunya Virus Infection on Cell-based and Murine Models. Scientific Reports 5: 12727
Svyatchenko, V.A.; Nikonov, S.D.; Mayorov, A.P.; Gelfond, M.L.; Loktev, V.B. 2021: Antiviral photodynamic therapy: Inactivation and inhibition of SARS-CoV-2 in vitro using methylene blue and Radachlorin. Photodiagnosis and Photodynamic Therapy 33: 102112
Li, K.; Liang, Y.; Cheng, A.; Wang, Q.; Li, Y.; Wei, H.; Zhou, C.; Wan, X. 2021: Antiviral Properties of Baicalin: a Concise Review. Revista Brasileira de Farmacognosia: Orgao Oficial da Sociedade Brasileira de Farmacognosia 31(4): 408-419
Hong, H.; Wang, C.; Huang, Y.; Xu, M.; Yan, J.; Feng, M.; Li, J.; Shi, Y.; Zhu, M.; Shen, D.; Wu, P.; Kormelink, R.; Tao, X. 2021: Antiviral RISC mainly targets viral mRNA but not genomic RNA of tospovirus. Plos Pathogens 17(7): E1009757
Tanguy, Mélanie.; Miska, E.A. 2013: Antiviral RNA interference in animals: piecing together the evidence. Nature Structural and Molecular Biology 20(11): 1239-1241
Leonard, J.N.; Schaffer, D.V. 2006: Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Therapy 13(6): 532-540
Ross, L.J. 1977: Antiviral T cell-mediated immunity in Marek's disease. Nature 268(5621): 644-646
Jefferies, C.; Wynne, C.; Higgs, R. 2011: Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease?. Nature Reviews. Immunology 11(9): 617-625
Testi, I.; Aggarwal, K.; Jaiswal, N.; Dahiya, N.; Thng, Z.X.; Agarwal, A.; Ahuja, A.; Duggal, M.; Kankaria, A.; Ling Ho, S.; Chee, S.-P.; Westcott, M.; Pavesio, C.; Agrawal, R.; Gupta, V. 2021: Antiviral Therapy for Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV)-Induced Anterior Uveitis: a Systematic Review and Meta-Analysis. Frontiers in Medicine 8: 686427
Wallick, C.; Wu, N.; To, T.My.; Keebler, D.; Moawad, D. 2021: Antiviral Use Is Associated with a Decrease in the Rate of Influenza-Related Complications, Health Care Resource Utilization, and Costs. Journal of Medical Economics 2021: 1
García, Mía.A.; Collado, M.; Muñoz-Fontela, César.; Matheu, A.; Marcos-Villar, L.; Arroyo, J.; Esteban, M.; Serrano, M.; Rivas, C. 2006: Antiviral action of the tumor suppressor ARF. EMBO Journal 25(18): 4284-4292
Shahzad, M.I.; Anwar, S.; Ashraf, H.; Manzoor, A.; Naseer, M.; Rani, U.; Aslam, Z.; Saba, N.; Kamran, Z.; Ali, S.; Aslam, J.; Arshad, M. 2020: Antiviral activities of Cholistani plants against common poultry viruses. Tropical Biomedicine 37(4): 1129-1140
Chen, S-Guang.; Cheng, M-Ling.; Chen, K-Hsing.; Horng, J-Tong.; Liu, C-Chuan.; Wang, S-Min.; Sakurai, H.; Leu, Y-Lii.; Wang, S-Der.; Ho, H-Yao. 2017: Antiviral activities of Schizonepeta tenuifolia Briq. against enterovirus 71 in vitro and in vivo. Scientific Reports 7(1): 935
Badshah, S.L.; Faisal, S.; Muhammad, A.; Poulson, B.G.; Emwas, A.H.; Jaremko, M. 2021: Antiviral activities of flavonoids. Biomedicine and PharmacoTherapy 140: 111596
Zoepfl, M.; Dwivedi, R.; Taylor, M.C.; Pomin, V.H.; McVoy, M.A. 2021: Antiviral activities of four marine sulfated glycans against adenovirus and human cytomegalovirus. Antiviral Research 190: 105077
Kato, F.; Matsuyama, S.; Kawase, M.; Hishiki, T.; Katoh, H.; Takeda, M. 2020: Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2. Microbiology and Immunology 64(9): 635-639
Tan, Y.Wah.; Ang, M.Jin.Yan.; Lau, Q.Ying.; Poulsen, A.; Ng, F.Mee.; Then, S.Wen.; Peng, J.; Hill, J.; Hong, W.Jin.; Chia, C.San.Brian.; Chu, J.Jang.Hann. 2016: Antiviral activities of peptide-based covalent inhibitors of the Enterovirus 71 3C protease. Scientific Reports 6: 33663
Huang, H.; Liao, D.; Zhou, G.; Zhu, Z.; Cui, Y.; Pu, R. 2020: Antiviral activities of resveratrol against rotavirus in vitro and in vivo. Phytomedicine: International Journal of PhytoTherapy and Phytopharmacology 77: 153230
Gan, H.J.; Harikishore, A.; Lee, J.; Jeon, S.; Rajan, S.; Chen, M.W.; Neo, J.L.; Kim, S.; Yoon, H.S. 2021: Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug. Antiviral Research 185: 104996
Chen, Y.; Luo, Q.; Li, S.; Li, C.; Liao, S.; Yang, X.; Zhou, R.; Zhu, Y.; Teng, L.; Chen, H.; Yang, Y. 2020: Antiviral activity against porcine epidemic diarrhea virus of Pogostemon cablin polysaccharide. Journal of Ethnopharmacology 259:: 113009
Choi, S.W.; Shin, J.S.; Park, S.-J.; Jung, E.; Park, Y.-G.; Lee, J.; Kim, S.J.; Park, H.-J.; Lee, J.-H.; Park, S.-M.; Moon, S.-H.; Ban, K.; Go, Y.Y. 2020: Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Research 184: 104955
Kang, B.R.; Park, J.S.; Jung, W.-J. 2021: Antiviral activity by lecithin-induced fengycin lipopeptides as a potent key substrate against Cucumber mosaic virus. Microbial Pathogenesis 155: 104910
Simurova, N.V.; Maiboroda, O.I. 2021: Antiviral activity of 1,2,4-triazole derivatives (microreview). Chemistry of Heterocyclic Compounds 57(4): 420-422
Baltina, L.A.; Hour, M.-J.; Liu, Y.-C.; Chang, Y.-S.; Huang, S.-H.; Lai, H.-C.; Kondratenko, R.M.; Petrova, S.F.; Yunusov, M.S.; Lin, C.-W. 2021: Antiviral activity of glycyrrhizic acid conjugates with amino acid esters against Zika virus. Virus Research 294: 198290
Maral, R.; Werner, G.H. 1971: Antiviral activity of L-asparaginase. Nature: new Biology 232(2): 187-188
Cao, Y.; Lei, E.; Li, L.; Ren, J.; He, X.; Yang, J.; Wang, S. 2021: Antiviral activity of Mulberroside C against enterovirus A71 in vitro and in vivo. European Journal of Pharmacology 906: 174204
Jeengar, M.K.; Kurakula, M.; Patil, P.; More, A.; Sistla, R.; Parashar, D. 2021: Antiviral activity of stearylamine against chikungunya virus. Chemistry and Physics of Lipids 235: 105049
Balta, I.; Stef, L.; Pet, I.; Ward, P.; Callaway, T.; Ricke, S.C.; Gundogdu, O.; Corcionivoschi, N. 2020: Antiviral activity of a novel mixture of natural antimicrobials, in vitro, and in a chicken infection model in vivo. Scientific Reports 10(1): 16631
Indu, P.; Arunagirinathan, N.; Rameshkumar, M.R.; Sangeetha, K.; Divyadarshini, A.; Rajarajan, S. 2021: Antiviral activity of astragaloside II, astragaloside IIi and astragaloside IV compounds against dengue virus: Computational docking and in vitro studies. Microbial Pathogenesis 152: 104563
Chang, Y.Jun.; Pong, L.Yih.; Hassan, S.S.; Choo, W.Sim. 2020: Antiviral activity of betacyanins from red pitahaya ( Hylocereus polyrhizus ) and red spinach ( Amaranthus dubius ) against dengue virus type 2 (GenBank accession no. MH488959). Access Microbiology 2(1): Acmi 000073
Eddowes, L.A.; Al-Hourani, K.; Ramamurthy, N.; Frankish, J.; Baddock, H.T.; Sandor, C.; Ryan, J.D.; Fusco, D.N.; Arezes, Jão.; Giannoulatou, E.; Boninsegna, S.; Chevaliez, S.; Owens, B.M.J.; Sun, C.Chi.; Fabris, P.; Giordani, M.Teresa.; Martines, D.; Vukicevic, S.; Crowe, J.; Lin, H.Y.; Rehwinkel, J.; McHugh, P.J.; Binder, M.; Babitt, J.L.; Chung, R.T.; Lawless, M.W.; Armitage, A.E.; Webber, C.; Klenerman, P.; Drakesmith, H. 2019: Antiviral activity of bone morphogenetic proteins and activins. Nature Microbiology 4(2): 339-351
Ding, Y.; Cao, Z.; Cao, L.; Ding, G.; Wang, Z.; Xiao, W. 2017: Antiviral activity of chlorogenic acid against influenza A (H1N1/H3N2) virus and its inhibition of neuraminidase. Scientific Reports 7: 45723
Otręba, M.ł; Kośmider, L.; Rzepecka-Stojko, A. 2020: Antiviral activity of chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine towards RNA-viruses. a review. European Journal of Pharmacology 887: 173553
Ming, L.; Li, Z.; Li, X.; Tang, L.; He, G. 2021: Antiviral activity of diallyl trisulfide against H9N2 avian influenza virus infection in vitro and in vivo. Virology Journal 18(1): 171
Cho, J.; Lee, Y.Jae.; Kim, J.Hyoung.; Kim, S.Il.; Kim, S.Soon.; Choi, B-Sun.; Choi, J-Hoon. 2020: Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19. Scientific Reports 10(1): 16200
Banks, G.T.; Buck, K.W.; Chain, E.B.; Darbyshire, J.E.; Himmelweit, F.; Ratti, G.; Sharpe, T.J.; Planterose, D.N. 1970: Antiviral activity of double stranded RNA from a virus isolated from Aspergillus foetidus. Nature 227(5257): 505-507
Choi, J-Gi.; Kim, Y.Soo.; Kim, J.Hye.; Chung, H-Suck. 2019: Antiviral activity of ethanol extract of Geranii Herba and its components against influenza viruses via neuraminidase inhibition. Scientific Reports 9(1): 12132